{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd \n",
    "from openai import OpenAI\n",
    "import requests"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>profile</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>age</th>\n",
       "      <td>53</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>condition</th>\n",
       "      <td>Amyotrophic Lateral Sclerosis</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>country</th>\n",
       "      <td>France</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>gender</th>\n",
       "      <td>Male</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>profile</th>\n",
       "      <td>Histology: None\\nPrevious treatment: riluzole ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                     profile\n",
       "age                                                       53\n",
       "condition                      Amyotrophic Lateral Sclerosis\n",
       "country                                               France\n",
       "gender                                                  Male\n",
       "profile    Histology: None\\nPrevious treatment: riluzole ..."
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Note: For Part 2, keep this dataset but keep only trials in Phase 1, 2 or 3.\n",
    "'''At myTomorrows, we index clinical trials against conditions ourselves, to improve the performance of our Search engine. \n",
    "Now, for three sample patients, we want to see what trials might be eligible for them.\n",
    "'''\n",
    "\n",
    "patient_1 = pd.read_json(\"mds_case/patient_01.json\")\n",
    "patient_2 = pd.read_json(\"mds_case/patient_02.json\")\n",
    "patient_3 = pd.read_json(\"mds_case/patient_03.json\")\n",
    "\n",
    "patients = [patient_1,patient_2,patient_3]\n",
    "\n",
    "patient_1.head()\n",
    "#patient_1.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Histology: None\\nPrevious treatment: riluzole since two months\\nBiomarkers: SOD1 mutation\\nTests: None\\nComorbidities: rheumatoid arthritis\\nOther: None'"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "patient_1['profile'].profile"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "10\n",
      "{'studies': [{'protocolSection': {'identificationModule': {'nctId': 'NCT05632757', 'orgStudyIdInfo': {'id': 'RCAPHM22_0204'}, 'secondaryIdInfos': [{'id': 'ID-RCB', 'type': 'OTHER', 'domain': '2022-A01748-35'}], 'organization': {'fullName': 'Assistance Publique Hopitaux De Marseille', 'class': 'OTHER'}, 'briefTitle': 'Anticipated Patient and Caregiver Burden', 'officialTitle': 'Anticipated Patient and Caregiver Burden: Impact in People With Amyotrophic Lateral Sclerosis', 'acronym': 'FARP'}, 'statusModule': {'statusVerifiedDate': '2024-01', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-06-22', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-12-22', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-06-22', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-11-16', 'studyFirstSubmitQcDate': '2022-11-27', 'studyFirstPostDateStruct': {'date': '2022-12-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-01-04', 'lastUpdatePostDateStruct': {'date': '2024-01-05', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Assistance Publique Hopitaux De Marseille', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': \"Amyotrophic lateral sclerosis (ALS) is a degenerative neurological disease that causes progressive motor disability and is life threatening within a few years. The severity of the disease, the progressive loss of autonomy that leads to dependence on family and caregivers, and the lack of effective treatment sometimes leads patients to a loss of hope and to dark thoughts. The prevalence of suicidal ideation is high, with more than one third of people with ALS experiencing it. The psychological suffering of patients is often associated with that of their caregivers. The evaluation of the patients' feeling of being a burden has rarely been addressed in previous studies in ALS on the notion of burden. In this work, the investigators wish to evaluate the patient's ideas of death by also taking into account the caregiver's burden and the patient's feeling of being a burden. They wish to better understand this difficult experience by refocusing the study on the patient himself, which has rarely been addressed in studies on ALS and the notion of burden. By working on the caregiver's burden, both from the caregiver's point of view and as perceived by the patient, the investigators hope to find avenues of intervention and define actions that could help patients and their families and improve the quality of life of the patient-caregiver couple.\"}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis'], 'keywords': ['amyotrophic lateral sclerosis', 'caregiver', 'burden', 'depression']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 126, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Psychological assessments', 'type': 'EXPERIMENTAL', 'interventionNames': ['Behavioral: Psychological assessments']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'Psychological assessments', 'description': 'The visit will take place during a multidisciplinary assessment in the ALS Center at the Timone Hospital, Neuromuscular Disease and ALS Department. The patient will be accompanied by his/her caregiver. During this multidisciplinary assessment, the patient is present at the hospital between 8am and 4pm. The various scales and self-questionnaires can be completed during this time. The time required to complete these scales and self-questionnaires is estimated to be about 90 minutes.', 'armGroupLabels': ['Psychological assessments']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': \"Impact of the patient's sense of being a burden on the patient's suicidal ideation\", 'description': 'Columbia scale (highest score meaning better outcome)', 'timeFrame': 'Inclusion visit (month 0)'}], 'secondaryOutcomes': [{'measure': \"Relationship between the patient's feeling of being a burden living\", 'description': \"Patient's Feelings of Burden Scale (highest score meaning worst outcome)\", 'timeFrame': 'Inclusion visit (month 0)'}, {'measure': \"Relationship between the patient's reasons for living\", 'description': 'Patient Reasons for Living Scale (highest score meaning worst outcome)', 'timeFrame': 'Inclusion visit (month 0)'}, {'measure': \"Relationship between the patient's feeling of being a burden and the caregiver's feeling of hardship\", 'description': \"Patient's sense of burden scale and Zarit Caregiver Exertion Scale\", 'timeFrame': 'Inclusion visit (month 0)'}, {'measure': \"Impact of the patient's sense of burden and the caregiver's sense of hardship on the quality of life of the patient and the caregiver\", 'description': 'WHOQOL-Bref (World Health Organization Quality of Life, highest score meaning better outcome)', 'timeFrame': 'Inclusion visit (month 0)'}, {'measure': \"Relationship between the patient's feeling of being a burden and the motor disability\", 'description': 'Beck scale (highest score meaning worse outcome)', 'timeFrame': 'Inclusion visit (month 0)'}, {'measure': \"Relationship between the patient's feeling of being a burden and the motor disability\", 'description': 'Rankin scale (highest score meaning worse outcome)', 'timeFrame': 'Inclusion visit (month 0)'}, {'measure': \"Relationship between the patient's feeling of being a burden and the motor disability\", 'description': 'ALSFRS score (highest score meaning better outcome)', 'timeFrame': 'Inclusion visit (month 0)'}, {'measure': 'Relationship between the depression of patient and the caregiver', 'description': 'Beck scale (highest score meaning worse outcome)', 'timeFrame': 'Inclusion visit (month 0)'}, {'measure': 'Relationship between the depression of patient and the caregiver', 'description': 'Rankin scale (highest score meaning worse outcome)', 'timeFrame': 'Inclusion visit (month 0)'}, {'measure': 'Relationship between the depression of patient and the caregiver', 'description': 'ALSFRS score (highest score meaning better outcome)', 'timeFrame': 'Inclusion visit (month 0)'}, {'measure': \"Impact of the caregiver's feeling of hardship on the patient's reasons for living\", 'description': 'Patient Reasons for Living Scale (highest score meaning worst outcome)', 'timeFrame': 'Inclusion visit (month 0)'}, {'measure': \"Impact of the caregiver's feeling of hardship on the patient's reasons for living\", 'description': 'Columbia Scale (highest score meaning better outcome)', 'timeFrame': 'Inclusion visit (month 0)'}, {'measure': \"Impact of the caregiver's feeling of hardship on the patient's and suicidal ideation\", 'description': 'Patient Reasons for Living Scale (highest score meaning worst outcome)', 'timeFrame': 'Inclusion visit (month 0)'}, {'measure': \"Impact of the caregiver's feeling of hardship on the patient's and suicidal ideation\", 'description': 'Columbia Scale (highest score meaning better outcome)', 'timeFrame': 'Inclusion visit (month 0)'}, {'measure': \"Relationship between the caregiver's perceived distress and the patient's suicidal ideation\", 'description': 'Zarit scale (highest score meaning worse outcome)', 'timeFrame': 'Inclusion visit (month 0)'}, {'measure': \"Relationship between the caregiver's perceived distress and the patient's suicidal ideation\", 'description': 'Columbia Scale (highest score meaning better outcome)', 'timeFrame': 'Inclusion visit (month 0)'}, {'measure': \"Relationship between caregiver's perceived distress and the patient's cognitive assessment\", 'description': 'ECAS score (Cognitif Edinburgh Cognitive and Behavioural ALS Screen) (highest score meaning better outcome)', 'timeFrame': 'Inclusion visit (month 0)'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria (patient) :\\n\\n* Patient is at least 18 years of age.\\n* Patient having given informed consent\\n* Patient with ALS who has already had at least two multidisciplinary assessments in the ALS center in Marseille with an evaluation by the clinical psychologist.\\n* Patient with a motor handicap of grade 3 to 5 on the Rankin score\\n* Patient with a primary family caregiver at home (spouse, child) willing to participate in the study\\n* Patient who is a beneficiary of or affiliated with a social security plan\\n\\nInclusion Criteria (caregiver) :\\n\\n* Adult subject at least 18 years of age.\\n* Subject who has given informed consent.\\n* Primary family caregiver of a patient with ALS who agrees to participate in the study\\n* Caregiver present during hospital visits.\\n\\nExclusion Criteria (patient):\\n\\n* Patients with a serious and unstable associated disease, cardiac, oncological, hepatic or renal, psychiatric (schizophrenia, bipolar)\\n* Autonomous patient, who does not need the help of a third party for the basic gestures of daily life (Rankin 0 to 2)\\n* Patient living in an institution or alone at home\\n* Patient with cognitive impairment that interferes with activities of daily living\\n* Patients with marked emotional lability (spasmodic crying) due to ALS\\n* Patients who have had a recent diagnosis of their disease (less than 6 months)\\n* Patients who are unaware of the severity of their condition\\n* Any condition that in the opinion of the investigator or psychologist would not be compatible with the study.\\n\\nExclusion Criteria (caregiver):\\n\\n* Subjects with severe and unstable cardiac, oncological, hepatic, renal or other illnesses.\\n* Subject with a history of psychiatric illness', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Annie Verschueren', 'role': 'CONTACT', 'phone': '0491386578', 'phoneExt': '33', 'email': 'annie.verschueren@ap-hm.fr'}, {'name': 'Annie Verschueren', 'role': 'CONTACT'}], 'overallOfficials': [{'name': 'Annie Verschueren', 'affiliation': 'AP-HM', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Service Maladies neuromusculaires et SLA', 'status': 'RECRUITING', 'city': 'Marseille', 'zip': '13005', 'country': 'France', 'contacts': [{'name': 'Annie Verschueren', 'role': 'CONTACT', 'email': 'annie.verschueren@ap-hm.fr'}], 'geoPoint': {'lat': 43.29551, 'lon': 5.38958}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000012598', 'term': 'Sclerosis'}, {'id': 'D000084802', 'term': 'Caregiver Burden'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}, {'id': 'D000013315', 'term': 'Stress, Psychological'}, {'id': 'D000001526', 'term': 'Behavioral Symptoms'}], 'browseLeaves': [{'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M7058', 'name': 'Depression', 'relevance': 'LOW'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M7061', 'name': 'Depressive Disorder', 'relevance': 'LOW'}, {'id': 'M2480', 'name': 'Caregiver Burden', 'asFound': 'Caregiver Burden', 'relevance': 'HIGH'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M16105', 'name': 'Stress, Psychological', 'relevance': 'LOW'}, {'id': 'M4818', 'name': 'Behavioral Symptoms', 'relevance': 'LOW'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05306457', 'orgStudyIdInfo': {'id': 'STUDY00000278'}, 'organization': {'fullName': 'Cedars-Sinai Medical Center', 'class': 'OTHER'}, 'briefTitle': 'CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS', 'officialTitle': 'Human Neural Progenitor Cells Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) Delivered to the Motor Cortex for the Treatment of Amyotrophic Lateral Sclerosis'}, 'statusModule': {'statusVerifiedDate': '2024-02', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-05-08', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-09', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-09', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2021-12-21', 'studyFirstSubmitQcDate': '2022-03-23', 'studyFirstPostDateStruct': {'date': '2022-04-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-05', 'lastUpdatePostDateStruct': {'date': '2024-02-06', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Clive Svendsen', 'investigatorTitle': 'Executive Director, Board of Governors Regenerative Medicine Institute', 'investigatorAffiliation': 'Cedars-Sinai Medical Center'}, 'leadSponsor': {'name': 'Cedars-Sinai Medical Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'California Institute for Regenerative Medicine (CIRM)', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The investigator is examining the safety of transplanting cells, that have been engineered to produce a growth factor, into the motor cortex (brain) of patients with Amyotrophic Lateral Sclerosis (ALS). The cells are called neural progenitor cells, which are a type of stem cell that can become several different types of cells in the nervous system. These cells have been derived to specifically become astrocytes, which is a type of neural cell. The growth factor is called glial cell line-derived neurotrophic factor, or GDNF. GDNF is a protein that promotes the survival of many types of neural cells. Therefore, the cells are called \"CNS10-NPC-GDNF.\" The investigational treatment has been tested in people by delivering it to the spinal cord. However, it has only been delivered to the motor cortex of animals. In this study, we want to learn if CNS10-NPC-GDNF cells are safe to transplant into the motor cortex (brain) of people.', 'detailedDescription': 'This study will be the first to use a genetically modified progenitor cell line delivered to the motor cortex to treat a neurodegenerative disease. This is a Phase 1/2a, single-center, safety study of two escalating doses of human neural progenitor cells expressing GDNF (CNS10-NPC-GDNF) delivered unilaterally to the \"hand-knob\" area of the motor cortex of patients with ALS.\\n\\nSubjects meeting all Eligibility Criteria and providing Informed Consent will be enrolled in one of three sequential dosing groups. Subjects will be treated sequentially with a minimum of one month interval between surgeries for the first three subjects in each dosing cohort. The remaining subjects in the cohort will be treated with a minimum interval of at least one week between surgeries.\\n\\nPrimary Outcome:\\n\\nSafety, as evaluated by:\\n\\n* Adverse Events and Serious Adverse Events\\n* Post-op MRI and/or CT (with contrast) and as clinically indicated'}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis'], 'keywords': ['ALS', 'Stem cells', 'Growth Factor', 'Regenerative', 'Neural Progenitor Cells', 'NPC', 'Transplantation']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 16, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'CNS10-NPC-GDNF - Group A', 'type': 'EXPERIMENTAL', 'description': 'Unilateral, Motor Cortex, 0.25x10\\\\^6 cells in 10 µL/site, 21 sites (5.25x10\\\\^6 total cells) - Motor cortex corresponding to the non-dominant hand', 'interventionNames': ['Biological: CNS10-NPC-GDNF']}, {'label': 'CNS10-NPC-GDNF - Group B', 'type': 'EXPERIMENTAL', 'description': 'Unilateral, Motor Cortex, 0.5x10\\\\^6 cells in 10 µL/site, 21 sites (10.5x10\\\\^6 total cells) - Motor cortex corresponding to the non-dominant hand', 'interventionNames': ['Biological: CNS10-NPC-GDNF']}, {'label': 'CNS10-NPC-GDNF - Group C', 'type': 'EXPERIMENTAL', 'description': 'Unilateral Motor Cortex, 0.5x10\\\\^6 cells in 10 µL/site, 21 sites (10.5x10\\\\^6 total cells) - Motor cortex corresponding to the dominant hand', 'interventionNames': ['Biological: CNS10-NPC-GDNF']}], 'interventions': [{'type': 'BIOLOGICAL', 'name': 'CNS10-NPC-GDNF', 'description': 'Unilateral injections of CNS10-NPC-GDNF into the motor cortex', 'armGroupLabels': ['CNS10-NPC-GDNF - Group A', 'CNS10-NPC-GDNF - Group B', 'CNS10-NPC-GDNF - Group C']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Safety, as evaluated by the incidence of Adverse Events and Serious Adverse Events and their relationship to the treatment', 'timeFrame': '12 months post-operatively'}, {'measure': 'Safety, as evaluated by changes from baseline in the brain MRI', 'timeFrame': '12 months post-operatively'}], 'secondaryOutcomes': [{'measure': 'Force Generation via Accurate Test of Limb Isometric Strength (ATLIS) testing', 'description': 'Change from baseline for force generation by ATLIS', 'timeFrame': 'ATLIS testing will be performed 7 times over 15 months'}, {'measure': 'Pinch Strength', 'description': 'Change from baseline for pinch strength', 'timeFrame': 'Pinch Strength testing will be performed 7 times over 15 months'}, {'measure': 'Hand/Wrist Strength', 'description': 'Change from baseline for Hand/Wrist strength using Hand-held dynamometer', 'timeFrame': 'Hand/Wrist strength testing will be performed 7 times over 15 months'}, {'measure': 'Compound Motor Action Potential (CMAP)', 'description': 'Change from baseline for CMAP', 'timeFrame': 'CMAP will be performed 7 times over 15 months'}, {'measure': 'Functional Hand assessments using 9-hole peg test', 'description': 'Change from baseline for 9-hole peg test', 'timeFrame': '9-hole peg testing will be performed 7 times over 15 months'}, {'measure': 'Penn Upper Motor Neuron Score (PUMNS)', 'description': 'Change from baseline for Penn Upper Motor Neuron Score. (Scale of 0-32, where 0 is normal)', 'timeFrame': 'PUMNS will be performed 7 times over 15 months'}, {'measure': 'Hand Knob - Functional MRI (fMRI)', 'description': 'Changes from baseline in brain activity in the hand knob area evaluated by fMRI', 'timeFrame': 'fMRI will be performed up to 4 times over 15 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion:\\n\\n1. Confirmed diagnosis of ALS (Possible, Lab-supported Probable, Probable or Definite El Escorial Criteria)\\n2. Duration of ALS symptoms ≤ 36 months\\n3. Progressive weakness in upper extremities, with EMG supported evidence of denervation in both upper extremities\\n4. Forced Vital Capacity ≥50% of predicted normal in supine\\n5. Age: 18 years or older\\n6. Able to provide Informed Consent\\n7. Be geographically accessible to the study site and able to travel to study site for required visits\\n8. Have caregiver to assist in the transportation and care required by participation in the study\\n9. Not taking riluzole and/or edaravone or on a stable dose for ≥ 30 day\\n10. For women of child bearing capacity, negative pregnancy test prior to surgery and willingness to use birth control for the duration of the trial.\\n11. Medically able to undergo craniotomy as determined by the site PI and/or investigators\\n12. Medically able to tolerate the immunosuppression regimen as determined by the site PI\\n\\nExclusion:\\n\\n1. Using invasive ventilatory assistance\\n2. Diagnosis of another active or unstable medical illness that may interfere with study participation at discretion of PI\\n3. Presence of any of the following conditions:\\n\\n   1. Current drug or alcohol abuse\\n   2. Any known immunodeficiency syndrome\\n   3. Unstable medical condition\\n   4. Unstable psychiatric illness including psychosis and untreated major depression within 90 days of screening\\n4. Persons of child bearing capacity not willing to practice birth control\\n5. Receiving any investigational device/biologic/drug in the past 30 days or any previous exposure to stem cell therapy\\n6. Any condition in the upper extremities that precludes serial strength or coordination testing\\n7. Any condition that the investigators feel may pose complications for the surgery\\n8. Any condition or ALS disease phenotype that the site PI feels may interfere with participation in the study or in the interpretation of study endpoints\\n9. Allergy to Beta-Lactam antibiotics\\n10. Donor Specific Antibodies (DSA) ≥ 2500MFI or CPRA ≥ 20%\\n11. Contraindications to MRI', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Pablo Avalos', 'role': 'CONTACT', 'phone': '310-248-8584', 'email': 'Pablo.avalos@cshs.org'}], 'overallOfficials': [{'name': 'Richard Lewis, MD', 'affiliation': 'Cedars-Sinai Medical Center', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Cedars-Sinai Medical Center', 'status': 'RECRUITING', 'city': 'Los Angeles', 'state': 'California', 'zip': '90048', 'country': 'United States', 'contacts': [{'name': 'Pablo Avalos', 'role': 'CONTACT', 'phone': '310-248-8584'}, {'name': 'Richard Lewis, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000012598', 'term': 'Sclerosis'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}], 'browseLeaves': [{'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M11900', 'name': 'Mitogens', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05137665', 'orgStudyIdInfo': {'id': '21-500-101-70-09'}, 'organization': {'fullName': 'Target ALS Foundation, Inc.', 'class': 'OTHER'}, 'briefTitle': 'Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures', 'officialTitle': 'Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At - Home Measures', 'acronym': 'TALSLB'}, 'statusModule': {'statusVerifiedDate': '2023-11', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-01-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2031-12-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2031-12-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2021-11-16', 'studyFirstSubmitQcDate': '2021-11-16', 'studyFirstPostDateStruct': {'date': '2021-11-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-11-13', 'lastUpdatePostDateStruct': {'date': '2023-11-15', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Target ALS Foundation, Inc.', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Brief Summary: The goal of the study is to generate a biorepository of longitudinal blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 200 Amyotrophic Lateral Sclerosis (ALS) patients and 80 healthy controls from multiple sites, over a 5 year time frame. Additionally, speech measures will be collected on weekly basis at home for all participants. The measurements are performed using a speech recording application installed on their personal device. For a subset of both ALS and healthy participants, we will also collect at-home vital capacity on a weekly basis. It is expected that increased frequency data sampling of these outcome measures will help in better tracking of disease progression. Biofluids and clinical information are collected over a 20-month time frame for each individual enrolled in the research study. ALS participants will be coming to clinic for 5 study visits with a 4-month interval between visits. Healthy participants will be coming for 2 study visits with a 12-month interval between visits. These samples and clinical information will be stored in a de-identified manner and made available for investigators to use in future research studies.', 'detailedDescription': 'An industry wide survey performed by Dr. Lyle Ostrow at Johns Hopkins University indicated that longitudinal bio-fluids linked to detailed clinical information are critical to continued drug development for amyotrophic lateral sclerosis (ALS), with CSF being the top biofluid often lacking in longitudinal sample biorepositories. There have been prior efforts for longitudinal collection of biofluids matched to clinical information (see https://cdmrp.army.mil/alsrp/resources/Biorepositories_biofluids_celllines for a listing of ALS biorepositories), but those sample sets are limited in size and quickly utilized by the research community. Based upon input from industry leaders, we propose the creation of a Target ALS longitudinal biofluids biorepository linked to patient genetic and clinical information.\\n\\nGiven the heterogeneous clinical and biologic nature of ALS, a repository of longitudinal samples linked to clinical and genetic information is essential to help identify and verify ALS biomarkers. Recent studies to identify ALS biomarkers have used longitudinal samples from either the sporadic patient population or from those that harbor genetic mutations known to cause ALS but are not yet symptomatic. Beyond exploring the relationship between known causative genes and candidate biomarkers, the Target ALS Postmortem Core has collected postmortem ALS tissue samples linked to whole genome sequencing information that have been valuable at finding new subtypes of ALS linked to transcriptomics profiles from the tissue samples. The current study utilizes medical centers participating in the Target ALS Postmortem Core to create a longitudinal biofluids repository from living patients and healthy controls. Given the impact of COVID-19 on ALS clinical research studies and clinical trials, all participants will participate in at home speech measures on a weekly basis and we will also enroll 100 ALS and 30 healthy control participants for at home measures of vital capacity that are completed once every two weeks. The added feature of these at home measures is to further evaluate the potential for at home measures in future clinical trials and ability to obtain enriched speech and vital capacity measures to correlate to downstream biomarker studies using biofluid or genetic data. There is a growing interest in the use of at home speech analytics to classify and monitor ALS patients, with recent studies indicating the value for these at home measures in both clinical research and clinical trial settings. Our study will not only expand upon these early findings but also include at home spirometry measures of vital capacity to evaluate the ability to obtain reliable vital capacity measures at home.\\n\\nOur proposed study will provide valuable longitudinal biofluids linked to clinical information, genetic data, at home speech and vital capacity measures for use in future research studies. These de-identified samples and clinical information will be available to investigators throughout the world to enhance ALS research and ultimately improved treatments for ALS. There is a long history of benefit for biorepositories with linked clinical data to be instrumental in research progress. Most studies that identify biomarkers or validate biomarkers for human diseases typically require banked samples that are linked to clinical information to determine sensitivity/specificity of the biomarker for that disease or to demonstrate change over course of disease.'}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis', 'Movement Disorders', 'Degenerative Disorder', 'Motor Neuron Disease'], 'keywords': ['Amyotrophic Lateral Sclerosis', 'ALS Amyotrophic Lateral Sclerosis', 'Target ALS', 'Longitudinal Biofluids', 'Barrow Neurological Institute', 'New York Genome Center', 'Biofluids Biorepository', 'Genomic-wide association studies']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': True, 'targetDuration': '5 Years', 'designInfo': {'observationalModel': 'OTHER', 'timePerspective': 'OTHER'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': \"Participating sites will label and freeze up to two blood tubes collected from each study participant for DNA extraction and analysis. DNA extraction will be done at Barrow Neurological Institute (BNI). DNA may be stored, used in genome-wide association studies (GWAS), whole genome sequencing, exome sequencing, or for any other known or as yet undiscovered DNA analysis applicable to understanding or targeting disease, with a particular emphasis on ALS. The whole genomic sequencing will be done at the New York Genome Center (NYGC). The information from these genetic studies may be made available to collaborators in academia, not-for-profit settings, or industry for appropriate research. Results of DNA testing from this study will not go into the participant's medical record.\"}, 'enrollmentInfo': {'count': 280, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Amyotrophic Lateral Sclerosis ALS', 'description': 'Amyotrophic Lateral Sclerosis (ALS): Clinical diagnosis of ALS requires the presence of UMN and LMN involvement in different body regions and evidence of progressive spread of symptoms or signs according to EEC. ALS clinic patients with suspected, possible, probable, probable-laboratory supported, or definite ALS will be included. ALS clinic participants with suspected, possible, probable, probable-laboratory supported, and definite Amyotrophic Lateral Sclerosis (ALS) according to revised El Escorial Criteria (EEC) will participate in 5 longitudinal visits; Screening/Baseline Visit 1, and four (4) follow-up visits which will occur at approximate 4-month intervals. Upon IRB approved consent, the study participant will undergo the assessments and bio-fluid collections at each visit as outlined in the Schedule of Events.'}, {'label': 'Healthy', 'description': 'Healthy participants (family or friends) will have a neurologic exam to confirm non-neurologic disease status and will participate in 2 longitudinal visits; Screening/baseline Visit 1, and one (1) follow-up which will occur at approximate 12-month interval. Upon IRB approved consent, the study participant will undergo the assessments and bio-fluid collections at each visit as outlined in the Schedule of Events.'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Biofluid Biorepository', 'description': 'This project will create a biorepository of longitudinal biofluid samples, linked to clinical measures, and at home measures', 'timeFrame': '+ 3.5 Years'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion ALS participants:\\n\\n1. Age 18 or older.\\n2. Ability to understand the purpose and risks of the study, provide informed consent and comply with trial procedures.\\n3. Diagnosis of ALS according to revised EEC, including suspected, possible, probable (+/- laboratory supported), and definite.\\n4. Vital capacity (VC) at least 50% predicted value for gender, height and age at screening\\n5. In the opinion of the study physician, able to tolerate study procedures, including lumbar puncture, for the duration of the study.\\n6. A Score of 2 or more on item one (SPEECH) of the ALSFRS-R scale.\\n7. Subjects medically able to undergo lumbar puncture (LP) as determined by the investigator 15 (i.e.: no bleeding disorder, allergy to local anesthetics, a skin infection at or near the LP site, or evidence of high intracranial pressure).\\n8. Access to a smartphone or tablet, and internet access at home.\\n\\nInclusion Healthy participants:\\n\\n1. Age 18 or older.\\n2. Capable of providing informed consent and complying with trial procedure.\\n3. No history of neurological disease, as determined by the investigator.\\n4. Individuals that harbor known genetic mutations that cause ALS yet are asymptomatic can also be enrolled in the Healthy participant cohort.\\n5. Access to a smartphone or tablet, and internet access at home.\\n\\nExclusion ALS and Healthy participants:\\n\\n1. Any known or suspected abnormal CSF pressure or intracranial/intraspinal tumors\\n2. Use of anticoagulant medication (eg. warfarin, dalteparin, enoxaparin, rivaroxaban, fondaparinux, dabigatran) that cannot be safely withheld until coagulation parameters have normalized prior to lumbar puncture and for up to a week following the lumbar puncture.\\n3. Blood dyscrasia, abnormal bleeding diathesis, or the use of dialysis for renal failure.\\n4. Clinical judgment of the Site Investigator that the participant would be unable to undergo multiple lumbar punctures.\\n5. Inability to perform at home speech measures using an app on a patient device (phone or iPad)\\n\\nIndividuals participating in other clinical research studies will be eligible to participate in this study. ALS patients on any currently approved therapies (riluzole, edaravone) are eligible to participate and continue their medications throughout this study.', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Clinic patients, with suspected, possible, probable-laboratory supported, and definite Amyotrophic Lateral Sclerosis, (ALS) according to revised El Escorial Criteria (EEC). Healthy volunteers will be family or friends of Clinic patients with suspected, possible probable, probable laboratory supported and definite Amyotrophic Lateral Sclerosis (ALS) according to revised El Escorial Criteria (EEC).', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Manish Raisinghani, MBBS PhD', 'role': 'CONTACT', 'phone': '332-333-4140', 'email': 'manish.raisinghani@targetals.org'}, {'name': 'Robert Bowser, PhD', 'role': 'CONTACT', 'phone': '602-406-8989', 'email': 'robert.bowser@dignityhealth.org'}], 'overallOfficials': [{'name': 'Manish J Raisinghani, MBBS PhD', 'affiliation': 'Target ALS Foundation, Inc.', 'role': 'STUDY_DIRECTOR'}, {'name': 'Amy Easton, PhD', 'affiliation': 'Target ALS Foundation, Inc.', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Barrow Neurological Institute', 'status': 'RECRUITING', 'city': 'Phoenix', 'state': 'Arizona', 'zip': '85013', 'country': 'United States', 'contacts': [{'name': 'Whitney Dailey, MS', 'role': 'CONTACT', 'phone': '602-406-7804', 'phoneExt': '67804', 'email': 'whitney.dailey@dignityhealth.org'}, {'name': 'Lisa Butler, MPH', 'role': 'CONTACT', 'phone': '602-406-4217', 'phoneExt': '64217', 'email': 'lisa.butler@dignityhealth.org'}, {'name': 'Shafeeq Ladha, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'facility': 'University of California San Diego', 'status': 'RECRUITING', 'city': 'San Diego', 'state': 'California', 'zip': '92121', 'country': 'United States', 'contacts': [{'name': 'Gil Gutierrez', 'role': 'CONTACT', 'email': 'grg005@health.ucsd.edu'}, {'name': 'John Ravits, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 32.71533, 'lon': -117.15726}}, {'facility': 'Georgetown University', 'status': 'RECRUITING', 'city': 'Georgetown', 'state': 'District of Columbia', 'zip': '20007', 'country': 'United States', 'contacts': [{'name': 'Charles Carpenter', 'role': 'CONTACT', 'email': 'cjc357@georgetown.edu'}, {'name': 'Luke Lovelace', 'role': 'CONTACT', 'email': 'll928@georgetwon.edu'}, {'name': 'Brent Harris, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 38.90483, 'lon': -77.06248}}, {'facility': 'Mayo Clinic', 'status': 'RECRUITING', 'city': 'Jacksonville', 'state': 'Florida', 'zip': '32224', 'country': 'United States', 'contacts': [{'name': 'Alexander Burch', 'role': 'CONTACT', 'email': 'burch.alexander@mayo.edu'}, {'name': 'Bjorn Oskarsson, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'facility': 'Washington University', 'status': 'RECRUITING', 'city': 'Saint Louis', 'state': 'Missouri', 'zip': '63110', 'country': 'United States', 'contacts': [{'name': 'Jeri Oranski', 'role': 'CONTACT', 'email': 'jerio@wustl.edu'}, {'name': 'Jesse Markway', 'role': 'CONTACT', 'email': 'jessemarkway@wustl.edu'}, {'name': 'Tim Miller, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Cindy Ly, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'facility': 'Columbia University', 'status': 'RECRUITING', 'city': 'New York', 'state': 'New York', 'zip': '10032', 'country': 'United States', 'contacts': [{'name': 'Ben Hoover', 'role': 'CONTACT', 'email': 'bnh2119@cumc.columbia.edu'}, {'name': 'Sarah Griffen', 'role': 'CONTACT', 'email': 'sjg2220@cumc.columbia.edu'}, {'name': 'Neil Schneider, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Matt Harms, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Temple University', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'zip': '19140', 'country': 'United States', 'geoPoint': {'lat': 39.95233, 'lon': -75.16379}}]}, 'referencesModule': {'references': [{'pmid': '21989244', 'type': 'BACKGROUND', 'citation': 'Bowser R, Turner MR, Shefner J. Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. Nat Rev Neurol. 2011 Oct 11;7(11):631-8. doi: 10.1038/nrneurol.2011.151.'}, {'pmid': '30941088', 'type': 'BACKGROUND', 'citation': 'Chipika RH, Finegan E, Li Hi Shing S, Hardiman O, Bede P. Tracking a Fast-Moving Disease: Longitudinal Markers, Monitoring, and Clinical Trial Endpoints in ALS. Front Neurol. 2019 Mar 19;10:229. doi: 10.3389/fneur.2019.00229. eCollection 2019.'}, {'pmid': '31432691', 'type': 'BACKGROUND', 'citation': 'Benatar M, Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, Malaspina A. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(7-8):538-548. doi: 10.1080/21678421.2019.1646769. Epub 2019 Aug 21.'}, {'pmid': '32515902', 'type': 'BACKGROUND', 'citation': 'Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, Glass JD, Brown RH Jr, Ladha SS, Lacomis D, Harris JM, Scearce-Levie K, Ho C, Bowser R, Berry JD. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020 Jul;7(7):1103-1116. doi: 10.1002/acn3.51078. Epub 2020 Jun 9.'}, {'pmid': '31665631', 'type': 'BACKGROUND', 'citation': 'Tam OH, Rozhkov NV, Shaw R, Kim D, Hubbard I, Fennessey S, Propp N; NYGC ALS Consortium; Fagegaltier D, Harris BT, Ostrow LW, Phatnani H, Ravits J, Dubnau J, Gale Hammell M. Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia. Cell Rep. 2019 Oct 29;29(5):1164-1177.e5. doi: 10.1016/j.celrep.2019.09.066.'}, {'pmid': '32126556', 'type': 'BACKGROUND', 'citation': 'Vieira H, Costa N, Sousa T, Reis S, Coelho L. Voice-Based Classification of Amyotrophic Lateral Sclerosis: Where Are We and Where Are We Going? A Systematic Review. Neurodegener Dis. 2019;19(5-6):163-170. doi: 10.1159/000506259. Epub 2020 Mar 3.'}, {'pmid': '32138555', 'type': 'BACKGROUND', 'citation': 'Barnett C, Green JR, Marzouqah R, Stipancic KL, Berry JD, Korngut L, Genge A, Shoesmith C, Briemberg H, Abrahao A, Kalra S, Zinman L, Yunusova Y. Reliability and validity of speech & pause measures during passage reading in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Feb;21(1-2):42-50. doi: 10.1080/21678421.2019.1697888. Epub 2019 Dec 6.'}, {'pmid': '32515889', 'type': 'BACKGROUND', 'citation': 'Rutkove SB, Narayanaswami P, Berisha V, Liss J, Hahn S, Shelton K, Qi K, Pandeya S, Shefner JM. Improved ALS clinical trials through frequent at-home self-assessment: a proof of concept study. Ann Clin Transl Neurol. 2020 Jul;7(7):1148-1157. doi: 10.1002/acn3.51096. Epub 2020 Jun 9. Erratum In: Ann Clin Transl Neurol. 2021 Aug;8(8):1770.'}, {'pmid': '23834161', 'type': 'BACKGROUND', 'citation': 'Quinn C, Macklin EA, Atassi N, Bowser R, Boylan K, Cudkowicz M, Fournier C, Ladha SS, Lacomis D, Berry J. Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):632-4. doi: 10.3109/21678421.2013.808227. Epub 2013 Jul 8. No abstract available.'}, {'pmid': '16705110', 'type': 'BACKGROUND', 'citation': 'Schievink WI. Spontaneous spinal cerebrospinal fluid leaks and intracranial hypotension. JAMA. 2006 May 17;295(19):2286-96. doi: 10.1001/jama.295.19.2286.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'These samples and clinical information will be stored in a de-identified manner and made available for investigators to use in future research studies.\\n\\nIt is expected to take approximately 5 years to complete all sample and data collection for the study. The first phase of the study will involve activating all sites participating in the study, and will take about 4 months to complete. The enrollment period is expected to be about 2-3.5 years. Active assessment for each subject will be for 16-18 months from the time of enrollment. After the end of active assessment period (5 years), the bio-samples and clinical information from the study will be made available for future research.', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR'], 'timeFrame': 'Greater than 5+ Years', 'accessCriteria': 'Access available using published manuscripts and stored biofluids using the BioLims Repository.', 'url': 'http://targetals.org'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000009069', 'term': 'Movement Disorders'}, {'id': 'D000012598', 'term': 'Sclerosis'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}], 'browseLeaves': [{'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Motor Neuron Disease', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M12029', 'name': 'Movement Disorders', 'asFound': 'Movement Disorders', 'relevance': 'HIGH'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05474235', 'orgStudyIdInfo': {'id': '07-005711'}, 'secondaryIdInfos': [{'id': '5P01NS084974', 'type': 'NIH', 'link': 'https://reporter.nih.gov/quickSearch/5P01NS084974'}], 'organization': {'fullName': 'Mayo Clinic', 'class': 'OTHER'}, 'briefTitle': 'Studies in Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Motor Neuron Disorders', 'officialTitle': 'Clinical & Genetic Studies in ALS and Other Neurodegenerative Motor Neuron Disorders'}, 'statusModule': {'statusVerifiedDate': '2023-08', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2007-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2038-12', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2038-12', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-07-14', 'studyFirstSubmitQcDate': '2022-07-22', 'studyFirstPostDateStruct': {'date': '2022-07-26', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-08-01', 'lastUpdatePostDateStruct': {'date': '2023-08-02', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Bjorn E. Oskarsson', 'investigatorTitle': 'Principal Investigator', 'investigatorAffiliation': 'Mayo Clinic'}, 'leadSponsor': {'name': 'Mayo Clinic', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institute of Neurological Disorders and Stroke (NINDS)', 'class': 'NIH'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to collect, from patients with sporadic and familial ALS and their family members, clinical data and blood samples for extraction of DNA, RNA, preparation of lymphocytes, plasma and serum to establish a repository for future investigations of genetic contributions to ALS pathogenesis. Blood samples for DNA extraction also would be collected from control subjects with no personal or family history of ALS phenotypes.'}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'CROSS_SECTIONAL'}, 'enrollmentInfo': {'count': 3000, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'ALS or Suspected ALS Patient', 'description': 'Subjects with clinical diagnosis of possible, laboratory-supported probable, probable or definite, ALS or diagnosis of a neurodegenerative disorder with evidence of ALS plus extramotor features or a blood relative (first, second or third degree) with history of ALS or neurodegenerative disorder with evidence of ALS plus extramotor features.'}, {'label': 'Blood Relative of ALS Patient', 'description': 'Subjects with family history (first, second or third degree blood relative) of ALS or other motor neuron disease.'}, {'label': 'Healthy Control', 'description': 'Subjects with no personal or family history (first, second or third degree blood relative) of ALS or other motor neuron disease'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Blood Collection', 'description': 'Total number of blood samples collected', 'timeFrame': '50 years'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria\\n\\nALS or Suspected ALS Patient\\n\\n* Clinical diagnosis of possible, laboratory-supported probable, probable or definite ALS according to modified EL Escorial criteria, suspected ALS according to original El Escorial criteria, or diagnosis of a neurodegenerative disorder with evidence of ALS plus extramotor features; OR\\n* Blood relative (first, second or third degree) with history of ALS or neurodegenerative disorder with evidence of ALS plus extramotor features; OR:\\n\\n  * A clinical suspicion or referral for ALS;\\n  * \\\\> 18 years of age;\\n  * Willing and able to give signed informed consent or assent that has been approved by the Institutional Review Board (IRB).\\n\\nBlood Relative of ALS Patient\\n\\n* Family history (first, second or third degree blood relative) of ALS or other motor neuron disease;\\n* \\\\> 18 years of age;\\n* Willing and able to give signed informed consent that has been approved by the Institutional Review Board (IRB).\\n\\nHealthy Control\\n\\n* No personal or family history (first, second or third degree blood relative) of ALS or other motor neuron disease;\\n* \\\\> 18 years of age;\\n* No personal history of other neurodegenerative disease (i.e., Alzheimer disease, Parkinson disease);\\n* Willing and able to give signed informed consent that has been approved by the Institutional Review Board (IRB).\\n\\nExclusion Criteria:\\n\\nALS or Suspected Patient • Limited mental capacity rendering the subject unable to provide written informed consent or assent or comply with standard phlebotomy procedures.\\n\\nBlood Relative of ALS Patient\\n\\n• Limited mental capacity rendering the subject unable to provide written informed consent or comply with standard phlebotomy procedures.\\n\\nHealthy Control Subject\\n\\n* Personal or family history of dementia or other neurodegenerative disease (Parkinson disease, Alzheimer disease, etc.);\\n* MoCA score \\\\< 26;\\n* Limited mental capacity rendering the subject unable to provide written informed consent or comply with standard phlebotomy procedures.', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Eligible subjects with ALS or suspected ALS or family history of ALS will be identified from patients seen in the Department of Neurology at Mayo Clinic Jacksonville. Inclusion criteria include standardized diagnostic criteria for ALS as used in ALS therapeutic trials and patients with clinically suspected ALS.', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Bjorn Oskarsson, MD', 'affiliation': 'Mayo Clinic', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Mayo Clinic Florida', 'status': 'RECRUITING', 'city': 'Jacksonville', 'state': 'Florida', 'zip': '32224', 'country': 'United States', 'contacts': [{'name': 'Alex Burch', 'role': 'CONTACT', 'phone': '904-953-4724', 'email': 'burch.alexander@mayo.edu'}], 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000012598', 'term': 'Sclerosis'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}], 'browseLeaves': [{'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT04885374', 'orgStudyIdInfo': {'id': 'ALS-2021-CARE-TCM'}, 'organization': {'fullName': 'Dongzhimen Hospital, Beijing', 'class': 'OTHER'}, 'briefTitle': 'China Amyotrophic Lateral Sclerosis Registry of Patients With Traditional Chinese Medicine', 'officialTitle': 'China Amyotrophic Lateral Sclerosis Registry of Patients With Traditional Chinese Medicine', 'acronym': 'CARE-TCM'}, 'statusModule': {'statusVerifiedDate': '2021-05', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-03-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-05-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2028-03-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2021-05-08', 'studyFirstSubmitQcDate': '2021-05-08', 'studyFirstPostDateStruct': {'date': '2021-05-13', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-05-08', 'lastUpdatePostDateStruct': {'date': '2021-05-13', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Ying Gao', 'investigatorTitle': 'MD, PhD, Professor', 'investigatorAffiliation': 'Dongzhimen Hospital, Beijing'}, 'leadSponsor': {'name': 'Dongzhimen Hospital, Beijing', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'A multi-center registration study of clinical characteristics of amyotrophic lateral sclerosis (ALS) patients with traditional Chinese medicine (TCM).', 'detailedDescription': \"The CARE-TCM is a prospective, multi-center, patient registry study. Eligible ALS patients with TCM treatments will be enrolled in the registry. After enrollment, this research collects the individual characteristics of patients' status. Longitudinal follow-up data are collected from both patients (primary caregivers) and their treating neurologists every 3 months for 5 years. The aims of the CARE-TCM are to: 1) explore the general characteristics of ALS patients with TCM and; 2) assess the effectiveness and safety of various TCMs on ALS based on nationwide registry outcome collecting process.\"}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': True, 'targetDuration': '5 Years', 'designInfo': {'observationalModel': 'OTHER', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 2000, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Amyotrophic lateral sclerosis patients', 'description': 'Amyotrophic lateral sclerosis patients with traditional Chinese medicine'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Effective Survival', 'description': 'The time from disease onset to death, tracheostomy, or permanent assisted ventilation', 'timeFrame': 'Through study completion, an average of 3 months'}], 'secondaryOutcomes': [{'measure': 'Overall Survival', 'description': 'Death owing to any causes', 'timeFrame': 'Through study completion, an average of 3 months'}, {'measure': 'Rate of Disease Progression', 'description': '(48-total ALSFRS-R)/symptom duration (months)', 'timeFrame': 'Through study completion, an average of 3 months'}, {'measure': 'Rate of Forced Vital Capacity (FVC) Decline', 'description': 'The slope of decline of forced vital capacity (FVC) to assess the respiratory function.', 'timeFrame': 'through study completion, an average of 3 months'}, {'measure': 'Rate of Body Mass Index (BMI) Decline', 'description': 'The slope of decline of body mass index (BMI) to assess the disease progression.', 'timeFrame': 'Through study completion, an average of 3 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Patients aged 18 years and older.\\n* Patients with possible, laboratory supported probable, probable, or definite ALS according to the revised El Escorial criteria.\\n* ALS patients treated with traditional Chinese medicine.\\n\\nExclusion Criteria:\\n\\n* Patients who refuse informed consent.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Patients who meet the criteria will be enrolled from multi-centers in China.', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Ying Gao, MD, PhD', 'role': 'CONTACT', 'phone': '+86-10-84013209', 'email': 'gaoying973@126.com'}], 'overallOfficials': [{'name': 'Ying Gao, MD, PhD', 'affiliation': 'Dongzhimen Hospital, Beijing University of Chinese Medicine', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Dongzhimen Hospital, Beijing University of Chinese Medicine', 'status': 'RECRUITING', 'city': 'Beijing', 'zip': '100700', 'country': 'China', 'contacts': [{'name': 'Ying Gao, MD, PhD', 'role': 'CONTACT', 'phone': '+86-10-84013209', 'email': 'gaoying973@126.com'}], 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}]}, 'referencesModule': {'references': [{'pmid': '34699945', 'type': 'DERIVED', 'citation': 'Song Y, Li M, Sugimoto K, Han Y, Liu J, Ma B, Song H, Zhang C, Gao Y; CARE-TCM Group. China amyotrophic lateral sclerosis registry of patients with Traditional Chinese Medicine (CARE-TCM): Rationale and design. J Ethnopharmacol. 2022 Feb 10;284:114774. doi: 10.1016/j.jep.2021.114774. Epub 2021 Oct 23.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000012598', 'term': 'Sclerosis'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}], 'browseLeaves': [{'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05716074', 'orgStudyIdInfo': {'id': 'E-74555795-050.01.04-531483'}, 'organization': {'fullName': 'Istanbul University - Cerrahpasa (IUC)', 'class': 'OTHER'}, 'briefTitle': 'The Effect of Low-İntensity Combined Exercises in Patients With Early Stage ALS.', 'officialTitle': 'The Effect of Low-İntensity Combined Exercises on Fatigue, Balance and Quality of Life in Patients With Early Stage ALS'}, 'statusModule': {'statusVerifiedDate': '2023-01', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-11-15', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-06', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2023-06', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-01-29', 'studyFirstSubmitQcDate': '2023-01-29', 'studyFirstPostDateStruct': {'date': '2023-02-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-01-29', 'lastUpdatePostDateStruct': {'date': '2023-02-08', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Xhennet Muriqi', 'investigatorTitle': 'Researcher', 'investigatorAffiliation': 'Istanbul University - Cerrahpasa (IUC)'}, 'leadSponsor': {'name': 'Istanbul University - Cerrahpasa (IUC)', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The aim of this study is to investigate the effects of low-intensity combined exercises on balance, fatigue and quality of life applied to patients with ALS.', 'detailedDescription': 'Balance problems and signs of fatigue are seen in early-stage ALS patients. While balance problems lead to falls in ALS patients, fatigue also affects a part of their lives. Studies investigating the effects of low-intensity exercise on fatigue, balance, and quality of life in patients with early-stage ALS are rare. This study will investigate the effects of low-intensity combined exercises on balance, fatigue and quality of life in patients with ALS.\\n\\nParticipants will be randomly divided into Supervised and Home groups. Low-intensity exercises will be applied to the home exercise group as a home program for 1 hour a day, 3 days a week, for 6 weeks. Low-intensity exercises will be applied to the supervised exercise group for 1 hour a day, 3 days a week for 6 weeks, accompanied by a physiotherapist. Evaluations will be made at the beginning and at the end of the treatment.\\n\\nBerg Balance Scale, Fatigue Severity Scale (FSS), Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) and revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) will be used to evaluate patients before and 6 weeks after treatment.'}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis'], 'keywords': ['Amyotrophic lateral sclerosis', 'balance', 'fatigue', 'quality of life']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Supervised-exercise group', 'type': 'EXPERIMENTAL', 'description': 'This group will be given combined low-intensity exercises under the supervision of a physiotherapist.', 'interventionNames': ['Other: Supervised exercise']}, {'label': 'Home-exercise group', 'type': 'EXPERIMENTAL', 'description': 'This group will exercise at home without the supervision of a physiotherapist.', 'interventionNames': ['Other: Home exercise']}], 'interventions': [{'type': 'OTHER', 'name': 'Supervised exercise', 'description': 'The supervised group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks.', 'armGroupLabels': ['Supervised-exercise group']}, {'type': 'OTHER', 'name': 'Home exercise', 'description': 'The home group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks in the home.', 'armGroupLabels': ['Home-exercise group']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The fatigue severity scale (FSS)', 'description': 'FSS is a self-report scale of nine items examining motivation, physical function, responsibilities, work, family or social life, exercise, fatigue, frequency of problems, and priority of symptoms.', 'timeFrame': 'Baseline, (one week before intervention)'}, {'measure': 'The fatigue severity scale (FSS)', 'description': 'FSS is a self-report scale of nine items examining motivation, physical function, responsibilities, work, family or social life, exercise, fatigue, frequency of problems, and priority of symptoms.', 'timeFrame': 'Post-intervention (7th week)'}], 'secondaryOutcomes': [{'measure': 'Berg Balance Scale (BBS)', 'description': \"The Berg Balance Scale (BBS) is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks.\", 'timeFrame': 'Baseline, (one week before intervention)'}, {'measure': 'Berg Balance Scale (BBS)', 'description': \"The Berg Balance Scale (BBS) is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks.\", 'timeFrame': 'Post-intervention (7th week)'}, {'measure': 'Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40)', 'description': 'The ALSAQ-40 provides scores for 5 scales: physical mobility, activities of daily living and independence, eating and drinking, communication, and emotional reactions.', 'timeFrame': 'Baseline, (one week before intervention)'}, {'measure': 'Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40)', 'description': 'The ALSAQ-40 provides scores for 5 scales: physical mobility, activities of daily living and independence, eating and drinking, communication, and emotional reactions.', 'timeFrame': 'Post-intervention (7th week)'}, {'measure': 'ALS Functional Rating Scale Revised (ALSFRS-R)', 'description': 'ALSFRS-R measures activities of daily living (ADL) and global function for patients with Amyotrophic Lateral Sclerosis.', 'timeFrame': 'Baseline, (one week before intervention)'}, {'measure': 'ALS Functional Rating Scale Revised (ALSFRS-R)', 'description': 'ALSFRS-R measures activities of daily living (ADL) and global function for patients with Amyotrophic Lateral Sclerosis.', 'timeFrame': 'Post-intervention (7th week)'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Being diagnosed with early-stage ALS by a neurologist\\n* Disease duration in the range of 1-18 months\\n* ALSFRS-R score \\\\> 24 higher\\n* Without infectious disease\\n* Saturation \\\\>95\\n* Heart rate \\\\<92\\n\\nExclusion Criteria:\\n\\n* History of other neurological disease\\n* Inability to walk\\n* With mechanical ventilation\\n* People with Heart and Respiratory Insufficiency\\n* People with neuropsychological or cognitive impairment\\n* Dyspnea after ALS', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '30 Years', 'maximumAge': '65 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Professor Ela Tarakci, PHD', 'role': 'CONTACT', 'phone': '+905422175730', 'email': 'etarakci@iuc.edu.tr'}, {'name': 'Xhennet Muriqi', 'role': 'CONTACT', 'phone': '+905314856657', 'email': 'xhennet.muriqi@ogr.iuc.edu.tr'}], 'overallOfficials': [{'name': 'Professor Ela Tarakci', 'affiliation': 'Istanbul University - Cerrahpasa (IUC)', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Istanbul University-Cerrahpasa', 'status': 'RECRUITING', 'city': 'Istanbul', 'state': 'Bakirkoy', 'zip': '34000', 'country': 'Turkey', 'contacts': [{'name': 'Prof Ela Tarakci', 'role': 'CONTACT', 'phone': '+905422175730', 'email': 'etarakci@iuc.edu.tr'}, {'name': 'Xhennet Muriqi', 'role': 'CONTACT', 'phone': '+905314856657', 'email': 'xhennet.muriqi@ogr.iuc.edu.tr'}], 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000012598', 'term': 'Sclerosis'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}], 'browseLeaves': [{'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M8364', 'name': 'Fatigue', 'relevance': 'LOW'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T6034', 'name': 'Quality of Life', 'relevance': 'LOW'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}, {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05819931', 'orgStudyIdInfo': {'id': 'RC31/22/0411'}, 'organization': {'fullName': 'University Hospital, Toulouse', 'class': 'OTHER'}, 'briefTitle': 'Breathing With Amyotrophic Lateral Sclerosis', 'officialTitle': 'Evaluation of the Effect of Respiratory Physiotherapy by Mechanical In-exsufflator on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis: A Pilot Study', 'acronym': '2SLA'}, 'statusModule': {'statusVerifiedDate': '2023-09', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-08-29', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-04-06', 'studyFirstSubmitQcDate': '2023-04-06', 'studyFirstPostDateStruct': {'date': '2023-04-19', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-09-04', 'lastUpdatePostDateStruct': {'date': '2023-09-07', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'University Hospital, Toulouse', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The study aims to evaluate the effect of mechanical insufflator-exsufflator on the respiratory functions of Amyotrophic Lateral Sclerosis (ALS) patients evaluated via peak expiratory flow on cough (PEFC) measurements. The evolution of their PEFC is monitored to see if the curative management can have a positive impact on the latter.', 'detailedDescription': 'Amyotrophic Lateral Sclerosis (ALS) is a rare neurodegenerative pathology without curative treatment at present, the outcome is fatal after 3 to 5 years of evolution on average. The disease results in progressive paralysis of the muscles involved in voluntary motricity (progressive and intricate impairment of locomotor, phonation and swallowing capacities as well as ventilatory function). In France, the management of ALS is based on a diversified multidisciplinary follow-up (physiotherapy, speech therapy, occupational therapy, neuropsychology) in the ALS Reference Center in conjunction with the city care networks. It is centered on the evaluation, and the early compensation of the various symptoms, especially the respiratory problems.\\n\\nThus, this study aims to evaluate the effect of mechanical insufflator-exsufflator on the respiratory functions of these patients, evaluated via cough peak expiratory flow measurements (CPEF).\\n\\nThe study is conducted in collaboration with the physiotherapists of each patient enrolled, to evaluate the respiratory function by peak expiratory flow on cough (PEFC) after 4 weeks of treatment with Mechanical In-Exsufflator (MIE) (3 weekly sessions for two weeks, then one daily session for 2 weeks) in ALS patients presenting with a poorly effective cough (PEFC between 160 and 255 L/min) and having an indication of punctual MIE.'}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis'], 'keywords': ['Mechanical In-Exsufflator', 'Physiotherapy', 'Cough', 'peak expiratory flow on cough']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SEQUENTIAL', 'interventionModelDescription': 'before-after comparison of the treatment', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 36, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Mechanical In-Exsufflator treatment', 'type': 'EXPERIMENTAL', 'interventionNames': ['Device: Mechanical In-Exsufflator treatment']}], 'interventions': [{'type': 'DEVICE', 'name': 'Mechanical In-Exsufflator treatment', 'description': 'The Mechanical In-Exsufflator (MIE) is a device that alternately inhales and exhales air and amplifies the respiratory cycles in flow and pressure. 15 breathing cycles (about 3 minutes) are recommended each day.\\n\\nPatients will practice the MIE daily independently and/or carried out by his physiotherapist (PT) during PT sessions.\\n\\nThe MIE is prescribed by the neurologist or pulmonologist and is covered by social security in France. It is gifted by an external service provider.\\n\\nThe Peak-Flow Cough is considered as the standardized score retaining the best of 3 consecutive measurements by Peak-Flow, a small portable device for personal use, which measures the maximum expiratory flow reached by the patient at the moment when the breath is most powerful.\\n\\nThe patient is his own control. At baseline, the patient will be treated as usual. He will be asked to read the Peak-Flow Cough measures. The PT will also perform the Peak flow measurement at each patient visit.', 'armGroupLabels': ['Mechanical In-Exsufflator treatment']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'cough peak expiratory flow evolution', 'description': 'evolution of respiratory function by peak expiratory flow on cough (PEFC) after 4 weeks of treatment with Mechanical In-Exsufflator (3 weekly sessions for two weeks then one daily session for 2 weeks) in ALS patients presenting with a poorly effective cough (Cough Peak Expiratory Flow between 160 and 255) and having an indication of punctual MIE.\\n\\nRatio between the PEFC 4 weeks post treatment initiation and PEFC at baseline can show decrease in respiratory function if \\\\<1 ; increase in respiratory functions if \\\\>1 and a conservation of respiratory function if = 1.\\n\\nA PEFC remaining within 10% of its initial value (rounded to the nearest ten) is considered unmodified', 'timeFrame': '4 weeks post treatment initiation'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Confirmed ALS categorized as probable or certain according to the revised Awaji-Shima criteria \\\\[27\\\\].\\n* ALS of spinal, bulbar or respiratory forms\\n* Peak Flow measure between 160 and 255 L/min (recommendation of MIE in case of congestion, with the possibility of daily sessions)\\n* Patient who has not benefited from treatment by MIE in the past year (less than 10 sessions in total)\\n* Patient able to use the MIE and perform the collection, or having a caregiver able to help\\n* Patient receiving physiotherapist treatment greater than or equal to twice a week\\n\\nExclusion Criteria:\\n\\n* Psychiatric (DSM-5) or cognitive disorders incompatible with participation in the study\\n* Contraindication to the use of an MIE (pneumothorax for example)\\n* Insufficient level in French for understanding the study and completing the questionnaires\\n* Current or past participation in another innovative research or care program relating to respiratory functions\\n* Emergency situation for which the MIE must be set up within less than a week\\n\\nExclusion during the study :\\n\\n* Appearance of a serious contraindication to the practice of MIE during the study (for example rib fracture during a fall)\\n* Patient's physiotherapist refusing to do the study\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '100 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Thierry LAGARDE, PT', 'role': 'CONTACT', 'phone': '+33561775570', 'email': 'lagarde.t@chu-toulouse.fr'}, {'name': 'Floriane LLORENS', 'role': 'CONTACT', 'email': 'llorens.fl@chu-toulouse.fr'}], 'overallOfficials': [{'name': 'Thierry Lagarde', 'affiliation': 'University Hospital, Toulouse', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'SLA Center - Purpan University Hospital Toulouse, FRANCE', 'status': 'RECRUITING', 'city': 'Toulouse', 'state': 'Occitanie', 'zip': '31000', 'country': 'France', 'contacts': [{'name': 'Floriane LLORENS', 'role': 'CONTACT', 'email': 'llorens.fl@chu-toulouse.fr'}], 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000012598', 'term': 'Sclerosis'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}], 'browseLeaves': [{'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M27137', 'name': 'Respiratory Aspiration', 'relevance': 'LOW'}, {'id': 'M6590', 'name': 'Cough', 'relevance': 'LOW'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT06325865', 'orgStudyIdInfo': {'id': '23C305'}, 'organization': {'fullName': 'Istituto Auxologico Italiano', 'class': 'OTHER'}, 'briefTitle': 'Perception of Unpleasant Sensations During Study Procedures in ALS Patients', 'officialTitle': 'Perception of Unpleasant Sensations in Patients With Amyotrophic Lateral Sclerosis During Procedures Performed in Clinical Trials', 'acronym': 'PESALS'}, 'statusModule': {'statusVerifiedDate': '2024-03', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-04-19', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-11', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2024-12', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-03-16', 'studyFirstSubmitQcDate': '2024-03-16', 'studyFirstPostDateStruct': {'date': '2024-03-22', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-03-16', 'lastUpdatePostDateStruct': {'date': '2024-03-22', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Istituto Auxologico Italiano', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': \"Diagnosis of Amyotrophic Lateral Sclerosis (ALS) is considered a traumatic life event for both the patient and their next-of-kin/carers, due to the lack of treatment. Clinical Trials can offer pioneering treatment to reduce the impact of the disease and improve future treatments worldwide. Research protocols may involve routine diagnostic and/or therapeutic procedures which the patients may be already aware of and, therefore, expecting specific sensations. These could compromise participation or drop-out rate. Despite everything, participation in a clinical trial can guarantee continuity of care also thanks to the execution of these same procedures, through preferential access compared to other patients.\\n\\nAim of this study is to investigate the unpleasant sensations perceived by ALS patients during procedures in clinical trials. Analysing what type of pain/discomfort frightens patients during diagnostic and/or therapeutic procedures, including the different methods of administration of the study drug. Provide data to implement effective therapy and offer constant patients support throughout ALS specific and needed procedures. Evaluate if this support could influence adherence rate of ALS patients to conduct clinical trials as required. Provide information for future studies to create an ALS Clinical Trials multiple-retention-factors adherence scale. Create and implement an ALS-specific pain scale accounting for its impact on daily activities, aiding an interdisciplinary approach of pain management. Identify the best pain management strategies and compliance techniques to address ALS, not merely in clinical trials. Provide the best individualized care for ALS patients improving their quality of life and mental state.\\n\\nThis is a descriptive phenomenological study and data will be analyzed according to Sundler's method. Based on the experience of the researchers and the recommendations proposed by Sandelowski, a total of 20 interviews are estimated in order to reach the theoretical saturation per category of reference. Data collection will be carried out through in-depth semi-structured interviews recorded (13 open-ended questions after the execution of the procedures).\"}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis'], 'keywords': ['Study procedures']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'CROSS_SECTIONAL'}, 'enrollmentInfo': {'count': 20, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'interventions': [{'type': 'OTHER', 'name': 'Interview', 'description': 'Interview with ALS patient in which the experiences of unpleasant sensations or pain during study procedures are assessed in a qualitative manner.'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Prevalence of experience of unpleasant sensations or pain', 'description': 'Prevalence of reported experience of unpleasant sensations orn pain during study procedures', 'timeFrame': 'At enrollment'}, {'measure': 'Study procedure that causes unpleasant sensations or pain', 'description': 'Qualitative description of study procedure that causes unpleasant sensations or pain', 'timeFrame': 'At enrollment'}, {'measure': 'Duration of unpleasant sensations or pain caused by the study procedure', 'description': 'Duration in minutes of unpleasant sensations or pain caused by the study procedure', 'timeFrame': 'At enrollment'}], 'secondaryOutcomes': [{'measure': 'HADS score', 'description': 'Score on Hospital Anxiety and Depression Scale (HADS) scale', 'timeFrame': 'At enrollment'}, {'measure': 'ALSFRS score', 'description': 'Score on Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) scale', 'timeFrame': 'At enrollment'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Spinal or bulbar Amyotrophic Lateral Sclerosis (ALS)\\n* Age \\\\> 18 years\\n* Adequate understanding of Italian language\\n* Full understanding of the study\\n* Informed consent signed\\n* Current or past participation in interventional clinical studies\\n* Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) score of item # 4 ≥ 2, or score of item #1 ≥ 1\\n\\nExclusion Criteria:\\n\\n* Clinically relevant cognitive dysfunction\\n* Inability to answer orally or by writing to the questions of the interview\\n* Hospital Anxiety and Depression Scale (HADS) scale ≥ 11', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Amyotrophic Lateral Sclerosis (ALS) patients who are currently participating in interventional clinical studies or who have particpated in the recent past.', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Martina Sodano', 'role': 'CONTACT', 'phone': '+3902619111', 'phoneExt': '2937', 'email': 'm.sodano@auxologico.it'}], 'locations': [{'facility': 'Istituto Auxologico italiano IRCSS, San Luca Hospital', 'status': 'RECRUITING', 'city': 'Milano', 'zip': '20145', 'country': 'Italy', 'contacts': [{'name': 'Martina Sodano', 'role': 'CONTACT', 'phone': '+39-02619111', 'phoneExt': '2937', 'email': 'm.sodano@auxologico.it'}], 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000012598', 'term': 'Sclerosis'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}], 'browseLeaves': [{'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT02916966', 'orgStudyIdInfo': {'id': 'D06019'}, 'organization': {'fullName': 'Dartmouth-Hitchcock Medical Center', 'class': 'OTHER'}, 'briefTitle': 'Environmental Exposure and Neurological Diseases Questionnaire', 'officialTitle': 'Case-control and Population Questionnaire Studying Environmental Risk Factors and Neurological Diseases'}, 'statusModule': {'statusVerifiedDate': '2023-09', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2016-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-12', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-12', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2016-09-26', 'studyFirstSubmitQcDate': '2016-09-27', 'studyFirstPostDateStruct': {'date': '2016-09-28', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2023-09-05', 'lastUpdatePostDateStruct': {'date': '2023-09-06', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Elijah W. Stommel', 'investigatorTitle': 'Professor of Neurology', 'investigatorAffiliation': 'Dartmouth-Hitchcock Medical Center'}, 'leadSponsor': {'name': 'Dartmouth-Hitchcock Medical Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'The Cleveland Clinic', 'class': 'OTHER'}]}, 'descriptionModule': {'briefSummary': 'The proposed research is particularly relevant to the National ALS Registry and public environmental health issues because it addresses the potential environmental causes of sporadic ALS. The research will develop an ALS surveillance program in Ohio that can be compared with the national and State-Metro Surveillance Programs of the National ALS Registry, and novel methodologies to determine the role of the cyanobacterial toxin, BMAA (beta-methylamino-L-alanine), and other environmental toxins/toxicants as risk factors for ALS. This work will advance the mission of the Centers for Disease Control Agency for Toxic Substances and Disease Registry (CDC ATSDR) National ALS Registry by offering data on ALS cases in Ohio that address public health concerns over the effects of chronic exposure to cyanobacterial blooms in Lake Erie.'}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 2000, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'ALS Patients in Case-Control', 'description': 'ALS patients enrolled by Cleveland Clinic Foundation (CCF)', 'interventionNames': ['Other: Patient Registry']}, {'label': 'Non-neurodegenerative patients in case control', 'description': 'Non-neurodegenerative patients enrolled by CCF', 'interventionNames': ['Other: Patient Registry']}, {'label': 'Non-neurodegeneration population in population control', 'description': 'Non-neurodegenerative general population enrolled by ABS mailing system from DHMC', 'interventionNames': ['Other: Patient Registry']}, {'label': 'ALS Patients in State of OH', 'description': 'ALS registry of all cases in Ohio', 'interventionNames': ['Other: Patient Registry']}], 'interventions': [{'type': 'OTHER', 'name': 'Patient Registry', 'description': 'Patient Registry', 'armGroupLabels': ['ALS Patients in Case-Control', 'ALS Patients in State of OH', 'Non-neurodegeneration population in population control', 'Non-neurodegenerative patients in case control']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Questionnaire for Environmental Exposures, Toxins, and Neurological Disease', 'timeFrame': '1 year'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* ALS\\n* Non-neurodegenerative controls\\n* Can willingly give consent\\n* Over 18 years of age\\n\\nExclusion Criteria:\\n\\n* Cannot give consent\\n* Under 18 years of age', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '80 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': '1. ALS patients in case-control at CCF\\n2. Non-neurodegenerative patients in case control at CCF\\n3. Non-neurodegenerative general population in Ohio\\n4. ALS patient registry in Ohio', 'samplingMethod': 'PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Elijah W Stommel, MD, PhD', 'role': 'CONTACT', 'phone': '866-894-8131', 'email': 'neuroresearch@hitchcock.org'}, {'name': 'Kathleen Sullivan', 'role': 'CONTACT', 'phone': '(603) 650-6496', 'email': 'neuroresearch@hitchcock.org'}], 'locations': [{'facility': 'Cleveland Clinic Foundation', 'status': 'RECRUITING', 'city': 'Cleveland', 'state': 'Ohio', 'zip': '44195', 'country': 'United States', 'contacts': [{'name': 'Erik Pioro, MD, PhD', 'role': 'CONTACT'}], 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}], 'ancestors': [{'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}], 'browseLeaves': [{'id': 'M15415', 'name': 'Sclerosis', 'relevance': 'LOW'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05340660', 'orgStudyIdInfo': {'id': 'BASEC Nr. 2021-01044'}, 'organization': {'fullName': 'Cantonal Hospital of St. Gallen', 'class': 'OTHER'}, 'briefTitle': 'mGluR5 Imaging in ALS Using PET', 'officialTitle': 'Metabotropic Glutamate Receptor 5 Imaging in Amyotrophic Lateral Sclerosis Using Positron Emission Tomography'}, 'statusModule': {'statusVerifiedDate': '2022-04', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-04', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2022-10', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-04', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-03-29', 'studyFirstSubmitQcDate': '2022-04-19', 'studyFirstPostDateStruct': {'date': '2022-04-22', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-04-19', 'lastUpdatePostDateStruct': {'date': '2022-04-22', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorFullName': 'Nathalie Braun', 'investigatorTitle': 'Principal Investigator', 'investigatorAffiliation': 'Cantonal Hospital of St. Gallen'}, 'leadSponsor': {'name': 'Nathalie Braun', 'class': 'OTHER'}, 'collaborators': [{'name': 'University of Zurich', 'class': 'OTHER'}, {'name': 'ETH Zurich', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'In ALS models, it was shown that receptors, that bind an important messenger substance (glutamate) in the brain, are increased. In this research project, the investigators want to use a specific radioactive substance to find out whether these receptors are more detectable in people with ALS than in healthy people and increase over the course of the disease.', 'detailedDescription': 'With this study, the investigators want to examine whether receptors (docking points on the surface of a nerve cell) that bind an important messenger substance in the brain (glutamate) are increased in patients with amyotrophic lateral sclerosis (ALS) as the disease progresses. Based on observations from ALS models, the investigators suspect that this increase in receptors contributes to the damage to the nerve cells in ALS.\\n\\nTo image these receptors, the investigators use a specific radioactive substance and imaging combining positron emission tomography (PET), magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI) of the brain and spinal cord.\\n\\nThe investigators will examine healthy people and ALS patients. The reason is that little is known about the receptor, even in healthy people. The investigators also do not know if and when the receptor is increasingly detectable in the course of the ALS disease. Only by comparing diseased and healthy people it can be determined if and when the receptor is built up in ALS patients. The investigators also hope to gain more information, e.g. about the distribution of receptors in the brain of healthy people compared to patients.'}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis'], 'keywords': ['Receptor, Metabotropic Glutamate 5', 'Brain / diagnostic imaging', 'Positron-Emission Tomography / methods', 'Radiopharmaceuticals / pharmacokinetics*', 'PSS232', 'Humans', 'Adult']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'ALS Patient', 'type': 'EXPERIMENTAL', 'interventionNames': ['Radiation: [ 18 F]PSS232']}], 'interventions': [{'type': 'RADIATION', 'name': '[ 18 F]PSS232', 'description': '\\\\[ 18 F\\\\]PSS232 for imaging metabotropic glutamate receptor subtype 5 and comparing expression of the receptor in healthy persons and ALS patients', 'armGroupLabels': ['ALS Patient']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change from baseline in [18F]PSS232 uptake in the brain and spinal cord in ALS patients at 6 months', 'description': 'Difference of \\\\[18F\\\\]PSS232 uptake in the brain and spinal cord of ALS patients at baseline and day 180, as assessed by PET and MRI to allow morphological mapping.', 'timeFrame': 'Baseline and 6 months'}], 'secondaryOutcomes': [{'measure': 'Difference of [18F]PSS232 uptake in the brain and spinal cord between ALS patients and healthy, age and gender-matched subjects.', 'description': 'Difference of \\\\[18F\\\\]PSS232 uptake in the brain and spinal cord of ALS patients and healthy subjects at baseline and day 180, as assessed by PET and MRI to allow morphological mapping', 'timeFrame': '6 months'}, {'measure': 'Correlation of change from baseline of [18F]PSS232 uptake with change from baseline of ALSFRS-R Score at day 180', 'description': 'Change from baseline to day 180 in \\\\[18F\\\\]PSS232 uptake in the brain and spinal cord in ALS patients will be correlated to change from baseline to 180d in the ALS Functional Rating Scale (ALSFRS-R), evaluating bulbar, respiratory, upper limb and lower limb function with a total score of 48 (minimal value 0, maximal value 48, higher scores mean a better outcome).', 'timeFrame': '6 months'}, {'measure': 'Correlation of change from baseline of [18F]PSS232 uptake with change from baseline of respiratory function, as measuerd by slow vital capacity (sVC) and sniff nasal inspiratory pressure (SNIP) at day 180', 'description': 'Change from baseline to day 180 in \\\\[18F\\\\]PSS232 uptake in the brain and spinal cord in ALS patients will be correlated to change from baseline to 180d in respiratory function, as measured by slow vital capacity (sVC) and sniff nasal inspiratory pressure (SNIP).', 'timeFrame': '6 months'}, {'measure': 'Correlation of change from baseline of [18F]PSS232 uptake with change from baseline of ECAS at day 180', 'description': 'Change from baseline to day 180 in \\\\[18F\\\\]PSS232 uptake in the brain and spinal cord in ALS patients will be correlated to change from baseline to 180d in cognitive and behavioral function, as assessed by Edinburgh cognitive and behavioral ALS Screen (ECAS, minimal value 0, maximal value 136, higher scores mean a better outcome).', 'timeFrame': '6 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Clinically probable, probable laboratory supported, or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria (EEC) (45)\\n* Disease duration ≤18 months\\n* Pre-study ALSFRS-R progression between disease onset and screening of - 0.4 points/month or worse (calculated by ALSFRS -R total score decline form 48 divided by the months since onset of ALS symptoms)\\n* Upright slow vital capacity (sVC) ≥65 % of normal (best of three measurements)\\n\\nExclusion Criteria :\\n\\n* Previous participation in another clinical study involving trial medication within the preceding 12 weeks\\n* History or presence of significant psychiatric disease, such as depression, evaluated with the ALS depression questionnaire (ADI-12) ≥ 23 (43) since depression has an impact on mGluR5 expression (44)\\n* Use of tobacco, including cigarettes, smokeless tobacco, cigars, and pipes; Ex- smoker having quit smoking ≥ 2 years', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Nathalie Braun, MD, PhD', 'role': 'CONTACT', 'phone': '+41 71 494 35 81', 'email': 'nathalie.braun@kssg.ch'}, {'name': 'Zylfije Dibrani', 'role': 'CONTACT', 'phone': '+41 71 494 35 81', 'email': 'Zylfije.Dibrani@kssg.ch'}], 'overallOfficials': [{'name': 'Nathalie Braun, MD, PhD', 'affiliation': 'Neuromuscular Center/ALS Clinic, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Neuromuscular Center/ALS Clinic, Cantonal Hospital St. Gallen', 'status': 'RECRUITING', 'city': 'St. Gallen', 'zip': '9007', 'country': 'Switzerland', 'contacts': [{'name': 'Nathalie Braun, MD, PhD', 'role': 'CONTACT', 'phone': '+41714943581', 'email': 'nathalie.braun@kssg.ch'}, {'name': 'Zylifije Dibrani', 'role': 'CONTACT', 'phone': '+41714943581', 'email': 'zylfije.dibrani@kssg.ch'}, {'name': 'Nathalie Braun, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 47.42391, 'lon': 9.37477}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000012598', 'term': 'Sclerosis'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}], 'browseLeaves': [{'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M21258', 'name': 'Radiopharmaceuticals', 'relevance': 'LOW'}, {'id': 'T5', 'name': 'Glutamic Acid', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'AA', 'name': 'Amino Acids'}]}}, 'hasResults': False}], 'nextPageToken': 'NF0g5JGDkvAryQ'}\n"
     ]
    }
   ],
   "source": [
    "\n",
    "\n",
    "def fetch_studies(query):\n",
    "    url = \"https://clinicaltrials.gov/api/v2/studies\"\n",
    "    headers = {\n",
    "        \"accept\": \"application/json\"\n",
    "    }\n",
    "    params = {\n",
    "        \"query.cond\": query,\n",
    "        \"filter.overallStatus\": \"RECRUITING|ENROLLING_BY_INVITATION|AVAILABLE\"\n",
    "    }\n",
    "    response = requests.get(url, headers=headers, params=params)\n",
    "    if response.status_code == 200:\n",
    "        return response.json()  # Return the JSON response if successful\n",
    "    else:\n",
    "        return response.status_code  # Return the HTTP status code if not successful\n",
    "\n",
    "\n",
    "\n",
    "query = \"Amyotrophic Lateral Sclerosis\"\n",
    "result = fetch_studies(query)\n",
    "print(len(result['studies']))\n",
    "print(result)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "10\n",
      "[{'protocolSection': {'identificationModule': {'nctId': 'NCT05933057', 'orgStudyIdInfo': {'id': 'DSC/14/2357/50'}, 'secondaryIdInfos': [{'id': '2023-503521-19', 'type': 'EUDRACT_NUMBER'}, {'id': 'U1111-1295-1799', 'type': 'OTHER', 'domain': 'Universal Trial Number (UTN)'}, {'id': '1008441', 'type': 'OTHER', 'domain': 'IRAS ID'}, {'id': '277453', 'type': 'OTHER', 'domain': 'Health Canada'}], 'organization': {'fullName': 'Italfarmaco', 'class': 'INDUSTRY'}, 'briefTitle': 'Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy', 'officialTitle': 'Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy', 'acronym': 'ULYSSES'}, 'statusModule': {'statusVerifiedDate': '2024-02', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-02-19', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2028-02', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2028-02', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-06-16', 'studyFirstSubmitQcDate': '2023-06-27', 'studyFirstPostDateStruct': {'date': '2023-07-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-20', 'lastUpdatePostDateStruct': {'date': '2024-02-22', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Italfarmaco', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'This is a randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy, safety, and tolerability of givinostat in non-ambulant male paediatric (aged 9 to \\\\<18 years) patients with DMD. 138 patients will be randomised 2:1 to givinostat or placebo and will be treated for 18 months.\\n\\n* Planned screening duration: approximately 4 weeks (±14 days)\\n* Planned treatment duration: 18 months (approximately 72 weeks)\\n* Planned follow-up duration: 4 weeks (±7 days) (for patients not participating in the long-term safety study)\\n* Total duration of study participation: up to 83 weeks (ie, 20-21 months)', 'detailedDescription': \"Duchenne muscular dystrophy is a rare, progressive, debilitating and life-threatening condition for which there is a critical need for novel therapies that are effective and well-tolerated in all DMD patients. Steroids are generally recognised as the standard of care in the general DMD population; however, they are not suitable for all patients.\\n\\nGivinostat, a HDAC inhibitor, was developed for the treatment of DMD based on: (i) the role that increased HDAC activity is thought to exert in contributing to DMD pathogenesis; and (ii) givinostat's ability to counter the pathophysiological and degenerative mechanisms causing muscle insufficiency in boys with DMD.\\n\\nThis study will evaluate the efficacy, safety, and tolerability of givinostat in non-ambulant patients to further corroborate data from the completed phase 3 pivotal study of givinostat in ambulant patients with DMD (ie, Study DSC/14/2357/48, NCT02851797). Primary Objective of the study is to demonstrate the efficacy of givinostat in reducing muscle decline in non-ambulant DMD patients, as measured by Performance of the Upper Limb (PUL) 2.0. Secondary Objectives of the study are to evaluate the safety and tolerability of givinostat in non-ambulant DMD patients, and to further explore the efficacy of givinostat in non-ambulant DMD patients.\\n\\nA total of 138 patients are planned for enrolment. Patients will be randomised 2:1 to givinostat or placebo and will be treated for 18 months.\\n\\nThe study will be comprised of:\\n\\n* A screening period, during which eligibility will be confirmed within 4 weeks (±14 days)\\n* A baseline visit, during which randomisation will be performed\\n* A double-blind treatment period, during which patients will receive either givinostat or placebo for 18 months (approximately 72 weeks)\\n* An end of study visit, occurring at Week 72 (±7 days) at the end of the treatment period. At the end of study visit, all the patients (regardless of treatment arm) will be offered enrolment in the long-term safety study DSC/14/2357/51 (NCT03373968) during which they will receive givinostat.\\n* A follow-up visit, for those patients not consenting to participation in the long-term safety study, that will occur 4 weeks after the end of study visit (ie, Week 76 ±7 days).\"}, 'conditionsModule': {'conditions': ['Duchenne Muscular Dystrophy'], 'keywords': ['Duchenne Muscular Dystrophy', 'givinostat']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 138, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Givinostat', 'type': 'EXPERIMENTAL', 'description': 'Patients will receive concomitant corticosteroid treatment as part of the standard of care.', 'interventionNames': ['Drug: Givinostat']}, {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Patients will receive concomitant corticosteroid treatment as part of the standard of care.', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'Givinostat', 'description': 'Givinostat has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.', 'armGroupLabels': ['Givinostat'], 'otherNames': ['ITF2357']}, {'type': 'DRUG', 'name': 'Placebo', 'description': 'Placebo, manufactured to mimic givinostat, has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.', 'armGroupLabels': ['Placebo']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change of Performance of Upper Limb 2.0 (PUL) total score at 18 months of treatment of givinostat compared to placebo group.', 'description': 'The PUL examines 3 major \"dimensions\" of upper extremity function: shoulder, middle, and distal functions. It includes 22 scored items; a score of 42 (12 for shoulder; 17 for mid-level, and 13 for distal) indicates the highest level of independent function and 0 the lowest.', 'timeFrame': 'Baseline and 18 months'}], 'secondaryOutcomes': [{'measure': 'Change from baseline of Peak Expiratory Flow percent predicted (PEF%p) at 18 months of treatment of givinostat compared to placebo group', 'timeFrame': 'Baseline and 18 months'}, {'measure': 'Change from baseline of Forced Vital Capacity percent predicted (FVC%p) at 18 months of treatment of givinostat compared to placebo group', 'timeFrame': 'Baseline and 18 months'}, {'measure': 'Cumulative loss of PUL total score over 18 months of treatment of givinostat compared to placebo group.', 'timeFrame': 'Baseline to 18 months'}, {'measure': 'Type, incidence, and severity of treatment-emergent adverse events', 'timeFrame': 'Baseline to 18 months'}, {'measure': 'Proportion of patients experiencing treatment-emergent adverse events', 'timeFrame': 'Baseline to 18 months'}, {'measure': 'Change from baseline vital signs and clinical laboratory tests', 'timeFrame': 'Baseline and 18 months'}, {'measure': 'Change from baseline electrocardiogram and echocardiogram', 'timeFrame': 'Baseline and 18 months'}, {'measure': 'Time to assisted ventilation and rate of respiratory infection including duration, severity of respiratory infection and use of antibiotics, of givinostat compared to placebo group.', 'timeFrame': 'Baseline to 18 months'}], 'otherOutcomes': [{'measure': 'Change from baseline of Fat Fraction of Deltoid and Biceps brachii using Dixon technique at 18 months of treatment of givinostat compared to placebo group', 'timeFrame': 'Baseline and 18 months'}, {'measure': 'Proportion of responders of givinostat compared to placebo group', 'description': 'Responders are defined as patients who did not change their baseline PUL entry score at the EOS', 'timeFrame': 'Baseline to 18 months'}, {'measure': 'Change from baseline of shoulder, elbow and distal level domains of PUL at 18 months of treatment of givinostat compared to placebo group', 'timeFrame': 'Baseline and 18 months'}, {'measure': 'Change from baseline in muscle strength (eg, elbow flexion) evaluated by hand held myometry at 18 months of treatment of givinostat compared to placebo group', 'timeFrame': 'Baseline and 18 months'}, {'measure': 'Change from baseline in grip strength of dominant hand as measured by Jamar Smart Hand dynamometer at 18 months of treatment of givinostat compared to placebo group', 'timeFrame': 'Baseline and 18 months'}, {'measure': 'Change from baseline in physical function as measured by Egen Klassifikation (EK) score at 18 months of treatment of givinostat compared to placebo group', 'timeFrame': 'Baseline and 18 months'}, {'measure': 'Change from baseline as measured by Motor Function Measure (MFM) at 18 months of treatment of givinostat compared to placebo group', 'timeFrame': 'Baseline and 18 months'}, {'measure': 'Change from baseline of Peak Cough Flow (PCF) at 18 months of treatment of givinostat compared to placebo group', 'timeFrame': 'Baseline and 18 months'}, {'measure': 'Age at loss of hand-to-mouth function assessed by PUL', 'timeFrame': 'Baseline to 18 months'}, {'measure': 'Age at loss of turn in bed ability assessed by EK', 'timeFrame': 'Baseline to 18 months'}, {'measure': 'Change from baseline in DMD Upper Limb Patient-Reported Outcome Measures questionnaire scores at 18 months of treatment of givinostat compared to placebo group', 'timeFrame': 'Baseline and 18 months'}, {'measure': 'Change from baseline in quality of life (as measured by Paediatric Quality of Life Inventory 4.0 Generic Core and 3.0 Neuromuscular Module) at 18 months of treatment of givinostat compared to placebo group', 'timeFrame': 'Baseline and 18 months'}, {'measure': 'Change from baseline in reports of activities of daily living (as measured by Barthel index) at 18 months of treatment of givinostat compared to placebo group', 'timeFrame': 'Baseline and 18 months'}, {'measure': 'Pharmacokinetic/Pharmacodynamic Endpoints', 'description': 'PK parameters including, but not limited to, Cmax, T1/2, and AUC, will be assessed using sparse sampling. PD parameters will include PUL, FVC, PEF, MFM, and muscle strength', 'timeFrame': 'Baseline and 18 months'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\nPatients must satisfy all the following criteria:\\n\\n1. Children and adolescent males aged ≥ 9 to \\\\<18 years at screening (patients ≥ 18 years of age at screening will not be enrolled into the study)\\n2. Are able to give informed assent and/or consent in writing signed by the patient and/or parent/legal guardian (according to local regulations)\\n3. A genetic diagnosis of DMD\\n4. Non-ambulant, defined as being wheelchair bound and:\\n\\n   1. Unable to perform the 10-meter walk/run test (10MWT), or\\n   2. Unable to complete the 10MWT in 30 seconds or less, without any support or devices\\n5. Performance of the Upper Limb test (PUL version 2.0) entry item scores 3 to 6\\n6. If on medication for DMD-associated cardiomyopathy (eg, ACE inhibitor, β-blocker, diuretics), stable for ≥1 month immediately prior to start of study treatment, if any\\n7. Stable corticosteroids, defined as:\\n\\n   1. Receiving systemic corticosteroids for a minimum of 6 months immediately prior to start of study treatment\\n   2. No significant change in dose or dosing regimen (except for adjustments due to body weight change) for a minimum of 6 months immediately prior to start of study treatment\\n8. Willing to use adequate contraception. Effective contraceptive methods must be used from randomisation visit through 3 months after the last dose of study drug, and include the following:\\n\\n   1. True abstinence (ie, absence of any sexual intercourse), when in line with the preferred and usual lifestyle of the patient. Periodic abstinence (eg, calendar, ovulation, post-ovulation, and symptothermal methods) and withdrawal are not acceptable methods of contraception\\n   2. Condom with spermicide and the female partner must use an effective method of contraception, such as an oral, transdermal, injectable or implanted hormonal contraceptive; intrauterine device; bilateral tubal occlusion, or a diaphragm or a barrier method of contraception in conjunction with spermicidal jelly such as for example cervical cap with spermicide jelly.\\n\\nExclusion Criteria:\\n\\nPatients will be excluded from the study if they satisfy any of the following criteria:\\n\\n1. Exposure to another investigational drug within 3 months prior to start of study treatment.\\n2. Have exposure to any dystrophin restoration product (eg, Ataluren, Exon skipping) within 6 months prior to the start of study treatment\\n3. Having received any gene therapy (eg, AAV Micro-dystrophin delivery) prior to start of study treatment\\n4. Use of any pharmacologic treatment or supplement (other than corticosteroids), that might have had an effect on muscle strength or function within 3 months prior to the start of study treatment (eg, growth hormone); vitamin D, calcium and any other supplements will be allowed\\n5. Use of testosterone, unless used as a replacement therapy for the treatment of delayed puberty. The testosterone dose and regimen should be stable within 6 months prior to the start of study treatment, and circulating testosterone levels should be within the normal ranges for the patient's age\\n6. Elbow-flexion contractures \\\\>30° in the dominant arm\\n7. Inability to perform consistent PUL 2.0 measurement within ±2 points without shoulder domain or within ±3 points with shoulder domain during paired testing at screening\\n8. Forced Vital Capacity % of predicted \\\\<40%\\n9. Requirement for daytime ventilator assistance (Note: Night ventilator assistance and use of bi-level positive airway pressure therapy is allowed)\\n10. Episode of respiratory failure within the 8 weeks prior to screening\\n11. Symptomatic cardiomyopathy or heart failure and/or left ventricular ejection fraction \\\\<45%\\n12. Baseline corrected QT interval using Fredericia's formula (QTcF) \\\\>450 msec (as the mean of 3 consecutive readings 5 minutes apart) or history of additional risk factors for torsades de pointes (eg, heart failure, hypokalaemia, or family history of long QT syndrome)\\n13. Major surgical procedure (including scoliosis surgery) planned within 1 year of the start of study treatment\\n14. Poorly controlled asthma or underlying lung disease such as bronchitis, bronchiectasis, emphysema, recurrent pneumonia that in the opinion of the Investigator might impact respiratory function\\n15. Platelets, white blood cells, and/or haemoglobin \\\\< lower limit of normal (LLN) at screening (Note: for abnormal screening laboratory test results \\\\[\\\\<LLN\\\\], the platelets count, white blood cell, and haemoglobin will be repeated once; if the repeat test result is still \\\\<LLN, the patient should be excluded)\\n16. Fasting triglycerides \\\\>300 mg/dL (3.42 mmol/L) at screening (Note: if the value is \\\\>300 mg/dL, the triglycerides will be repeated once; if the repeated test result is still \\\\>300 mg/dL, the patient should be excluded)\\n17. Current or history of liver disease or impairment, including but not limited to a baseline elevated total bilirubin (ie, \\\\>1.5 × upper limit of normal \\\\[ULN\\\\]), unless secondary to Gilbert disease or pattern consistent with Gilbert disease\\n18. Inadequate renal function, as defined by serum Cystatin C result \\\\>2 × ULN (Note: if the value is \\\\>2 × ULN, the serum Cystatin C will be repeated once; if the repeated test result is still \\\\>2 × ULN, the patient should be excluded)\\n19. Positive test for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus at screening\\n20. Hypersensitivity to any component of study medication\\n21. Sorbitol intolerance or malabsorption, or have the hereditary form of fructose intolerance\\n22. Diagnosis of other uncontrolled neurological diseases or presence of relevant uncontrolled somatic disorders that are not related to DMD, based on Investigator judgement\\n23. Psychiatric illness or social situations rendering the potential patient unable to understand and comply with the muscle function tests and/or with the study protocol procedures, based on Investigator judgement\\n24. Have contraindications to MRI scan (eg, claustrophobia, metal implants, or uncontrolled seizure disorder), based on Investigator's judgement.\", 'healthyVolunteers': False, 'sex': 'MALE', 'minimumAge': '9 Years', 'maximumAge': '17 Years', 'stdAges': ['CHILD']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Paolo Tornese, PhD', 'role': 'CONTACT', 'phone': '+39 02 6443 1', 'email': 'patientadvocacy@italfarmacogroup.com'}], 'locations': [{'facility': 'Universitaire Ziekenhuizen Leuven', 'status': 'NOT_YET_RECRUITING', 'city': 'Leuven', 'zip': '3000', 'country': 'Belgium', 'contacts': [{'name': 'Liesbeth De Waele', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'facility': \"British Columbia Children's Hospital\", 'status': 'NOT_YET_RECRUITING', 'city': 'Vancouver', 'state': 'British Columbia', 'zip': 'V6H 3V4', 'country': 'Canada', 'contacts': [{'name': 'Kathryn Selby', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'facility': \"The University of Western Ontario - Children's Health Research Institute\", 'status': 'NOT_YET_RECRUITING', 'city': 'London', 'state': 'Ontario', 'zip': 'N6A 5W9', 'country': 'Canada', 'contacts': [{'name': 'Craig Campbell', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'facility': \"University of Ottawa - Children's Hospital of Eastern Ontario\", 'status': 'NOT_YET_RECRUITING', 'city': 'Ottawa', 'state': 'Ontario', 'zip': 'K1H 8L1', 'country': 'Canada', 'contacts': [{'name': 'Hugh McMillan', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 45.41117, 'lon': -75.69812}}, {'facility': 'University of Toronto - Holland Bloorview Kids Rehabilitation Hospital', 'status': 'NOT_YET_RECRUITING', 'city': 'Toronto', 'state': 'Ontario', 'zip': 'M4G 1R8', 'country': 'Canada', 'contacts': [{'name': 'Laura McAdam', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}}, {'facility': 'Centre Hospitalier Régional Universitaire de Lille', 'status': 'NOT_YET_RECRUITING', 'city': 'Lille', 'zip': '59037', 'country': 'France', 'contacts': [{'name': 'Jean-Baptiste Davion', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 50.63297, 'lon': 3.05858}}, {'facility': 'Centre hospitalier universitaire - Hôpitaux de Marseille', 'status': 'NOT_YET_RECRUITING', 'city': 'Marseille', 'zip': '13385', 'country': 'France', 'contacts': [{'name': 'Cecile Halbert', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 43.29551, 'lon': 5.38958}}, {'facility': 'Hôpital Armand-Trousseau - I-Motion', 'status': 'NOT_YET_RECRUITING', 'city': 'Paris', 'zip': '75935', 'country': 'France', 'contacts': [{'name': 'Marina Colella', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'Charite-Universitaetsmedizin Berlin', 'status': 'NOT_YET_RECRUITING', 'city': 'Berlin', 'zip': '10117', 'country': 'Germany', 'contacts': [{'name': 'Corinna Stoltenburg', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'facility': 'Universitaetsklinikum Freiburg', 'status': 'NOT_YET_RECRUITING', 'city': 'Freiburg', 'zip': '53113', 'country': 'Germany', 'contacts': [{'name': 'Janbernd Kirschner', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 47.9959, 'lon': 7.85222}}, {'facility': 'Associazione La Nostra Famiglia - IRCCS Eugenio Medea - Bosisio Parini', 'status': 'NOT_YET_RECRUITING', 'city': 'Lecco', 'zip': '23842', 'country': 'Italy', 'contacts': [{'name': 'Maria Grazia D´Angelo', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 45.85589, 'lon': 9.39704}}, {'facility': \"Fondazione Serena Onlus - Azienda Ospedaliera Niguarda Ca' Granda - NeuroMuscular Omnicentre\", 'status': 'NOT_YET_RECRUITING', 'city': 'Milano', 'zip': '20162', 'country': 'Italy', 'contacts': [{'name': 'Valeria Sansone', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}}, {'facility': 'Università degli Studi di Padova - Azienda Ospedaliera di Padova', 'status': 'NOT_YET_RECRUITING', 'city': 'Padova', 'zip': '35128', 'country': 'Italy', 'contacts': [{'name': 'Elena Pegoraro', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 45.40797, 'lon': 11.88586}}, {'facility': 'Ospedale Pediatrico Bambino Gesù', 'status': 'NOT_YET_RECRUITING', 'city': 'Roma', 'zip': '00165', 'country': 'Italy', 'contacts': [{'name': 'Adele D´Amico', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'facility': 'Policlinico Universitario \"Agostino Gemelli\" - Università Cattolica del Sacro Cuore', 'status': 'NOT_YET_RECRUITING', 'city': 'Roma', 'zip': '00165', 'country': 'Italy', 'contacts': [{'name': 'Eugenio M Mercuri', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'facility': 'Leids Universitair Medisch Centrum (LUMC)', 'status': 'NOT_YET_RECRUITING', 'city': 'Leiden', 'zip': '2300 RC', 'country': 'Netherlands', 'contacts': [{'name': 'Erik Niks', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 52.15833, 'lon': 4.49306}}, {'facility': 'Radboud Universitair Medisch Centrum (Radboudumc)', 'status': 'RECRUITING', 'city': 'Nijmegen', 'zip': '6500 HB', 'country': 'Netherlands', 'contacts': [{'name': 'Saskia Houwen-van Opstal', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 51.8425, 'lon': 5.85278}}, {'facility': 'Newcastle upon Tyne Hospitals NHS Foundation Trust - Newcastle University', 'status': 'NOT_YET_RECRUITING', 'city': 'Newcastle Upon Tyne', 'state': 'England', 'zip': 'NE1 3BZ', 'country': 'United Kingdom', 'contacts': [{'name': 'Michela Guglieri', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 54.97328, 'lon': -1.61396}}, {'facility': 'Oxford University Hospitals NHS Foundation Trust', 'status': 'NOT_YET_RECRUITING', 'city': 'Oxford', 'state': 'England', 'zip': 'OX3 9DU', 'country': 'United Kingdom', 'contacts': [{'name': 'Laurent Servais', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 51.75222, 'lon': -1.25596}}, {'facility': 'NHS Greater Glasgow and Clyde - Royal Hospital for Children', 'status': 'RECRUITING', 'city': 'Glasgow', 'state': 'Scotland', 'zip': 'G51 4TF', 'country': 'United Kingdom', 'contacts': [{'name': 'Ian Horrocks', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}]}, 'referencesModule': {'references': [{'pmid': '27566866', 'type': 'BACKGROUND', 'citation': \"Bettica P, Petrini S, D'Oria V, D'Amico A, Catteruccia M, Pane M, Sivo S, Magri F, Brajkovic S, Messina S, Vita GL, Gatti B, Moggio M, Puri PL, Rocchetti M, De Nicolao G, Vita G, Comi GP, Bertini E, Mercuri E. Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2016 Oct;26(10):643-649. doi: 10.1016/j.nmd.2016.07.002. Epub 2016 Jul 11.\"}, {'pmid': '23552722', 'type': 'BACKGROUND', 'citation': 'Consalvi S, Mozzetta C, Bettica P, Germani M, Fiorentini F, Del Bene F, Rocchetti M, Leoni F, Monzani V, Mascagni P, Puri PL, Saccone V. Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat. Mol Med. 2013 May 20;19(1):79-87. doi: 10.2119/molmed.2013.00011.'}], 'seeAlsoLinks': [{'label': 'Website to inform potential study participants', 'url': 'https://ulyssesdmd.study/'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000009136', 'term': 'Muscular Dystrophies'}, {'id': 'D000020388', 'term': 'Muscular Dystrophy, Duchenne'}], 'ancestors': [{'id': 'D000020966', 'term': 'Muscular Disorders, Atrophic'}, {'id': 'D000009135', 'term': 'Muscular Diseases'}, {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D000040181', 'term': 'Genetic Diseases, X-Linked'}], 'browseLeaves': [{'id': 'M12093', 'name': 'Muscular Dystrophies', 'asFound': 'Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'M22185', 'name': 'Muscular Dystrophy, Duchenne', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'M4589', 'name': 'Atrophy', 'relevance': 'LOW'}, {'id': 'M12092', 'name': 'Muscular Diseases', 'relevance': 'LOW'}, {'id': 'M22697', 'name': 'Muscular Disorders, Atrophic', 'relevance': 'LOW'}, {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M23686', 'name': 'Genetic Diseases, Inborn', 'relevance': 'LOW'}, {'id': 'M24877', 'name': 'Genetic Diseases, X-Linked', 'relevance': 'LOW'}, {'id': 'T3963', 'name': 'Muscular Dystrophy', 'asFound': 'Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'T698', 'name': 'Becker Muscular Dystrophy', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'T1945', 'name': 'Duchenne Muscular Dystrophy', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC16', 'name': 'Diseases and Abnormalities at or Before Birth'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000502418', 'term': 'Givinostat hydrochloride'}], 'ancestors': [{'id': 'D000056572', 'term': 'Histone Deacetylase Inhibitors'}, {'id': 'D000004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D000045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}], 'browseLeaves': [{'id': 'M214835', 'name': 'Givinostat hydrochloride', 'asFound': 'Spoon', 'relevance': 'HIGH'}, {'id': 'M28511', 'name': 'Histone Deacetylase Inhibitors', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT04322357', 'orgStudyIdInfo': {'id': 'IRB201901339'}, 'secondaryIdInfos': [{'id': 'MD 180023', 'type': 'OTHER_GRANT', 'domain': 'U.S. Army Medical Research and Development Command'}, {'id': 'OCR27142', 'type': 'OTHER', 'domain': 'UF OnCore'}], 'organization': {'fullName': 'University of Florida', 'class': 'OTHER'}, 'briefTitle': 'Twice Weekly Steroids and Exercise as Therapy for DMD', 'officialTitle': 'Impact and Interplay of Corticosteroid Regimen and Exercise Training on DMD Muscle Function'}, 'statusModule': {'statusVerifiedDate': '2024-01', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2020-07-30', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-10-07', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-10-07', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2020-03-24', 'studyFirstSubmitQcDate': '2020-03-24', 'studyFirstPostDateStruct': {'date': '2020-03-26', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-01-30', 'lastUpdatePostDateStruct': {'date': '2024-01-31', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'University of Florida', 'class': 'OTHER'}, 'collaborators': [{'name': 'U.S. Army Medical Research and Development Command', 'class': 'FED'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The study team will determine the potential of low dose twice weekly prednisone and whether exercise training can synergize to delay disease progression and improve muscle strength/physical function in boys with Duchenne muscular dystrophy (DMD). Current standard of care (daily prednisone) is associated with adverse side effects. Evidence from DMD mouse models suggest that weekly dosing provides same efficacy without side effects. Appropriate exercise may also benefit but this area has not been adequately explored.'}, 'conditionsModule': {'conditions': ['Duchenne Muscular Dystrophy (DMD)'], 'keywords': ['steroid side effects, low dose steroid regimen, exercise training therapy']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 89, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Daily Glucocorticoid (GC)', 'type': 'NO_INTERVENTION', 'description': 'Existing data from age-matched, ambulatory, on daily GC therapy, and similar exclusion criteria will be selected from the ImagingDMD database to serve as a historical control.'}, {'label': 'Twice weekly glucocorticoid with or without exercise', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patients will be randomized to one of 2 groups:\\n\\n* Twice weekly prednisone alone for 12 months\\n* Twice weekly prednisone for 6 months followed by twice weekly prednisone plus 6 months of structured, supervised and home-based exercise training.', 'interventionNames': ['Drug: Prednisone']}, {'label': 'Daily glucocorticoid with exercise', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patients on daily glucocorticoids will undergo 6 months of structured, supervised and home-based exercise training.', 'interventionNames': ['Drug: Prednisone', 'Behavioral: In-home Exercise Training', 'Drug: Prednisone plus exercise']}], 'interventions': [{'type': 'DRUG', 'name': 'Prednisone', 'description': 'A 12-month treatment period with twice weekly, low-dose prednisone (dose of 0.75 mg/kg per day).', 'armGroupLabels': ['Daily glucocorticoid with exercise', 'Twice weekly glucocorticoid with or without exercise'], 'otherNames': ['Glucocorticoid (GC)']}, {'type': 'BEHAVIORAL', 'name': 'In-home Exercise Training', 'description': 'For boys on current standard of care (daily glucocorticoid use), 6-months in-home, remotely supervised exercise training program involving a combination of aerobic and isometric leg strength exercises.', 'armGroupLabels': ['Daily glucocorticoid with exercise']}, {'type': 'DRUG', 'name': 'Prednisone plus exercise', 'description': 'Twice weekly prednisone for 6 months followed by twice weekly prednisone plus exercise for 6 months.', 'armGroupLabels': ['Daily glucocorticoid with exercise']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in BMI', 'description': 'Participant body mass index change (weight and height will be combined to report BMI in kg/m\\\\^2) over the course of one year', 'timeFrame': 'Baseline up to 12 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Diagnosis of DMD confirmed by 1) clinical history with features before the age of five, 2) physical examination, 3) elevated serum creatine kinase level and 4) absence of dystrophin expression, as determined by immunostain or Western blot (\\\\<2%) and/or DNA confirmation of dystrophin mutation.\\n* Age 5.0 to 9 years: a lower age limit of 5.0 years is selected as children younger than that are likely unable to cooperate and comply with all of the exercise measures as needed. An upper age limit of 9 years has been set as boys with DMD tend to reach a rapid progression into a late ambulatory phase soon after this age.\\n* Ambulatory at the time of the first visit, defined as the ability to walk for at least 100 m without an external assistive device and able to climb four stairs.\\n* Aim 1 only: GC-naïve at baseline (and prior 6 months)\\n* Aim 2 only: on stable daily GC regimen for 6 months prior to baseline\\n\\nExclusion Criteria:\\n\\n* Contraindication to an MR examination (e.g. aneurysm clip, severe claustrophobia, magnetic implants)\\n* Presence of unstable medical problems, significant concomitant illness including cardiomyopathy or cardiac conduction abnormalities\\n* Presence of a secondary condition that impacts muscle function or muscle metabolism (e.g. myasthenia gravis, endocrine disorder, mitochondrial disease)\\n* Presence of a secondary condition leading to developmental delay or impaired motor control (e.g. cerebral palsy)\\n* Presence of an unstable medical condition (e.g. uncontrolled seizure disorder)\\n* Behavioral problems causing an inability to cooperate during testing or understand exercise instruction\\n* Participation in other forms of drug or gene therapy during the period of the study', 'healthyVolunteers': False, 'sex': 'MALE', 'minimumAge': '5 Years', 'maximumAge': '9 Years', 'stdAges': ['CHILD']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Tanja Taivassalo, PhD', 'role': 'CONTACT', 'phone': '(352) 294-8748', 'email': 'ttaivassalo@ufl.edu'}], 'overallOfficials': [{'name': 'Tanja Taivassalo, MD', 'affiliation': 'University of Florida', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'University of Florida', 'status': 'RECRUITING', 'city': 'Gainesville', 'state': 'Florida', 'zip': '32610', 'country': 'United States', 'contacts': [{'name': 'Tanja Taivassalo', 'role': 'CONTACT', 'phone': '352-294-8748', 'email': 'ttaivassalo@ufl.edu'}, {'name': 'Tanja Taivassalo', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 29.65163, 'lon': -82.32483}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000009136', 'term': 'Muscular Dystrophies'}, {'id': 'D000020388', 'term': 'Muscular Dystrophy, Duchenne'}], 'ancestors': [{'id': 'D000020966', 'term': 'Muscular Disorders, Atrophic'}, {'id': 'D000009135', 'term': 'Muscular Diseases'}, {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D000040181', 'term': 'Genetic Diseases, X-Linked'}], 'browseLeaves': [{'id': 'M12093', 'name': 'Muscular Dystrophies', 'asFound': 'Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'M22185', 'name': 'Muscular Dystrophy, Duchenne', 'asFound': 'Duchenne Muscular Dystrophy (DMD)', 'relevance': 'HIGH'}, {'id': 'M4589', 'name': 'Atrophy', 'relevance': 'LOW'}, {'id': 'M12092', 'name': 'Muscular Diseases', 'relevance': 'LOW'}, {'id': 'M22697', 'name': 'Muscular Disorders, Atrophic', 'relevance': 'LOW'}, {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M23686', 'name': 'Genetic Diseases, Inborn', 'relevance': 'LOW'}, {'id': 'M24877', 'name': 'Genetic Diseases, X-Linked', 'relevance': 'LOW'}, {'id': 'T3963', 'name': 'Muscular Dystrophy', 'asFound': 'Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'T698', 'name': 'Becker Muscular Dystrophy', 'asFound': 'Duchenne Muscular Dystrophy (DMD)', 'relevance': 'HIGH'}, {'id': 'T1945', 'name': 'Duchenne Muscular Dystrophy', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC16', 'name': 'Diseases and Abnormalities at or Before Birth'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000011241', 'term': 'Prednisone'}, {'id': 'D000005938', 'term': 'Glucocorticoids'}], 'ancestors': [{'id': 'D000000893', 'term': 'Anti-Inflammatory Agents'}, {'id': 'D000006728', 'term': 'Hormones'}, {'id': 'D000006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}, {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D000018931', 'term': 'Antineoplastic Agents, Hormonal'}, {'id': 'D000000970', 'term': 'Antineoplastic Agents'}], 'browseLeaves': [{'id': 'M14121', 'name': 'Prednisone', 'asFound': 'Usual', 'relevance': 'HIGH'}, {'id': 'M9047', 'name': 'Glucocorticoids', 'asFound': 'After treatment', 'relevance': 'HIGH'}, {'id': 'M4217', 'name': 'Anti-Inflammatory Agents', 'relevance': 'LOW'}, {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'}, {'id': 'M9788', 'name': 'Hormone Antagonists', 'relevance': 'LOW'}, {'id': 'M20966', 'name': 'Antineoplastic Agents, Hormonal', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Infl', 'name': 'Anti-Inflammatory Agents'}, {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05601986', 'orgStudyIdInfo': {'id': 'MI on DMD'}, 'organization': {'fullName': 'Halic University', 'class': 'OTHER'}, 'briefTitle': 'Motor Imagery on Children With DMD on Gait and Balance Functions', 'officialTitle': 'Investigation of the Effect of Motor Imagery on Gait and Balance Functions in Children With Duchenne Muscular Dystrophy'}, 'statusModule': {'statusVerifiedDate': '2024-02', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-12-16', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-07-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2024-12-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-10-20', 'studyFirstSubmitQcDate': '2022-10-31', 'studyFirstPostDateStruct': {'date': '2022-11-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-28', 'lastUpdatePostDateStruct': {'date': '2024-02-29', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorFullName': 'Gülsena Utku', 'investigatorTitle': 'Principal Investigator', 'investigatorAffiliation': 'Halic University'}, 'leadSponsor': {'name': 'Gülsena Utku', 'class': 'OTHER'}}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The most common muscular dystrophy among pediatric neuromuscular diseases is Duchenne Muscular Dystrophy (DMD). There is no consensus on a standardized physiotherapy and rehabilitation program or exercise prescription in DMD. Motor imagery (MI) is defined as visualizing motor activities in one\\'s mind without performing any movement. There are studies examining the effectiveness of motor imagery in stroke, cerebral palsy, Parkinson\\'s, peripheral facial paralysis, and phantom pain. This study is aimed to examine the effect of motor imagery on gait and balance functions in children with Duchenne Muscular Dystrophy. Boys residing in Istanbul Turkey, between the ages of 5 and 12, with a diagnosis of DMD who have not lost their ability to ambulate independently will be included in the study. The included individuals will be divided into two groups due to randomization: Group A (Control Group Physiotherapy and Rehabilitation Program) and Group B (Additional Motor Imagery Training to Intervention Group Physiotherapy and Rehabilitation Program). While the physiotherapy and rehabilitation program is applied to the participants in Group A with 40-minute sessions on 2 non-consecutive days of the week for 8 weeks, the participants in Group B will receive an additional 25-30-minute motor imagery program to the physiotherapy and rehabilitation program. Participants were tested with Kinovea Gait Analysis, Timed Up and Go Test, 2 Minute Walking Test, Motor Function Rating Scale for Neuromuscular Diseases, timed performance tests, Pediatric Berg Balance Scale, Pediatric Fear of Fall Questionnaire (Ped-FOF) before and after the program. will be evaluated later. IBM SPSS (Statistical Package for Social Sciences) statistical program version 22.0 will be used for statistical analysis. The conformity of the variables to the normal distribution will be determined by the \"Shapiro-Wilk Test\". If the variables show normal distribution, the variation within the group will be analyzed with the \"Paired Sample T Test\", if not, the \"Wilcoxon Test\" will be analyzed. In the comparison between groups, if the variables show normal distribution, it will be done with the \"Independent T Test\" in independent groups and the \"Mann Whitney U Test\" if they do not show normal distribution. Categorical data distributions will be evaluated with the \"Chi-square test\". In all analyses, p\\\\<0.05 will be considered statistically significant.'}, 'conditionsModule': {'conditions': ['Duchenne Muscular Dystrophy'], 'keywords': ['Gait', 'Balance', 'Duchenne Muscular Dystrophy']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER']}}, 'enrollmentInfo': {'count': 34, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Physiotherapy and Rehabilitation Program', 'type': 'OTHER', 'description': 'Control Group', 'interventionNames': ['Other: Physiotherapy and Rehabilitation Program']}, {'label': 'Additional Motor Imagery Training to Physiotherapy and Rehabilitation Program', 'type': 'EXPERIMENTAL', 'description': 'Intervention Group', 'interventionNames': ['Other: Physiotherapy and Rehabilitation Program', 'Other: Additional Motor Imagery Training to Physiotherapy and Rehabilitation Program']}], 'interventions': [{'type': 'OTHER', 'name': 'Physiotherapy and Rehabilitation Program', 'description': 'The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase: Progressive relaxation. Stretching phase: Stretching exercises for the muscles of the gastrocnemius, hamstrings, hip flexors, hip adductors Strengthening phase: Isometric strengthening exercises for the tibialis anterior, quadriceps, hip extensors, and hip abductors muscles.\\n\\nBalance training phase: Two legs, one leg, balance with eyes open and eyes closed.\\n\\nWeight-bearing phase: Weight transfer to the front, back, and sides using the balance board.', 'armGroupLabels': ['Additional Motor Imagery Training to Physiotherapy and Rehabilitation Program', 'Physiotherapy and Rehabilitation Program'], 'otherNames': ['Control group']}, {'type': 'OTHER', 'name': 'Additional Motor Imagery Training to Physiotherapy and Rehabilitation Program', 'description': 'The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase, Stretching phase, Strengthening phase,Balance training phase and Weight-bearing phase. Additional to the Physiotherapy and Rehabilitation Program, the Additional Motor Imagery Training program will be carried out for 8 weeks, 2 days a week, in addition to the 40-minute physiotherapy and rehabilitation program, accompanied by 25-30 minutes of supervision. It will be conducted by the researcher on two non-consecutive days of the week, by making appropriate appointments for the participants. During the program, participants will be asked to be in a quiet room. Sessions will consist of 4 consecutive phases: video watching, relaxation, motor imagery, and return to the environment.', 'armGroupLabels': ['Additional Motor Imagery Training to Physiotherapy and Rehabilitation Program'], 'otherNames': ['Intervention group']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'gait analysis1', 'description': 'Change from Baseline Stride length in meters', 'timeFrame': 'one week before the intervention and one week after the intervention'}, {'measure': 'gait analysis2', 'description': 'Change from Baseline stride width in meters', 'timeFrame': 'one week before the intervention and one week after the intervention'}, {'measure': 'gait analysis3', 'description': 'Change from Baseline Systolic cadence', 'timeFrame': 'one week before the intervention and one week after the intervention'}, {'measure': 'gait analysis4', 'description': 'Change from Baseline walking speed in meters/second', 'timeFrame': 'one week before the intervention and one week after the intervention'}, {'measure': 'balance', 'description': 'Change from Baseline Pediatric Balance Scale in grades 0-56 points', 'timeFrame': 'one week before the intervention and one week after the intervention'}], 'secondaryOutcomes': [{'measure': 'muscle strength measurement', 'description': 'Strength measurements of lower extremity muscles', 'timeFrame': 'one week before the intervention and one week after the intervention'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Have a physician-prescribed diagnosis of Duchenne Muscular Dystrophy\\n* Not having any injury or surgical operation in the last 6 months\\n* Being between Levels 1-5 (children who continue to ambulate independently) according to - Brooke Lower Extremity Functional Classification Modified Mini-Mental Test score \\\\>27\\n* Having the level of cooperation to follow the physiotherapist's instructions\\n* Volunteering to participate in research\\n\\nExclusion Criteria:\\n\\n* Having severe contractures that interfere with functional activities\\n* Level 6-10 (children not capable of independent ambulation) according to the Brooke Lower Extremity Functional Classification\\n* To receive applications in addition to the physiotherapy and rehabilitation program or different from the physiotherapy and rehabilitation program\", 'healthyVolunteers': False, 'sex': 'MALE', 'minimumAge': '5 Years', 'maximumAge': '12 Years', 'stdAges': ['CHILD']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Gülsena Utku Umut', 'role': 'CONTACT', 'phone': '+905370664646', 'email': 'gulsenautku@halic.edu.tr'}], 'overallOfficials': [{'name': 'Arzu Razak Özdinçler, Prof', 'affiliation': 'Biruni University', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Biruni University', 'status': 'RECRUITING', 'city': 'Istanbul', 'country': 'Turkey', 'contacts': [{'name': 'Gülsena Utku Umut', 'role': 'CONTACT', 'phone': '+905370664646', 'email': 'gulsenautkuumut@gmail.com'}], 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000009136', 'term': 'Muscular Dystrophies'}, {'id': 'D000020388', 'term': 'Muscular Dystrophy, Duchenne'}], 'ancestors': [{'id': 'D000020966', 'term': 'Muscular Disorders, Atrophic'}, {'id': 'D000009135', 'term': 'Muscular Diseases'}, {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D000040181', 'term': 'Genetic Diseases, X-Linked'}], 'browseLeaves': [{'id': 'M12093', 'name': 'Muscular Dystrophies', 'asFound': 'Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'M22185', 'name': 'Muscular Dystrophy, Duchenne', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'M4589', 'name': 'Atrophy', 'relevance': 'LOW'}, {'id': 'M12092', 'name': 'Muscular Diseases', 'relevance': 'LOW'}, {'id': 'M22697', 'name': 'Muscular Disorders, Atrophic', 'relevance': 'LOW'}, {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M23686', 'name': 'Genetic Diseases, Inborn', 'relevance': 'LOW'}, {'id': 'M24877', 'name': 'Genetic Diseases, X-Linked', 'relevance': 'LOW'}, {'id': 'T3963', 'name': 'Muscular Dystrophy', 'asFound': 'Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'T698', 'name': 'Becker Muscular Dystrophy', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'T1945', 'name': 'Duchenne Muscular Dystrophy', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC16', 'name': 'Diseases and Abnormalities at or Before Birth'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT04626674', 'orgStudyIdInfo': {'id': 'SRP-9001-103'}, 'organization': {'fullName': 'Sarepta Therapeutics, Inc.', 'class': 'INDUSTRY'}, 'briefTitle': 'A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)', 'officialTitle': 'An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression From SRP-9001 in Subjects With Duchenne Muscular Dystrophy (ENDEAVOR)', 'acronym': 'ENDEAVOR'}, 'statusModule': {'statusVerifiedDate': '2023-07', 'overallStatus': 'ENROLLING_BY_INVITATION', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2020-11-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-11-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-07-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2020-11-06', 'studyFirstSubmitQcDate': '2020-11-06', 'studyFirstPostDateStruct': {'date': '2020-11-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-07-28', 'lastUpdatePostDateStruct': {'date': '2023-08-01', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Sarepta Therapeutics, Inc.', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Hoffmann-La Roche', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This is an open-label gene transfer therapy study evaluating the safety of and expression from delandistrogene moxeparvovec in participants with DMD. The maximum participant duration for this study is 156 weeks.'}, 'conditionsModule': {'conditions': ['Muscular Dystrophy, Duchenne'], 'keywords': ['Duchenne Muscular Dystrophy', 'Gene-Delivery', 'DMD', 'Ambulatory Non-ambulatory', 'Pediatric', 'Dystrophin']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 58, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Delandistrogene Moxeparvovec', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive a single intravenous (IV) infusion of delandistrogene moxeparvovec on Day 1.', 'interventionNames': ['Genetic: delandistrogene moxeparvovec']}], 'interventions': [{'type': 'GENETIC', 'name': 'delandistrogene moxeparvovec', 'description': 'Single IV infusion of delandistrogene moxeparvovec', 'armGroupLabels': ['Delandistrogene Moxeparvovec'], 'otherNames': ['SRP-9001', 'delandistrogene moxeparvovec-rokl', 'ELEVIDYS']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Part 1: Change from Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Expression at Week 12, as Measured by Western Blot', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Part 1: Quantity of Delandistrogene Moxeparvovec Dystrophin Expression at Week 12 as Measured by Western Blot', 'timeFrame': 'Week 12'}], 'secondaryOutcomes': [{'measure': 'Vector Shedding, Measured in Urine, Saliva, and Stool Samples Post-Infusion', 'timeFrame': 'Day 1 up to Week 104'}, {'measure': 'Level of Antibody Titers to Recombinant Adeno-Associated Virus Serotype rh74 (rAAVrh74)', 'timeFrame': 'Day 2 up to Week 156'}, {'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) of Special Interest', 'timeFrame': 'Baseline up to Week 156'}, {'measure': 'Change from Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression at Week 12, as Measured by Immunofluorescence (IF) Fiber Intensity', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change from Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression at Week 12, as Measured by IF Percent Dystrophin Positive Fibers (PDPF)', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression at Week 12 as Measured by IF Fiber Intensity:', 'timeFrame': 'Week 12'}, {'measure': 'Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression at Week 12 as Measured by IF PDPF', 'timeFrame': 'Week 12'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* For Cohorts 1-7: Has a definitive diagnosis of DMD based on documented clinical findings and prior genetic testing.\\n* Cohort 1: Is ambulatory, and ≥4 to \\\\<8 years of age at the time of Screening.\\n* Cohort 2: Is ambulatory, and ≥8 to \\\\<18 years of age at the time of Screening.\\n* Cohort 3: Non-ambulatory per protocol specified criteria at the time of Screening.\\n* Cohort 4: Is ambulatory and ≥3 to \\\\<4 years of age at the time of Screening.\\n* Cohort 5a: Is ambulatory and ≥4 to \\\\<9 years of age.\\n* Cohort 5b: Non-ambulatory per protocol specified criteria at the time of Screening.\\n* Cohort 6: Is ambulatory, and ≥2 to \\\\<3 years of age at the time of Screening.\\n* Cohort 7: Non-ambulatory per protocol-specified criteria at the time of Screening.\\n* Ability to cooperate with motor assessment testing.\\n* Cohorts 1, 2, 3, 5, and 7 only: Stable dose equivalent of oral glucocorticoids for at least 12 weeks before screening and the dose is expected to remain constant (except for modifications to accommodate changes in weight) throughout the first year of the study.\\n* Cohorts 4 and 6: Do not yet require use of chronic steroids for treatment of their DMD, in the opinion of the Investigator, and are not receiving steroids at the time of Screening.\\n* rAAVrh74 antibody titers are not elevated as per protocol-specified requirements.\\n* Genetic mutation inclusion criteria vary by cohort.\\n\\nExclusion Criteria:\\n\\n* Has a concomitant illness, autoimmune disease, chronic drug treatment, and/or cognitive delay/impairment that in the opinion of the Investigator creates unnecessary risks for gene transfer.\\n* Exposure to gene therapy, investigational medication, or any treatment designed to increase dystrophin expression within protocol-specified time limits.\\n* Abnormality in protocol-specified diagnostic evaluations or laboratory tests.\\n\\nOther inclusion/exclusion criteria apply.', 'healthyVolunteers': False, 'sex': 'MALE', 'minimumAge': '2 Years', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Medical Director', 'affiliation': 'Sarepta Therapeutics, Inc.', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Stanford University', 'city': 'Palo Alto', 'state': 'California', 'zip': '94304', 'country': 'United States', 'geoPoint': {'lat': 37.44188, 'lon': -122.14302}}, {'facility': 'University of California, Davis', 'city': 'Sacramento', 'state': 'California', 'zip': '95616', 'country': 'United States', 'geoPoint': {'lat': 38.58157, 'lon': -121.4944}}, {'facility': 'Washington University in St. Louis', 'city': 'Saint Louis', 'state': 'Missouri', 'zip': '21205', 'country': 'United States', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'facility': \"Nationwide Children's Hospital\", 'city': 'Columbus', 'state': 'Ohio', 'zip': '43205', 'country': 'United States', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'facility': \"Children's Hospital of The King's Daughters\", 'city': 'Norfolk', 'state': 'Virginia', 'zip': '23507', 'country': 'United States', 'geoPoint': {'lat': 36.84681, 'lon': -76.28522}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000009136', 'term': 'Muscular Dystrophies'}, {'id': 'D000020388', 'term': 'Muscular Dystrophy, Duchenne'}], 'ancestors': [{'id': 'D000020966', 'term': 'Muscular Disorders, Atrophic'}, {'id': 'D000009135', 'term': 'Muscular Diseases'}, {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D000040181', 'term': 'Genetic Diseases, X-Linked'}], 'browseLeaves': [{'id': 'M12093', 'name': 'Muscular Dystrophies', 'asFound': 'Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'M22185', 'name': 'Muscular Dystrophy, Duchenne', 'asFound': 'Muscular Dystrophy, Duchenne', 'relevance': 'HIGH'}, {'id': 'M4589', 'name': 'Atrophy', 'relevance': 'LOW'}, {'id': 'M12092', 'name': 'Muscular Diseases', 'relevance': 'LOW'}, {'id': 'M22697', 'name': 'Muscular Disorders, Atrophic', 'relevance': 'LOW'}, {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M23686', 'name': 'Genetic Diseases, Inborn', 'relevance': 'LOW'}, {'id': 'M24877', 'name': 'Genetic Diseases, X-Linked', 'relevance': 'LOW'}, {'id': 'T3963', 'name': 'Muscular Dystrophy', 'asFound': 'Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'T698', 'name': 'Becker Muscular Dystrophy', 'asFound': 'Duchenne', 'relevance': 'HIGH'}, {'id': 'T1945', 'name': 'Duchenne Muscular Dystrophy', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC16', 'name': 'Diseases and Abnormalities at or Before Birth'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT06244082', 'orgStudyIdInfo': {'id': 'AOC 1044-CS2'}, 'organization': {'fullName': 'Avidity Biosciences, Inc.', 'class': 'INDUSTRY'}, 'briefTitle': 'Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping', 'officialTitle': 'A Phase 2 Open-label Study to Evaluate the Pharmacodynamics and Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants With Mutations Amenable to Exon 44 Skipping', 'acronym': 'EXPLORE44OLE'}, 'statusModule': {'statusVerifiedDate': '2024-02', 'overallStatus': 'ENROLLING_BY_INVITATION', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-01-22', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-01-26', 'studyFirstSubmitQcDate': '2024-02-02', 'studyFirstPostDateStruct': {'date': '2024-02-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-02', 'lastUpdatePostDateStruct': {'date': '2024-02-06', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Avidity Biosciences, Inc.', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'AOC 1044-CS2 (EXPLORE44-OLE) is an Open-label Study to Evaluate the Pharmacodynamics and Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants with Mutations Amenable to Exon 44 Skipping.', 'detailedDescription': 'AOC 1044-CS2 (EXPLORE44-OLE) is an open label, extension study to Part B of AOC 1044-CS1 (EXPLORE44). AOC 1044-CS2 is designed to evaluate the pharmacodynamic effect of AOC 1044 on dystrophin protein production in skeletal muscle as well as the long-term safety, tolerability, pharmacokinetics, and exploratory efficacy of AOC 1044.\\n\\nParticipants from AOC 1044-CS1 Part B are eligible to enroll in AOC 1044-CS2 if they have satisfactorily completed AOC 1044-CS1.\\n\\nAll participants who enroll in AOC 1044-CS2 will receive active treatment regardless of whether they received active treatment or placebo in AOC 1044-CS1. The treatment period is 2 years with IV dosing every 6 or 8 weeks.\\n\\nOnce participants have completed active treatment, they will be followed through a 3-month safety follow-up period. The sponsor may extend active treatment beyond 2 years at a future timepoint.'}, 'conditionsModule': {'conditions': ['DMD', 'Duchenne Muscular Dystrophy', 'Duchenne', 'Exon 44'], 'keywords': ['EXPLORE44', 'EXPLORE44-OLE', 'EXPLORE44 OLE', 'Avidity Biosciences', 'Avidity', 'AOC 1044', 'AOC 1044-CS1', 'AOC 1044-CS2', 'AOC']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE', 'maskingDescription': 'Randomization from the parent study, AOC 1044-CS1 will remain blinded.'}}, 'enrollmentInfo': {'count': 24, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'AOC 1044 Multiple Dose Levels', 'type': 'EXPERIMENTAL', 'description': 'AOC 1044 will be IV infused every 6 weeks or 8 weeks for approximately 2 years.', 'interventionNames': ['Drug: AOC 1044']}], 'interventions': [{'type': 'DRUG', 'name': 'AOC 1044', 'description': 'AOC 1044 will be administered via intravenous (IV) infusion', 'armGroupLabels': ['AOC 1044 Multiple Dose Levels']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change from baseline to biopsy visit in dystrophin protein level as measured in skeletal muscle by western blot', 'timeFrame': 'Baseline collection in AOC 1044-CS1 to 8 months after targeted dose starts in AOC 1044-CS2'}], 'secondaryOutcomes': [{'measure': 'Incidence of treatment emergent adverse events (TEAEs)', 'timeFrame': 'Through study completion (approximately 2 years)'}, {'measure': 'Change from baseline to biopsy visit in dystrophin protein levels as measured in skeletal muscle by mass spectrometry', 'timeFrame': 'Baseline collection in AOC 1044-CS1 to 8 months after targeted dose starts in AOC 1044-CS2.'}, {'measure': 'Change from baseline to biopsy visit in exon skipping as measured in skeletal muscle', 'timeFrame': 'Baseline collection in AOC 1044-CS1 to 8 months after targeted dose starts in AOC 1044-CS2.'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Key Inclusion Criteria\\n\\nRollover Participants:\\n\\n* Satisfactorily completed AOC 1044-CS1 (EXPLORE44) as determined by the Investigator and Sponsor\\n* No significant tolerability issues with AOC 1044\\n\\nKey Exclusion Criteria\\n\\nRollover Participants:\\n\\n* Presence of any new condition or worsening of existing condition that could affect a participant's safety or ability to comply with study procedures\", 'healthyVolunteers': False, 'sex': 'MALE', 'minimumAge': '7 Years', 'maximumAge': '27 Years', 'stdAges': ['CHILD', 'ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Mark Stahl, MD, PhD', 'affiliation': 'Avidity Biosciences, Inc.', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Rare Disease Research - Atlanta', 'city': 'Atlanta', 'state': 'Georgia', 'zip': '30329', 'country': 'United States', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000009136', 'term': 'Muscular Dystrophies'}, {'id': 'D000020388', 'term': 'Muscular Dystrophy, Duchenne'}], 'ancestors': [{'id': 'D000020966', 'term': 'Muscular Disorders, Atrophic'}, {'id': 'D000009135', 'term': 'Muscular Diseases'}, {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D000040181', 'term': 'Genetic Diseases, X-Linked'}], 'browseLeaves': [{'id': 'M12093', 'name': 'Muscular Dystrophies', 'asFound': 'Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'M22185', 'name': 'Muscular Dystrophy, Duchenne', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'M4589', 'name': 'Atrophy', 'relevance': 'LOW'}, {'id': 'M12092', 'name': 'Muscular Diseases', 'relevance': 'LOW'}, {'id': 'M22697', 'name': 'Muscular Disorders, Atrophic', 'relevance': 'LOW'}, {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M23686', 'name': 'Genetic Diseases, Inborn', 'relevance': 'LOW'}, {'id': 'M24877', 'name': 'Genetic Diseases, X-Linked', 'relevance': 'LOW'}, {'id': 'T3963', 'name': 'Muscular Dystrophy', 'asFound': 'Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'T698', 'name': 'Becker Muscular Dystrophy', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'T1945', 'name': 'Duchenne Muscular Dystrophy', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC16', 'name': 'Diseases and Abnormalities at or Before Birth'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03689660', 'orgStudyIdInfo': {'id': 'Merve Kurt'}, 'organization': {'fullName': 'Dokuz Eylul University', 'class': 'OTHER'}, 'briefTitle': 'Feasibility of Virtual Reality in Children With Neuromuscular Disease, Effectiveness of Virtual Reality and Biofeedback', 'officialTitle': 'The Feasibility of Virtual Reality in Children With Neuromuscular Disease and the Effectiveness of Virtual Reality and Biofeedback Training on Functional Levels of Children With Neuromuscular Disease'}, 'statusModule': {'statusVerifiedDate': '2022-06', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2019-02-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-05-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2023-10-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2018-09-26', 'studyFirstSubmitQcDate': '2018-09-26', 'studyFirstPostDateStruct': {'date': '2018-09-28', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-06-16', 'lastUpdatePostDateStruct': {'date': '2022-06-22', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorFullName': 'Merve Kurt', 'investigatorTitle': 'Research Assistant', 'investigatorAffiliation': 'Dokuz Eylul University'}, 'leadSponsor': {'name': 'Merve Kurt', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Our study is a randomized controlled study and the subjects included in the study will be divided into three groups as virtual reality training, biofeedback training, and conventional rehabilitation.', 'detailedDescription': 'We have 3 purposes:\\n\\n1. Determine the feasibility of virtual reality training in children with neuromuscular disease.\\n2. To determine the effect of virtual reality, biofeedback training, and conventional rehabilitation on functional levels and balances of children with neuromuscular disease.\\n3. To compare the motivation of children with neuromuscular disease to virtual reality, biofeedback training, and conventional rehabilitation.'}, 'conditionsModule': {'conditions': ['Neuromuscular Disease', 'Duchenne Muscular Dystrophy', 'Spinal Muscular Atrophy', 'Virtual Reality', 'Biofeedback'], 'keywords': ['motivation', 'neuromuscular disease', 'duchenne muscular dystrophy', 'spinal Muscular Atrophy', 'virtual reality', 'biofeedback training']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'maskingDescription': 'Nope', 'whoMasked': ['OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 24, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Virtual Reality Training', 'type': 'EXPERIMENTAL', 'description': 'Virtual reality treatment will be applied during the 12 weeks. The training will consist of three sessions per week and 30 minutes per session.', 'interventionNames': ['Other: Virtual Reality Training']}, {'label': 'Biofeedback Training', 'type': 'EXPERIMENTAL', 'description': 'Biofeedback training will be applied during the 12 weeks. The training will consist of three sessions per week and 30 minutes per session.', 'interventionNames': ['Other: Biofeedback Training']}, {'label': 'Conventional Rehabilitation', 'type': 'OTHER', 'description': 'Participants will continue this rehabilitation program if they are already getting rehabilitation in a rehabilitation center. If they do not participate in any rehabilitation program, they will be included in the conventional rehabilitation program by us.', 'interventionNames': ['Other: Conventional rehabilitation']}], 'interventions': [{'type': 'OTHER', 'name': 'Virtual Reality Training', 'description': 'Participants will be given a game-based workout program that includes balance and weight transfers using the XBOX Kinect ™ device in a low-to-medium intensity for 3 weeks, 3 days a week, 30 minutes per day.', 'armGroupLabels': ['Virtual Reality Training']}, {'type': 'OTHER', 'name': 'Biofeedback Training', 'description': 'biofeedback training will be applied to participants in 10-minute sessions with 10 seconds of voluntary contraction and 15 seconds of rest at each session. Training will last 12 weeks.', 'armGroupLabels': ['Biofeedback Training']}, {'type': 'OTHER', 'name': 'Conventional rehabilitation', 'description': 'Participants will receive a 12-week conventional rehabilitation program.', 'armGroupLabels': ['Conventional Rehabilitation']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The Motor Function Measure-32', 'description': 'MFM-32 is a scale developed to evaluate motor functions of children and adults with neuromuscular disease. The scale can be used to evaluate both in children with and without walking problems.The MFM-32 consists of 32 items. Each item is answered with a 4-point likert scale (0 = cannot initiate the exercise or maintain its starting position, 1 = partially completes the exercise, 2 = completes exercises with compensations, slowly or roughly, 3 = completes the exercise in the standard pattern). The scale can be used for the evaluation of individuals aged between 6 and 60 years.', 'timeFrame': '30 minutes'}, {'measure': 'Pediatric Functional Independence Measure', 'description': 'WeeFIM consists of 18 items divided into 6 sub-scales (self-care, sphincter control, mobility, locomotion, communication, social communication). Each item is scored from 1 to 7. A higher score indicates a better functional level.', 'timeFrame': '5 minutes'}, {'measure': 'Balance Master System', 'description': 'The static and dynamic balance evaluated using the Balance Master System ver. 8.1. (NeuroCom International Inc. Clackamas, OR, USA) force platform system which has multiple testing protocols designed to examine balance. The system includes a computer linked force plate that records data with the aid of crystal transducers.', 'timeFrame': '20 minutes'}, {'measure': 'Vignos Scale', 'description': 'The Vignos Scale has been developed to evaluate the lower extremity functions. The scale allows the lower extremity functions to be scored between 1 (can walk and climb stairs without help) and -10 (bed dependent).', 'timeFrame': '2 Minutes'}, {'measure': 'Feasibility of Virtual Reality', 'description': 'The feasibility of virtual reality will be examined by laboratory tests. Laboratory tests to be carried out are as follows: Creatine Kinase, Lactate Dehydrogenase (LDH), Myoglobin, Serum Electrolytes, C-Reactive Protein levels. These are agents that are indicative of muscle destruction or inflammation. Will be evaluated in order to follow muscle destruction.', 'timeFrame': '1 Minutes'}, {'measure': 'Pediatric Motivation Scale', 'description': \"The PMOT is recommended for assessing motivation to rehabilitation program in children aged 8 to 18 years. It comprises six subscales (effort-importance, interest-enjoyment, competence, relatedness, autonomy, and value-usefulness) with total 21 items. While the 19 items of the scale are answered with a 6-point smiley face scale (1 = absolutely false, 6 = absolutely correct), there are 2 open-ended questions on the scale. The high scores in each sub-scales indicate that the child's motivation in that sub-section is high. A higher total score indicates that the motivation is intrinsically arranged and that the child has a high motivation. From this point of view, the scale gives information about both the type of motivation and the amount of motivation of the child.\", 'timeFrame': '5 Minutes'}, {'measure': 'Visual Analog Scale', 'description': 'Visual Analog Scale will be applied to evaluate muscle pain. It has a fixed line between two end adjectives of 100 mm length. The end adjectives in our study will be \"no pain\" and \"too much pain\".', 'timeFrame': '1 Minute'}], 'secondaryOutcomes': [{'measure': 'Pediatric Functional Reaching Test', 'description': 'For the Pediatric Functional Reach test, children will be asked to raise their arms 90o in an upright posture position, extending to the maximum possible distance in three directions, forward, right, and left. Reach distances will be measured by pointing the wall with the end point of the third finger, and distances; \"start\", \"final\" and \"difference\" will be determined in cm using tape measure.', 'timeFrame': '1 Minute'}, {'measure': 'Fall Frequency', 'description': \"The frequency of the fall will be questioned with a chart created by the researchers. The family will be asked to record the children's each fall a week before the study and a week after the treatment.\", 'timeFrame': '1 Minute'}, {'measure': 'Muscle Strength Test with Hand Held Dinamometer', 'description': 'Upper and lower limb muscles strength will be evaluated with hand held dinamometer device. This device allows recording of muscle strength in kilograms.', 'timeFrame': '20 minutes'}, {'measure': 'Timed Up Go Test', 'description': 'For the time up go test, children will be asked to walk with two walking cones at a distance of 10 meters, at normal walking speeds, and the elapsed time will be recorded in seconds.', 'timeFrame': '2 Minutes'}, {'measure': 'Stair Climb Test', 'description': 'Children will be asked to climb up and down as quickly as they can, without running the steps, on a ladder of 16-20 cm height and 8-14 steps and the elapsed time will be recorded in seconds.', 'timeFrame': '2 Minutes'}, {'measure': 'T-shirt Wear Remove Test', 'description': 'For the T-shirt pull-out test, the children will be asked to wear a T-Shirt in the sitting position as soon as possible and the elapsed time will be recorded in seconds; then they will be asked to remove the T-Shirt as soon as possible and the elapsed time will be recorded in seconds.', 'timeFrame': '2 Minutes'}, {'measure': 'Stand Up from Supine Position Test', 'description': 'From the supine position to stand up, children will be asked to lie on the back of the body, the arms next to the body, the legs as closed as possible, and the head on the midline on a mat. Then, from this position, they will be asked to stand as soon as possible and the elapsed time will be recorded in seconds.', 'timeFrame': '1 Minutes'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Volunteer to participate in the study\\n* Being diagnosed with the neuromuscular disease\\n* No other systemic or neurological disease\\n* No significant visual or auditory loss\\n* Continuation of ambulation (10 m walking independently)\\n* Be able to understand simple commands\\n\\nExclusion Criteria:\\n\\n* Performing a drug change at 3 months before treatment or during treatment which may affect muscle strength\\n* Acute inflammation in the musculoskeletal system\\n* Finding any orthopedic problem that prevents activities during the research', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '6 Years', 'maximumAge': '18 Years', 'stdAges': ['CHILD', 'ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Merve Kurt', 'role': 'CONTACT', 'phone': '5537241324', 'phoneExt': '+90', 'email': 'merveekurtt93@gmail.com'}, {'name': 'Tülay Tarsuslu Şimşek', 'role': 'CONTACT', 'phone': '2324124923', 'email': 'tulay_tarsuslu@yahoo.com'}], 'overallOfficials': [{'name': 'Tülay Tarsuslu Şimşek', 'affiliation': 'Professor Dr.', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Dokuz Eylul University', 'status': 'RECRUITING', 'city': 'Izmir', 'state': 'Balcova', 'zip': '35340', 'country': 'Turkey', 'contacts': [{'name': 'Tülay Tarsuslu Simsek, Prof.', 'role': 'CONTACT'}], 'geoPoint': {'lat': 38.41273, 'lon': 27.13838}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'The IPD may share when requested', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF'], 'timeFrame': 'IPD: Balance results, Functional Level, Diagnosis, demographic data', 'accessCriteria': 'The IPD may share when requested.'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000009136', 'term': 'Muscular Dystrophies'}, {'id': 'D000020388', 'term': 'Muscular Dystrophy, Duchenne'}, {'id': 'D000009133', 'term': 'Muscular Atrophy'}, {'id': 'D000009134', 'term': 'Muscular Atrophy, Spinal'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000001284', 'term': 'Atrophy'}], 'ancestors': [{'id': 'D000020763', 'term': 'Pathological Conditions, Anatomical'}, {'id': 'D000020966', 'term': 'Muscular Disorders, Atrophic'}, {'id': 'D000009135', 'term': 'Muscular Diseases'}, {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D000040181', 'term': 'Genetic Diseases, X-Linked'}, {'id': 'D000020879', 'term': 'Neuromuscular Manifestations'}, {'id': 'D000009461', 'term': 'Neurologic Manifestations'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}], 'browseLeaves': [{'id': 'M12093', 'name': 'Muscular Dystrophies', 'asFound': 'Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'M22185', 'name': 'Muscular Dystrophy, Duchenne', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'M4589', 'name': 'Atrophy', 'asFound': 'Atrophy', 'relevance': 'HIGH'}, {'id': 'M12090', 'name': 'Muscular Atrophy', 'asFound': 'Muscular Atrophy', 'relevance': 'HIGH'}, {'id': 'M12091', 'name': 'Muscular Atrophy, Spinal', 'asFound': 'Spinal Muscular Atrophy', 'relevance': 'HIGH'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'asFound': 'Neuromuscular Diseases', 'relevance': 'HIGH'}, {'id': 'M22519', 'name': 'Pathological Conditions, Anatomical', 'relevance': 'LOW'}, {'id': 'M12092', 'name': 'Muscular Diseases', 'relevance': 'LOW'}, {'id': 'M22697', 'name': 'Muscular Disorders, Atrophic', 'relevance': 'LOW'}, {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'}, {'id': 'M23686', 'name': 'Genetic Diseases, Inborn', 'relevance': 'LOW'}, {'id': 'M24877', 'name': 'Genetic Diseases, X-Linked', 'relevance': 'LOW'}, {'id': 'M22619', 'name': 'Neuromuscular Manifestations', 'relevance': 'LOW'}, {'id': 'M12404', 'name': 'Neurologic Manifestations', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'relevance': 'LOW'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'relevance': 'LOW'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'T3963', 'name': 'Muscular Dystrophy', 'asFound': 'Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'T698', 'name': 'Becker Muscular Dystrophy', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'T1945', 'name': 'Duchenne Muscular Dystrophy', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'T5342', 'name': 'Spinal Muscular Atrophy', 'asFound': 'Spinal Muscular Atrophy', 'relevance': 'HIGH'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC16', 'name': 'Diseases and Abnormalities at or Before Birth'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT02972580', 'orgStudyIdInfo': {'id': 'IRB16-00319'}, 'organization': {'fullName': \"Nationwide Children's Hospital\", 'class': 'OTHER'}, 'briefTitle': 'Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD', 'officialTitle': 'Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD)'}, 'statusModule': {'statusVerifiedDate': '2023-08', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2016-06'}, 'primaryCompletionDateStruct': {'date': '2025-12', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-12', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2016-07-25', 'studyFirstSubmitQcDate': '2016-11-21', 'studyFirstPostDateStruct': {'date': '2016-11-23', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2023-08-29', 'lastUpdatePostDateStruct': {'date': '2023-08-31', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'May Ling Mah', 'investigatorTitle': 'Principal Investigator', 'investigatorAffiliation': \"Nationwide Children's Hospital\"}, 'leadSponsor': {'name': \"Nationwide Children's Hospital\", 'class': 'OTHER'}, 'collaborators': [{'name': 'Parent Project Muscular Dystrophy', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'Longitudinal prospective observational study. This is a 24-month study with the possibility of extending the data time points. Initially baseline, then 12 and 24 months follow up studies will be completed.', 'detailedDescription': 'Four cohorts are enrolled in this study. The target population is the cohort of genetically confirmed DMD/BMD female carriers (Cohort A). This cohort will consist of 150 DMD/BMD mothers who are somatic carriers of a mutation in the DMD gene. The data collected for this cohort will be compared to three control groups; Control Group B is a cohort of 50 DMD/BMD mothers who are NOT somatic carriers, Control Group C is a cohort of 50 age-matched healthy controls and Control Group D is a cohort of 25 genetically confirmed carriers who do not have an affected child. The inclusion of a Control Group B allows for a comparison to a group of mothers that share the emotional and cognitive burden of caring for an affected male without having the physical or cognitive risks of being a female carrier. The Control Group C offers robust data from an age-matched healthy cohort for purposes of comparison. Control Group D allows for comparison to a group of women that have the same physical or cognitive risks as the Cohort A female carriers, but do not have the same burden of care giving.'}, 'conditionsModule': {'conditions': ['Duchenne Muscular Dystrophy', 'Becker Muscular Dystrophy']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': \"The blood sample for genetic testing will be delivered to the Molecular Genetics lab at Nationwide Children's Hospital, where genomic DNA will be isolated from peripheral white blood cells. DNA will be banked frozen while a portion of the sample will be delivered to the Emory Molecular Genetics Laboratories for testing of the DMD gene.\"}, 'enrollmentInfo': {'count': 250, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Cohort A', 'description': 'DMD/BMD Female Carriers who have/had an affected child (n=150)', 'interventionNames': ['Genetic: Genetic characterization']}, {'label': 'Cohort B', 'description': 'DMD/BMD Female non-carriers controls who have/had an affected child (n=50)', 'interventionNames': ['Genetic: Genetic characterization']}, {'label': 'Cohort C', 'description': 'Healthy Age-Matched Controls (n=50)', 'interventionNames': ['Genetic: Genetic characterization']}, {'label': 'Cohort D', 'description': 'DMD/BMD Female Carriers with no affected children (n=25)', 'interventionNames': ['Genetic: Genetic characterization']}], 'interventions': [{'type': 'GENETIC', 'name': 'Genetic characterization', 'description': 'Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts', 'armGroupLabels': ['Cohort A', 'Cohort B', 'Cohort C', 'Cohort D']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Compromise of cardiac function based on Cardiac Magnetic Resonance Imaging', 'description': 'Cardiac function as compromised by evidence of scarring of cardiac muscles, particularly of the base of the left ventricle via cardiac MRI studies with gadolinium contrast.', 'timeFrame': '2 years'}], 'secondaryOutcomes': [{'measure': 'Cardiac Function Assessment Treadmill SVO2', 'description': 'Stress on heart muscle measured by SVO2 (percentage of oxygen saturation in the blood of the pulmonary artery). SVO2 represents an average of all the venous oxygen saturation of major organs and tissues. This measure provides assessment of cardiopulmonary function and helps measure the degree of cardiac instability and can be an indicator of deterioration from normal.', 'timeFrame': '2 years'}, {'measure': 'Physical Therapy Assessments Maximum Voluntary Isometric Contraction Testing', 'description': 'MVICT measures strength of skeletal muscles by assessing the force generated by by individual muscles. The results can be compared to norms and deterioration can be assessed over time.', 'timeFrame': '2 Years'}, {'measure': 'Physical Therapy Assessments 6 Minute Walk Test', 'description': 'A timed test to assess distance walked in 6 minutes is very quantitative and can be assessed in comparison to normal controls. Deterioration over time can be clearly measured.', 'timeFrame': '2 years'}, {'measure': 'Physical Therapy Assessments ACTIVE-seated', 'description': 'Exploratory outcome quantifying upper extremity reaching ability using a custom-designed game telling how far the arm reaches in comparison to overall functional ability of the individual ability.', 'timeFrame': '2 Years'}, {'measure': 'Physical Therapy Assessments Time-to-Rise', 'description': 'A timed-test to measure ability to rise from the floor is quantifiable and measuring over time tells if there is loss of function.', 'timeFrame': '2 Years'}, {'measure': 'Laboratory biomarkers - Creatine Kinase', 'description': 'CK levels are an indicator of muscle breakdown.', 'timeFrame': '2 Years'}, {'measure': 'Laboratory biomarkers - C-Reactive Protein', 'description': 'Pro-inflammatory marker indicating the degree of inflammation of muscle when there is muscle breakdown.', 'timeFrame': '2 Years'}, {'measure': 'Laboratory biomarkers - Interleukin-6', 'description': 'Pro-inflammatory marker indicating the degree of inflammation of muscle when there is muscle breakdown.', 'timeFrame': '2 Years'}, {'measure': 'Laboratory biomarkers - Cortisol levels', 'description': 'Hair cortisol levels measure stress levels as a means of understanding coping with disease.', 'timeFrame': '2 Years'}, {'measure': 'Cognitive Assessment', 'description': 'Cognitive function measured by Wechsler Abbreviated Scale of Intelligence (WASI) provides a possible tool to measure disease awareness and establish if IQ level correlates with disease-related stress.', 'timeFrame': '2 Years'}, {'measure': 'Caregiver Stress', 'description': 'Online self-report survey to assess stress burden on caregiver.', 'timeFrame': '2 Years'}, {'measure': 'Pulmonary function testing (PFTs)', 'description': 'Stable or improved FVC', 'timeFrame': '2 Years'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Age \\\\>18 years\\n* Cohort A requires a genetically confirmed mutation in the DMD gene with an affected child\\n* Cohort B includes DMD/BMD mothers with NO somatic mutation in the DMD gene\\n* Cohort C age-matched healthy controls with a normal CK level\\n* Cohort D requires a genetically confirmed mutation in the DMD gene without an affected child\\n* Able to complete testing in English\\n* Able to consent\\n\\nExclusion Criteria:\\n\\n* Subjects with a contraindication to cardiac or skeletal muscle MRI\\n* Subjects on heart failure medication at time of enrollment\\n* Subjects on steroid treatment\\n* Presence of an inherited neurologic disease or comorbidity that may affect their ability to complete this study\\n* Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with the protocol required testing or procedures or compromise the subject's wellbeing, safety, or clinical interpretability\", 'healthyVolunteers': True, 'sex': 'FEMALE', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Cohort A: DMD/BMD Female Carriers who have/had an affected child (n=150) Cohort B: DMD/BMD Female non-carriers controls who have/had an affected child (n=50) Cohort C: Healthy Age-Matched Controls (n=50) Cohort D: DMD/BMD Female Carriers who do not have/had an affected child (n=25)', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Kate Kanwar, MS', 'role': 'CONTACT', 'phone': '614-355-5649', 'email': 'Kate.Kanwar@nationwidechildrens.org'}, {'name': 'Victoria Shay, MS', 'role': 'CONTACT', 'phone': '615-355-5819', 'email': 'Victoria.Shay@nationwidechildrens.org'}], 'overallOfficials': [{'name': 'May Ling Mah, MD', 'affiliation': 'PI', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': \"Nationwide Children's Hosptial\", 'status': 'RECRUITING', 'city': 'Columbus', 'state': 'Ohio', 'zip': '43205', 'country': 'United States', 'contacts': [{'name': 'Kate Kanwar, MS', 'role': 'CONTACT', 'phone': '614-355-5649', 'email': 'Kate.kanwar@nationwidechildrens.org'}, {'name': 'Victoria Shay, MS', 'role': 'CONTACT', 'phone': '615-355-5819', 'email': 'victoria.shay@nationwidechildrens.org'}, {'name': 'May Ling Mah, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Jerry Mendell, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Kan Hor, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Linda Cripe, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Jamie Jackson, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Lindsay Alfano, DPT', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Kelly Lehman, CNP', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}]}, 'referencesModule': {'references': [{'pmid': '32473283', 'type': 'DERIVED', 'citation': 'Mah ML, Cripe L, Slawinski MK, Al-Zaidy SA, Camino E, Lehman KJ, Jackson JL, Iammarino M, Miller N, Mendell JR, Hor KN. Duchenne and Becker muscular dystrophy carriers: Evidence of cardiomyopathy by exercise and cardiac MRI testing. Int J Cardiol. 2020 Oct 1;316:257-265. doi: 10.1016/j.ijcard.2020.05.052. Epub 2020 May 27.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000009136', 'term': 'Muscular Dystrophies'}, {'id': 'D000020388', 'term': 'Muscular Dystrophy, Duchenne'}], 'ancestors': [{'id': 'D000020966', 'term': 'Muscular Disorders, Atrophic'}, {'id': 'D000009135', 'term': 'Muscular Diseases'}, {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D000040181', 'term': 'Genetic Diseases, X-Linked'}], 'browseLeaves': [{'id': 'M12093', 'name': 'Muscular Dystrophies', 'asFound': 'Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'M22185', 'name': 'Muscular Dystrophy, Duchenne', 'asFound': 'Becker Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'M4589', 'name': 'Atrophy', 'relevance': 'LOW'}, {'id': 'M12092', 'name': 'Muscular Diseases', 'relevance': 'LOW'}, {'id': 'M22697', 'name': 'Muscular Disorders, Atrophic', 'relevance': 'LOW'}, {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M23686', 'name': 'Genetic Diseases, Inborn', 'relevance': 'LOW'}, {'id': 'M24877', 'name': 'Genetic Diseases, X-Linked', 'relevance': 'LOW'}, {'id': 'T3963', 'name': 'Muscular Dystrophy', 'asFound': 'Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'T698', 'name': 'Becker Muscular Dystrophy', 'asFound': 'Becker Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'T1945', 'name': 'Duchenne Muscular Dystrophy', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC16', 'name': 'Diseases and Abnormalities at or Before Birth'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT06013839', 'orgStudyIdInfo': {'id': 'TXA127-DMD-002'}, 'organization': {'fullName': 'Constant Therapeutics LLC', 'class': 'INDUSTRY'}, 'briefTitle': 'TXA127 in Non-Ambulant Patients With DMD Cardiomyopathy', 'officialTitle': 'A Phase 2, Single-Arm, Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of TXA127/Angiotensin [1-7] in Non-Ambulant Patients With Duchenne Muscular Dystrophy (DMD) Cardiomyopathy Who Are Receiving Systemic Glucocorticoids'}, 'statusModule': {'statusVerifiedDate': '2023-09', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-08-31', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-08', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2024-12', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-08-16', 'studyFirstSubmitQcDate': '2023-08-22', 'studyFirstPostDateStruct': {'date': '2023-08-28', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-01-22', 'lastUpdatePostDateStruct': {'date': '2024-01-23', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Constant Therapeutics LLC', 'class': 'INDUSTRY'}}, 'oversightModule': {'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False, 'isUsExport': True}, 'descriptionModule': {'briefSummary': 'This open-label, single-arm multi-center study studying the safety and efficacy of TXA127 on non-ambulant patients with DMD Cardiomyopathy will comprise of two phases:\\n\\n1. 6-month open-label treatment phase: Male DMD patients with documented cardiomyopathy, will receive a daily subcutaneous injection of TXA127 0.5 mg/kg. Treatment will be provided for 6 months. Treatment safety will be assessed by collection and review of AEs, vital signs, ECGs, physical examinations, PFTs, and laboratory parameters on Day 1, Month 1, and Month 6. Ejection Fraction, upper extremity strength and biomarker levels will be assessed at these study visits as well. In addition, an abbreviated safety visit will be conducted at Month 3.\\n2. 12-month optional extension phase: Patients will continue the same study drug regime for an additional 12 months. The primary objective of this phase is to obtain long-term safety data. Efficacy data will also be collected. Safety, efficacy, and exploratory biomarkers will be assessed at Month 12 and Month 18, using the same methods as in the treatment phase. In addition, abbreviated safety visits will be conducted at Month 9 and Month 15.'}, 'conditionsModule': {'conditions': ['DMD-Associated Dilated Cardiomyopathy']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 10, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'TXA127 SC 0.5mg/kg/day', 'type': 'EXPERIMENTAL', 'description': 'TXA127 (talfirastide) 0.5mg/kg/day given via subcutaneous injection for 6 months', 'interventionNames': ['Drug: talfirastide']}], 'interventions': [{'type': 'DRUG', 'name': 'talfirastide', 'description': 'TXA127 (talfirastide) is a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II).', 'armGroupLabels': ['TXA127 SC 0.5mg/kg/day'], 'otherNames': ['TXA127', 'Angiotensin-(1-7)']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'To evaluate the safety of TXA127 in patients with DMD', 'description': 'Incidence of adverse events (AEs), their severity and relationship to treatment', 'timeFrame': '6 months plus 12 month extension'}, {'measure': 'To evaluate the effects of treatment on ejection fraction (EF)', 'description': 'Percent change in EF, as measured by echocardiogram (ECHO); Absolute change in EF, as measured by echocardiogram', 'timeFrame': '6 months plus 12 month extension'}], 'secondaryOutcomes': [{'measure': 'To evaluate the effects of treatment on upper extremity muscle function', 'description': 'Percent change in upper extremity strength, as measured by grip strength with a dynamometer; Absolute change in upper extremity strength, as measured by grip strength with a dynamometer', 'timeFrame': '6 months plus 12 month extension'}, {'measure': 'To evaluate the effects of treatment on fractional shortening (FS)', 'description': 'Percent and absolute change in fractional shortening as measured by echocardiogram', 'timeFrame': '6 months plus 12 month extension'}], 'otherOutcomes': [{'measure': 'To evaluate the effects of treatment on exploratory DMD-related clinical signs, FVC', 'description': 'Forced Vital Capacity (FVC) % predicted\\n\\nAbsolute and percent (where applicable) change in the following biomarkers in the blood:\\n\\n* Troponin and Brain Natriuretic Peptide (BNP)\\n* Brain-derived neurotrophic factor (BDNF)', 'timeFrame': '6 months plus 12 month extension'}, {'measure': 'To evaluate the effects of treatment on exploratory DMD-related clinical signs, PEF', 'description': 'Peak Expiratory Flow (PEF) % predicted (if available)\\n\\nAbsolute and percent (where applicable) change in the following biomarkers in the blood:\\n\\n* Troponin and Brain Natriuretic Peptide (BNP)\\n* Brain-derived neurotrophic factor (BDNF)', 'timeFrame': '6 months plus 12 month extension'}, {'measure': 'To evaluate the effects of treatment on exploratory DMD-related biomarkers, Troponin', 'description': 'Absolute and percent (where applicable) change in Troponin', 'timeFrame': '6 months plus 12 month extension'}, {'measure': 'To evaluate the effects of treatment on exploratory DMD-related biomarkers, BNP', 'description': 'Absolute and percent (where applicable) change in Brain Natriuretic Peptide (BNP)', 'timeFrame': '6 months plus 12 month extension'}, {'measure': 'To evaluate the effects of treatment on exploratory DMD-related biomarkers, BDNF', 'description': 'Absolute and percent (where applicable) change in Brain-derived neurotrophic factor (BDNF)', 'timeFrame': '6 months plus 12 month extension'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n1. Male subjects 16 years of age or older who provide informed consent and can follow up with protocol procedures. Parental or guardian consent is required for subjects at least 16 years of age but younger than 18 years of age.\\n2. Documented diagnosis of Duchenne muscular dystrophy by genetic mutation analysis.\\n3. Documented cardiomyopathy, as assessed by echocardiogram with:\\n\\n   1. For a patient ≤ 20 years of age, EF \\\\> 35% and \\\\< 55% and fractional shortening of ≤ 28% at the time of screening.\\n   2. For a patient \\\\> 20 years of age, EF \\\\> 20% and fractional shortening ≤ 28% at the time of screening.\\n4. Reproducible (+/- 10%) difference between screening and baseline of percent predicted FVC , using the best out of 3 efforts at each visit:\\n\\n   1. For a patient ≤ 20 years of age, FVC between 45% and 85%, inclusive. Patient should not utilize non-invasive ventilation such as CPAP or BiPAP.\\n   2. For a patient \\\\>20 years of age, all of the following should exist: FVC \\\\> 20%, EF \\\\> 20% in baseline ECHO and ability to be off non-invasive ventilation, such as CPAP and BiPAP, for at least 4 consecutive hours a day (24 hours period).\\n5. Subjects must be taking systemic glucocorticoids for at least six months prior to screening.\\n6. Subjects taking mineralocorticoid receptor antagonists, must be taking the drug for at least three months prior to screening\\n7. Non-ambulant and cared for by a trained caregiver\\n\\nExclusion Criteria:\\n\\n1. Therapy with intravenous inotropic or vasoactive medications at the time of screening\\n2. Planned or likelihood of major surgery in the 6 months after planned enrollment.\\n3. Patient is using a left ventricular assist device (LVAD) or actively in the process of acquiring a LVAD.\\n4. Estimated glomerular filtration rate (GFR) \\\\<50 mL/min, as calculated by the CKD-EPI Creatinine equation 2021 (https://www.kidney.org/professionals/kdoqi/gfr_calculator)\\n5. Patient is suffering from unstable systemic allergic reaction(s), connective tissue disease or autoimmune disorder(s), requiring active intervention\\n6. History of cardiac tumor or current cardiac tumor\\n7. Known moderate-to-severe aortic stenosis/insufficiency or severe mitral stenosis/regurgitation\\n8. Current alcohol or drug abuse\\n9. Known history of chronic viral hepatitis unless considered cured based on hepatitis C RNA negative results\\n10. Hepatic dysfunction upon screening evidenced by bilirubin levels or gamma-GT levels above normal, deemed as clinically significant by the PI/Sub-I, and/or abnormal hematology (hematocrit \\\\<25%, WBC \\\\<3000/μl, platelets \\\\<100,000/μl), without a reversible, identifiable cause. Total bilirubin elevations \\\\> 2 times the upper reference range, consistent with Gilbert's Syndrome, may be enrolled if there is no other evidence of liver dysfunction\\n11. Uncontrolled diabetes (HbA1c \\\\>9.0 percent)\\n12. Inability to comply with protocol-related procedures, including required study visits\\n13. Any condition or other reason that, in the opinion of the investigator or Medical Monitor, would render the subject unsuitable for the study\\n14. Currently receiving or received within 90 days of enrollment (Day 1) an investigational treatment on another clinical study or expanded access protocol. This will include patients currently being treated or who have not completed follow-up to treatment with an investigational cell-based therapy within 6 months prior to enrollment and patients actively receiving an investigational therapy for cardiovascular repair/regeneration.\", 'healthyVolunteers': False, 'sex': 'MALE', 'minimumAge': '16 Years', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Richard L Franklin, MD, PhD', 'role': 'CONTACT', 'phone': '1-617-245-0289', 'phoneExt': '101', 'email': 'rfranklin@constanttherapeutics.com'}, {'name': 'Elizabeth Wagner, MS, MBA', 'role': 'CONTACT', 'phone': '1-617-245-0289', 'phoneExt': '102', 'email': 'ewagner@constanttherapeutics.com'}], 'overallOfficials': [{'name': 'Richard L Franklin, MD, PhD', 'affiliation': 'Constant Therapeutics LLC', 'role': 'STUDY_CHAIR'}], 'locations': [{'facility': 'Hadassah Medical Center', 'status': 'RECRUITING', 'city': 'Jerusalem', 'country': 'Israel', 'contacts': [{'name': 'Talia Dor, MD', 'role': 'CONTACT'}, {'name': 'Talia Dor, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'facility': 'Sheba Medical Center', 'status': 'RECRUITING', 'city': 'Ramat Gan', 'country': 'Israel', 'contacts': [{'name': 'Amir Dori, MD, PhD', 'role': 'CONTACT'}, {'name': 'Amir Dori, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 32.08227, 'lon': 34.81065}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000009202', 'term': 'Cardiomyopathies'}, {'id': 'D000002311', 'term': 'Cardiomyopathy, Dilated'}], 'ancestors': [{'id': 'D000006331', 'term': 'Heart Diseases'}, {'id': 'D000002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D000006332', 'term': 'Cardiomegaly'}, {'id': 'D000083083', 'term': 'Laminopathies'}, {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'}], 'browseLeaves': [{'id': 'M12154', 'name': 'Cardiomyopathies', 'asFound': 'Cardiomyopathy', 'relevance': 'HIGH'}, {'id': 'M12093', 'name': 'Muscular Dystrophies', 'relevance': 'LOW'}, {'id': 'M22185', 'name': 'Muscular Dystrophy, Duchenne', 'relevance': 'LOW'}, {'id': 'M5567', 'name': 'Cardiomyopathy, Dilated', 'asFound': 'Dilated Cardiomyopathy', 'relevance': 'HIGH'}, {'id': 'M9419', 'name': 'Heart Diseases', 'relevance': 'LOW'}, {'id': 'M9420', 'name': 'Cardiomegaly', 'relevance': 'LOW'}, {'id': 'M2392', 'name': 'Laminopathies', 'relevance': 'LOW'}, {'id': 'M23686', 'name': 'Genetic Diseases, Inborn', 'relevance': 'LOW'}, {'id': 'T3963', 'name': 'Muscular Dystrophy', 'relevance': 'LOW'}, {'id': 'T698', 'name': 'Becker Muscular Dystrophy', 'relevance': 'LOW'}, {'id': 'T1945', 'name': 'Duchenne Muscular Dystrophy', 'relevance': 'LOW'}, {'id': 'T1876', 'name': 'Dilated Cardiomyopathy', 'asFound': 'Dilated Cardiomyopathy', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC16', 'name': 'Diseases and Abnormalities at or Before Birth'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000118790', 'term': 'Angiotensin I (1-7)'}], 'ancestors': [{'id': 'D000000959', 'term': 'Antihypertensive Agents'}, {'id': 'D000014665', 'term': 'Vasodilator Agents'}], 'browseLeaves': [{'id': 'M4132', 'name': 'Angiotensin II', 'relevance': 'LOW'}, {'id': 'M289354', 'name': 'Giapreza', 'relevance': 'LOW'}, {'id': 'M4135', 'name': 'Angiotensinogen', 'relevance': 'LOW'}, {'id': 'M9047', 'name': 'Glucocorticoids', 'relevance': 'LOW'}, {'id': 'M351387', 'name': 'Angiotensin I (1-7)', 'asFound': 'Visceral fat', 'relevance': 'HIGH'}, {'id': 'M4277', 'name': 'Antihypertensive Agents', 'relevance': 'LOW'}, {'id': 'M17412', 'name': 'Vasodilator Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'VaCoAg', 'name': 'Vasoconstrictor Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'AnAg', 'name': 'Antihypertensive Agents'}, {'abbrev': 'VaDiAg', 'name': 'Vasodilator Agents'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05185622', 'orgStudyIdInfo': {'id': 'VBP15-006'}, 'organization': {'fullName': 'Santhera Pharmaceuticals', 'class': 'INDUSTRY'}, 'briefTitle': 'A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)', 'officialTitle': 'A Phase II Open-Label, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)'}, 'statusModule': {'statusVerifiedDate': '2023-11', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': True, 'nctId': 'NCT03863119', 'statusForNctId': 'AVAILABLE'}, 'startDateStruct': {'date': '2022-03-21', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-03', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2024-03', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2021-11-09', 'studyFirstSubmitQcDate': '2021-12-22', 'studyFirstPostDateStruct': {'date': '2022-01-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-11-07', 'lastUpdatePostDateStruct': {'date': '2023-11-09', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Santhera Pharmaceuticals', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This Phase II study is an open-label, multiple dose study to evaluate the safety, tolerability, PK, PD, clinical efficacy, behavior and neuropsychology, and physical functioning vamorolone over a treatment period of 12 weeks in steroid-naïve boys ages 2 to \\\\<4 years, and glucocorticoid-treated and currently untreated boys ages 7 to \\\\<18 years with DMD.', 'detailedDescription': 'This Phase II study is an open-label, multiple dose study to evaluate the safety, tolerability, PK, PD, clinical efficacy, behavior and neuropsychology, and physical functioning of vamorolone administered orally at daily doses of 2.0 mg/kg and 6.0 mg/kg over a treatment period of 3 months in steroid-naïve boys ages 2 to \\\\<4, and glucocorticoid-treated and currently untreated boys ages 7 to \\\\<18 years with DMD.\\n\\nThe study is comprised of a 5-week Pretreatment Screening Period; a 1-day Pretreatment Baseline Period; a 3-month open-label Treatment Period (Weeks 1-12); and a 4-week open-label Dose-tapering Period (Weeks 13-16) for subjects who will not transition directly to further vamorolone or standard of care (SoC) glucocorticoid treatment at the end of the study.\\n\\nSubjects will be enrolled into the study at the Screening Visit, at the time written informed consent is obtained.\\n\\nWithin the 2 to \\\\<4 years age group, the initial 10 eligible subjects will be assigned to the 2.0 mg/kg/day treatment group at the Baseline Day -1 Visit. The subsequent 10 eligible subjects will be assigned to the 6.0 mg/kg/day treatment group at the Baseline Day -1 Visit.\\n\\nWithin the 7 to \\\\<18 years age group, both corticosteroid-treated and untreated, the initial 12 eligible subjects will be assigned to the 2.0 mg/kg/day treatment group at the Baseline Day -1 Visit. The subsequent 12 eligible subjects will be assigned to the 6.0 mg/kg/day treatment group at the Baseline Day -1 Visit.\\n\\nThe first 6 subjects in each age group at 2 mg/kg will serve as the PK/safety run-in cohorts. PK assessments will be performed at week 2 and together with the safety assessment during the first 4 weeks of treatment this will be the basis to confirm whether 2 and 6 mg/kg/day will be used in the subsequent patients or if a dose adjustment is needed to avoid over or under-exposure in patients for any of the two age groups.\\n\\nGlucocorticoid-treated subjects in the 7 to \\\\<18 years age group will take their final dose of SoC glucocorticoid therapy for DMD on Baseline Day -1, within 24 hours prior to administration of the first dose of vamorolone study medication.\\n\\nAll subjects in both age groups will begin their assigned vamorolone treatment on Treatment Period Day 1, and will continue to receive their assigned vamorolone treatment throughout the duration of the 3 month Treatment Period (Weeks 1-12).\\n\\nAt the end of the 3-month Treatment Period (Week 12), subjects will be given the option to receive vamorolone in an expanded access or compassionate use program, if possible, or to transition to SoC treatment for DMD (may include glucocorticoids). Subjects completing VBP15-006 and enrolling directly into the expanded access or compassionate use program or transitioning directly to SoC glucocorticoid treatment will not need to taper their vamorolone dose prior to participation in the expanded access or compassionate use program or initiation of SoC glucocorticoid treatment. All subjects who will not transition directly to further vamorolone or SoC glucocorticoid treatment will begin a 4 week open label Dose tapering Period during which the dose of study medication will be progressively reduced and discontinued.'}, 'conditionsModule': {'conditions': ['Duchenne Muscular Dystrophy'], 'keywords': ['Duchenne Muscular Dystrophy', 'Becker Muscular Dystrophy', 'Duchenne and Becker Muscular Dystrophy', 'Muscular Dystrophy']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 54, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Treatment Group 1', 'type': 'EXPERIMENTAL', 'description': 'Patients in Treatment Group 1 must be ages 2-\\\\<4 years and will receive Vamorolone at 2.0 mg/kg/day for the duration of the study. Treatment Group 1 will be enrolled prior to Treatment Group 2.', 'interventionNames': ['Drug: Vamorolone']}, {'label': 'Treatment Group 2', 'type': 'EXPERIMENTAL', 'description': 'Patients in Treatment Group 2 must be ages 2-\\\\<4 years and will receive Vamorolone at 6.0 mg/kg/day for the duration of the study. Treatment Group 2 will be enrolled after Treatment Group 1.', 'interventionNames': ['Drug: Vamorolone']}, {'label': 'Treatment Group 3', 'type': 'EXPERIMENTAL', 'description': 'Patients in Treatment Group 3 must be ages 7-\\\\<18 years and must be steroid untreated at entry. Treatment Group 3 will receive Vamorolone at 2.0 mg/kg/day for the duration of the study.', 'interventionNames': ['Drug: Vamorolone']}, {'label': 'Treatment Group 4', 'type': 'EXPERIMENTAL', 'description': 'Patients in Treatment Group 4 must be ages 7-\\\\<18 years and must be on a stable dose of steroid for 3 months prior to entry. Treatment Group 4 will receive Vamorolone at 2.0 mg/kg/day for the duration of the study.', 'interventionNames': ['Drug: Vamorolone']}, {'label': 'Treatment Group 5', 'type': 'EXPERIMENTAL', 'description': 'Patients in Treatment Group 5 must be ages 7-\\\\<18 years and must be steroid untreated at entry. Treatment Group 5 will receive Vamorolone at 6.0 mg/kg/day for the duration of the study.', 'interventionNames': ['Drug: Vamorolone']}, {'label': 'Treatment Group 6', 'type': 'EXPERIMENTAL', 'description': 'Patients in Treatment Group 6 must be ages 7-\\\\<18 years and must be on a stable dose of steroid for 3 months prior to entry. Treatment Group 6 will receive Vamorolone at 6.0 mg/kg/day for the duration of the study.', 'interventionNames': ['Drug: Vamorolone']}, {'label': 'Treatment Group 7', 'type': 'EXPERIMENTAL', 'description': 'Patients in Treatment Group 7 must be ages 12-\\\\<18 years and must be on a stable dose of steroid for 3 months prior to entry. Treatment Group 7 will receive Vamorolone at 6.0 mg/kg/day for the duration of the study.', 'interventionNames': ['Drug: Vamorolone']}], 'interventions': [{'type': 'DRUG', 'name': 'Vamorolone', 'description': 'Oral administration of vamorolone for 12 weeks.', 'armGroupLabels': ['Treatment Group 1', 'Treatment Group 2', 'Treatment Group 3', 'Treatment Group 4', 'Treatment Group 5', 'Treatment Group 6', 'Treatment Group 7'], 'otherNames': ['VBP15']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in Body Mass Index (BMI) from baseline to Week 12', 'description': 'Body Mass Index is a measure of weight adjusted for height.', 'timeFrame': '12 weeks'}, {'measure': 'Change in Body Mass Index (BMI) z-score from baseline to Week 12', 'description': 'Body Mass Index z-scores is a measure of relative weight adjusted for child age and sex.', 'timeFrame': '12 weeks'}, {'measure': 'Change in Weight from baseline to each of the scheduled on treatment and post-treatment assessment time points', 'description': 'Body weight will be assessed at each of the scheduled time points.', 'timeFrame': 'Week 2, Week 6, Week 12, Week 16'}, {'measure': 'Change in Height from baseline to Week 12', 'description': 'Standing height will be assessed for subjects ages 2-\\\\<4 years; height calculated from ulnar length in subjects ages 7-\\\\<18.', 'timeFrame': 'Week 12'}, {'measure': 'Change in Height z score from baseline to Week 12', 'description': 'Standing height will be assessed for subjects ages 2-\\\\<4 years; height calculated from ulnar length in subjects ages 7-\\\\<18.', 'timeFrame': 'Week 12'}, {'measure': 'Change in sitting blood pressure from baseline to each of the scheduled on-treatment and post-treatment assessment time points', 'description': 'Sitting blood pressure will be assessed at scheduled on-treatment and post-treatment time points.', 'timeFrame': 'Day 1, Week 2, Week 6, Week 12, Week 16'}, {'measure': 'Change in heart rate from baseline to each of the scheduled on-treatment and post-treatment assessment time points', 'description': 'Heart rate will be assessed at scheduled on-treatment and post-treatment time points.', 'timeFrame': 'Day 1, Week 2, Week 6, Week 12, Week 16'}, {'measure': 'Change in respiratory rate from baseline to each of the scheduled on-treatment and post-treatment assessment time points', 'description': 'Respiratory rate will be assessed at scheduled on-treatment and post-treatment time points.', 'timeFrame': 'Day 1, Week 2, Week 6, Week 12, Week 16'}, {'measure': 'Change in body temperature from baseline to each of the scheduled on-treatment and post-treatment assessment time points', 'description': 'Body temperature will be assessed at scheduled on-treatment and post-treatment time points.', 'timeFrame': 'Day 1, Week 2, Week 6, Week 12, Week 16'}, {'measure': 'Number of participants with Cushingoid features', 'description': 'Cushingoid features measured by the presence of buffalo hump obesity, striations, adiposity, hypertension, diabetes, or osteoporosis. Change from baseline to each of the scheduled on-treatment and post-treatment assessment time points.', 'timeFrame': 'Week 6, Week 12, Week 16'}, {'measure': 'Number of participants with abnormal blood laboratory test results', 'description': 'Blood samples will be collected from subjects for the analysis of clinical chemistry parameters, including White Blood cells (WBCs), Red Blood Cells, (RBCs), hemoglobin, Platelets, Sodium, Potassium, Chloride, Calcium, Inorganic Phosphorus, Blood Urea Nitrogen (BUN), Creatinine, Total Protein, Albumin, Bicarbonate, Lactate Dehydrogenase (LDH), Cystatin C, Total Bilirubin, Uric Acid, Glucose, Alkaline Phosphatase (ALP), Gamma Glutamyl Transferase (GGT), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Creatine kinase (CK), Lipase, Amylase, Vitamin D, Triglycerides, Total cholesterol, Low Density Lipoprotein (LDL) and High density Lipoprotein (HDL). Change from baseline to each of the scheduled on treatment and post-treatment time points will be assessed.', 'timeFrame': 'Day 1, Week 6, Week 12, Week 16'}, {'measure': 'Number of participants with abnormal urine laboratory test results', 'description': 'Urine biomarkers will include protein, glucose, ketones, leukocyte esterase, White Blood Cells (WBCs), Red Blood Cells, (RBCs) and bacteria and will be assessed by dipstick and microscopic analysis. Change from baseline to each of the scheduled on treatment and post-treatment time points will be assessed.', 'timeFrame': 'Day 1, Week 6, Week 12, Week 16'}, {'measure': 'Number of participants with abnormal ECGs', 'description': '12-lead 1electrocardiogram (ECG) as recorded after subject has rested quietly in a supine position for at least 5 minutes. ECG components are QRS duration, PR \\\\[PQ\\\\] interval, RR interval, QT interval and QTc. Change from baseline to Week 12', 'timeFrame': 'Week 12'}, {'measure': 'Number of participants with Glaucoma', 'description': 'Glaucoma as by measured by ocular pressure.Week 12 assessments compared to baseline.', 'timeFrame': '12 weeks'}, {'measure': 'Number of participants with Cataracts', 'description': 'Cataracts as measured by the presence of partial or complete opacity of the crystalline lens of one or both eyes. Week 12 assessments compared to baseline.', 'timeFrame': '12 weeks'}, {'measure': 'Number of Participants with Adverse Events as Assessed by Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03)', 'description': 'An Adverse Event is any untoward medical occurrence in a subject and does not necessarily have to have a causal relationship with the intervention. Pre-existing conditions that worsen during the study are to be reported as AEs.', 'timeFrame': '12 weeks'}], 'secondaryOutcomes': [{'measure': 'Area under the Curve infinity (AUCinf) following oral administration', 'description': 'The pre-dose and post-dose plasma concentration measurements of vamorolone at Day 1 and Week 2 will be used for comparison of drug exposures by age group, dose level, and glucocorticoid treatment at entry (7 to \\\\<18 years only).', 'timeFrame': 'Day 1, Week 2'}, {'measure': 'Change in morning cortisol concentration from baseline to Week 12', 'description': 'Adrenal suppression is directly associated with risk of adrenal crisis, delay of puberty and stunting of growth. Measurement of morning cortisol concentrations will reflect the degree of adrenal suppression. Cortisol measures falling below 3.6 µg/dL (or 100 nM) will be considered to be indicative of the development of adrenal suppression.', 'timeFrame': 'Week 12'}, {'measure': 'Change in fasting serum concentration of glucose from baseline to Week 12', 'description': 'Glucocorticoids cause both acute and chronic insulin resistance, with serum elevations of both insulin and glucose. Measures of hyperinsulinemia and hyperglycemia are accepted measures of insulin resistance. Fasting glucose will be measured at baseline and Week 12.', 'timeFrame': 'Week 12'}, {'measure': 'Change in fasting serum concentration of insulin from baseline to Week 12', 'description': 'Glucocorticoids cause both acute and chronic insulin resistance, with serum elevations of both insulin and glucose. Measures of hyperinsulinemia and hyperglycemia are accepted measures of insulin resistance. Fasting insulin will be measured at baseline and Week 12.', 'timeFrame': 'Week 12'}, {'measure': 'Change in serum concentration of hemoglobin A1c (HbA1c) from baseline to Week 12', 'description': 'Glucocorticoids cause both acute and chronic insulin resistance, with serum elevations of both insulin and glucose. Measures of hyperinsulinemia and hyperglycemia are accepted measures of insulin resistance. Hemoglobin A1c (HbA1c) will be measured at baseline and Week 12.', 'timeFrame': 'Week 12'}], 'otherOutcomes': [{'measure': 'Change in Bayley Scales of Infant and Toddler Development-III (Bayley-III) Gross Motor scale (ages 2 to <4 years only) from baseline to Week 12', 'description': 'The Bayley-III Gross Motor scale is a functional assessment which was chosen as an accurate reflection of muscle strength for subjects with DMD ages 2 to \\\\<4 years. The minimum score value is 0 and the maximum score value is 72. Higher scores mean a better outcome.', 'timeFrame': 'Week 12'}, {'measure': 'Change in Performance of Upper Limb (PUL) test (7 to <18 years only) from baseline to Week 12', 'description': 'The Performance of Upper Limb is a functional assessment which was chosen as an accurate reflection of muscle strength for subjects with DMD ages 7 to \\\\<18 years. The minimum score value is 0 and the maximum score value is 42. Higher scores mean a better outcome.', 'timeFrame': 'Week 12'}, {'measure': 'Change in Personal Adjustment and Role Skills Scale, ed. 3 (PARS III) questionnaire from baseline to Week 12', 'description': 'The PARS III is a scale designed to assess behavior and measure psychosocial adjustment of children with chronic physical illnesses. The PARS III will be completed by the parent(s)/guardian(s) at the Screening and Week 12 Visits. The minimum score value is 28 and the maximum score value is 112. Higher scores mean better personal adjustment.', 'timeFrame': 'Week 12'}, {'measure': 'Change in Pediatric Outcome Data Collection Instrument (PODCI) from baseline to Week 12', 'description': 'Physical functioning will be measured using the Pediatric Outcomes Data Collection Instrument (PODCI). The minimum score value is 0 and the maximum score value is 100. Higher scores mean a better outcome.', 'timeFrame': 'Week 12'}, {'measure': 'Study Medication Acceptability Assessment (ages 7 to <18 years only) at each of the scheduled study assessment time points', 'description': 'Subjects in the 7 to \\\\<18 years age group will complete the Study Medication Acceptability Assessment. The minimum score value is 2 and the maximum score value is 10. Higher scores mean the medication is more acceptable.', 'timeFrame': 'Week 6, Week 12'}, {'measure': 'Ease of Study Medication Administration Assessment (ages 2 to <4 years only) at each of the scheduled study assessment time points', 'description': 'The parent(s)/legal guardian(s) of each subject in the 2 to \\\\<4 years age group will be asked to complete the Ease of Study Medication Administration Assessment. The minimum score value is 2 and the maximum score value is 10. Higher scores mean the medication is easier to administer.', 'timeFrame': 'Week 6, Week 12'}, {'measure': 'Change in concentration of serum osteocalcin from baseline to Week 12', 'description': 'Measures of serum osteocalcin are reflective of bone formation, and measures of serum C terminal peptide fragment of collagen 1 (CTX) are reflective of bone reabsorption. Ratios of osteocalcin and CTX predict later clinical safety concerns of osteopenia and bone fragility.', 'timeFrame': 'Week 12'}, {'measure': 'Change in concentration of serum aminoterminal propeptide of type I collagen (P1NP) from baseline to Week 12', 'description': 'Measures of serum P1NP are reflective of bone formation.', 'timeFrame': 'Week 12'}, {'measure': 'Change in serum concentration of C terminal peptide fragment of collagen 1 (CTX) from baseline to Week 12', 'description': 'Measures of serum osteocalcin are reflective of bone formation, and measures of serum CTX are reflective of bone reabsorption. Ratios of osteocalcin and CTX predict later clinical safety concerns of osteopenia and bone fragility.', 'timeFrame': 'Week 12'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n1. Subject's parent(s) or legal guardian(s) has (have) provided written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization, where applicable, prior to any study-related procedures; participants will be asked to give written or verbal assent according to local requirements;\\n2. Subject has a centrally confirmed (by TRiNDS central genetic counselor\\\\[s\\\\]) diagnosis of DMD, defined as:\\n\\n   1. Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency, and clinical picture consistent with typical DMD, OR\\n   2. Identifiable mutation within the DMD gene (deletion/duplication of one or more exons), where reading frame can be predicted as 'out-of-frame,' and clinical picture consistent with typical DMD, OR\\n   3. Complete dystrophin gene sequencing showing an alteration (point mutation, duplication, other) that is expected to preclude production of the dystrophin protein (i.e., nonsense mutation, deletion/duplication leading to a downstream stop codon), with a clinical picture consistent with typical DMD;\\n3. Subject is male, 2 to \\\\<4 years or 7 to \\\\<18 years of age at time of enrollment in the study;\\n4. If 7 to \\\\<18 years of age and currently taking standard of care glucocorticoids for treatment of DMD, subject has been taking standard of care glucocorticoids at stable dose for at least 3 months prior to enrollment in the study, and will continue the same stable dose regimen through the date of the Baseline Day -1 Visit. \\\\[Note: Inhaled and/or topical glucocorticoids are permitted if last use is at least 4 weeks prior to enrollment or if administered at stable dose beginning at least 4 weeks prior to enrollment and anticipated to be used at the stable dose regimen for the duration of the study\\\\];\\n5. If 7 to \\\\<18 years of age, and not currently glucocorticoid-treated, subject has not received oral glucocorticoids or other oral immunosuppressive agents for at least 3 months prior to enrollment. \\\\[Note: Inhaled and/or topical glucocorticoids are permitted if last use is at least 4 weeks prior to enrollment or if administered at stable dose beginning at least 4 weeks prior to enrollment and anticipated to be used at the stable dose regimen for the duration of the study\\\\];\\n6. Clinical laboratory test results are within the normal range at the Screening Visit, or if abnormal, are not clinically significant, in the opinion of the Investigator. \\\\[Notes: Serum gamma glutamyl transferase (GGT), creatinine, and total bilirubin all must be ≤ upper limit of the normal range at the Screening Visit. An abnormal vitamin D level that is considered clinically significant will not exclude a subject from participating\\\\];\\n7. Subject has evidence of chicken pox immunity as determined by:\\n\\n   * Presence of IgG antibodies to varicella, as documented by a positive test result from the local laboratory from blood collected during the Screening Period; OR\\n   * Documentation, provided at the Screening Visit, that the subject has had 2 doses of varicella vaccine, with or without serologic evidence of immunity; the second of the 2 immunizations must have been given at least 14 days prior to assignment to a dose group;\\n8. Subject and parent(s)/guardian(s) are willing and able to comply with scheduled visits, study drug administration plan, and study procedures.\\n\\nExclusion Criteria:\\n\\n1. Subject has current or history of major renal or hepatic impairment, diabetes mellitus or immunosuppression;\\n2. Subject has current or history of chronic systemic fungal or viral infections;\\n3. Subject has used mineralocorticoid receptor agents, such as spironolactone, eplerenone, canrenone (canrenoate potassium), prorenone (prorenoate potassium), or mexrenone (mexrenoate potassium) within 4 weeks prior to enrollment;\\n4. Subject has a history of primary hyperaldosteronism;\\n5. Subject has evidence of symptomatic cardiomyopathy \\\\[Note: Asymptomatic cardiac abnormality on investigation would not be exclusionary\\\\];\\n6. If 2 to \\\\<4 years of age, subject is currently being treated or has received previous treatment with oral glucocorticoids or other immunosuppressive agents \\\\[Notes: Past transient use of oral glucocorticoids or other oral immunosuppressive agents for no longer than 1 month cumulative, with last use at least 3 months prior to enrollment, will be considered for eligibility on a case-by-case basis, unless discontinued for intolerance. Inhaled and/or topical glucocorticoids are permitted if last use is at least 4 weeks prior to enrollment or if administered at stable dose beginning at least 4 weeks prior to enrollment and anticipated to be used at the stable dose regimen for the duration of the study\\\\];\\n7. Subject has an allergy or hypersensitivity to the study medication or to any of its constituents;\\n8. Subject has used idebenone within 4 weeks prior to enrollment;\\n9. Subject has severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the Investigator;\\n10. Subject has previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and follow-up will be correctly completed or impair the assessment of study results, in the opinion of the Investigator;\\n11. Subject is taking (or has taken within 4 weeks prior to enrollment) herbal remedies and supplements which can impact muscle strength and function (e.g., Co-enzyme Q10, creatine, etc);\\n12. Subject is taking (or has taken within 3 months prior to enrollment) any medication indicated for DMD, including Exondys51, Exondys53, Exondys45, Viltepso and Translarna;\\n13. Subject has been administered a live attenuated vaccine within 14 days prior to the first dose of study medication;\\n14. Subject is currently taking any other investigational drug or has taken any other investigational drug within 3 months prior to enrollment;\\n15. Subject has previously been enrolled in the VBP15-006 study or any other vamorolone study.\", 'healthyVolunteers': False, 'sex': 'MALE', 'minimumAge': '2 Years', 'maximumAge': '17 Years', 'stdAges': ['CHILD']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Jean K Mah, M.D.', 'affiliation': \"Alberta Children's Hospital Research Institute, University of Calgary\", 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': \"Alberta's Children Hospital\", 'status': 'RECRUITING', 'city': 'Calgary', 'state': 'Alberta', 'zip': 'AB T3B 6A8', 'country': 'Canada', 'contacts': [{'name': 'Julie Dao', 'role': 'CONTACT', 'email': 'julie.dao@ucalgary.ca'}, {'name': 'Jean Mah, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 51.05011, 'lon': -114.08529}}, {'facility': \"British Columbia Children's Hospital\", 'status': 'RECRUITING', 'city': 'Vancouver', 'state': 'British Columbia', 'zip': 'V6H 3N1', 'country': 'Canada', 'contacts': [{'name': 'Kathryn Selby, MBChB', 'role': 'CONTACT', 'phone': '604-875-2345', 'phoneExt': '2161', 'email': 'kselby@cw.bc.ca'}, {'name': 'Nela Martic', 'role': 'CONTACT', 'email': 'NMartic3@cw.bc.ca'}], 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'facility': \"Children's Hospital of Eastern Ontario\", 'status': 'RECRUITING', 'city': 'Ottawa', 'state': 'Ontario', 'zip': 'K1H 8L1', 'country': 'Canada', 'contacts': [{'name': 'Laura Thompson', 'role': 'CONTACT', 'email': 'LaThompson@cheo.on.ca'}, {'name': 'Hanns Lochmuller, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 45.41117, 'lon': -75.69812}}, {'facility': 'The Hospital for Sick Children', 'status': 'RECRUITING', 'city': 'Toronto', 'state': 'Ontario', 'zip': 'M5G 1X8', 'country': 'Canada', 'contacts': [{'name': 'Ana Stosic', 'role': 'CONTACT', 'email': 'ana.stosic@sickkids.ca'}, {'name': 'Hernan Gonorazky, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}}, {'facility': 'Montreal Childrens Hospital', 'status': 'RECRUITING', 'city': 'Montréal', 'zip': 'H4A 3J1', 'country': 'Canada', 'contacts': [{'name': 'Patricia Deeb', 'role': 'CONTACT', 'phone': '5149341934', 'phoneExt': '24925', 'email': 'patricia.deeb@muhc.mcgill.ca'}, {'name': 'Maryam Oskoui, MD, M.Sc.', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}]}, 'referencesModule': {'references': [{'pmid': '31451516', 'type': 'BACKGROUND', 'citation': 'Hoffman EP, Schwartz BD, Mengle-Gaw LJ, Smith EC, Castro D, Mah JK, McDonald CM, Kuntz NL, Finkel RS, Guglieri M, Bushby K, Tulinius M, Nevo Y, Ryan MM, Webster R, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Siener C, Jaros M, Shale P, McCall JM, Nagaraju K, van den Anker J, Conklin LS, Cnaan A, Gordish-Dressman H, Damsker JM, Clemens PR; Cooperative International Neuromuscular Research Group. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology. 2019 Sep 24;93(13):e1312-e1323. doi: 10.1212/WNL.0000000000008168. Epub 2019 Aug 26.'}, {'pmid': '32956407', 'type': 'BACKGROUND', 'citation': 'Smith EC, Conklin LS, Hoffman EP, Clemens PR, Mah JK, Finkel RS, Guglieri M, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, Kerchner L, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, Gordish-Dressman H, Hagerty L, Dang UJ, Damsker JM, Schwartz BD, Mengle-Gaw LJ, McDonald CM; CINRG VBP15 and DNHS Investigators. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study. PLoS Med. 2020 Sep 21;17(9):e1003222. doi: 10.1371/journal.pmed.1003222. eCollection 2020 Sep.'}, {'pmid': '30745312', 'type': 'BACKGROUND', 'citation': 'Heier CR, Yu Q, Fiorillo AA, Tully CB, Tucker A, Mazala DA, Uaesoontrachoon K, Srinivassane S, Damsker JM, Hoffman EP, Nagaraju K, Spurney CF. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci Alliance. 2019 Feb 11;2(1):e201800186. doi: 10.26508/lsa.201800186. Print 2019 Feb.'}, {'pmid': '30742306', 'type': 'BACKGROUND', 'citation': 'Mavroudis PD, van den Anker J, Conklin LS, Damsker JM, Hoffman EP, Nagaraju K, Clemens PR, Jusko WJ. Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy. J Clin Pharmacol. 2019 Jul;59(7):979-988. doi: 10.1002/jcph.1388. Epub 2019 Feb 11.'}, {'pmid': '31446438', 'type': 'BACKGROUND', 'citation': 'Damsker JM, Cornish MR, Kanneboyina P, Kanneboyina I, Yu Q, Lipson R, Phadke A, Knoblach SM, Panchapakesan K, Morales M, Fiorillo AA, Partridge T, Nagaraju K. Vamorolone, a dissociative steroidal compound, reduces collagen antibody-induced joint damage and inflammation when administered after disease onset. Inflamm Res. 2019 Nov;68(11):969-980. doi: 10.1007/s00011-019-01279-z. Epub 2019 Aug 24.'}, {'pmid': '30120816', 'type': 'BACKGROUND', 'citation': 'Akkad H, Cacciani N, Llano-Diez M, Corpeno Kalamgi R, Tchkonia T, Kirkland JL, Larsson L. Vamorolone treatment improves skeletal muscle outcome in a critical illness myopathy rat model. Acta Physiol (Oxf). 2019 Feb;225(2):e13172. doi: 10.1111/apha.13172. Epub 2018 Sep 6.'}, {'pmid': '32434278', 'type': 'BACKGROUND', 'citation': 'Li X, Conklin LS, van den Anker J, Hoffman EP, Clemens PR, Jusko WJ. Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy. J Clin Pharmacol. 2020 Oct;60(10):1385-1396. doi: 10.1002/jcph.1632. Epub 2020 May 20.'}, {'pmid': '29524454', 'type': 'BACKGROUND', 'citation': 'Hoffman EP, Riddle V, Siegler MA, Dickerson D, Backonja M, Kramer WG, Nagaraju K, Gordish-Dressman H, Damsker JM, McCall JM. Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroids. 2018 Jun;134:43-52. doi: 10.1016/j.steroids.2018.02.010. Epub 2018 Mar 8.'}, {'pmid': '29666400', 'type': 'BACKGROUND', 'citation': 'Almeida LEF, Damsker JM, Albani S, Afsar N, Kamimura S, Pratt D, Kleiner DE, Quezado M, Gordish-Dressman H, Quezado ZMN. The corticosteroid compounds prednisolone and vamorolone do not alter the nociception phenotype and exacerbate liver injury in sickle cell mice. Sci Rep. 2018 Apr 17;8(1):6081. doi: 10.1038/s41598-018-24274-6.'}, {'pmid': '28030841', 'type': 'BACKGROUND', 'citation': 'Wells E, Kambhampati M, Damsker JM, Gordish-Dressman H, Yadavilli S, Becher OJ, Gittens J, Stampar M, Packer RJ, Nazarian J. Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor. Oncotarget. 2017 Feb 7;8(6):9366-9374. doi: 10.18632/oncotarget.14070.'}, {'pmid': '30219580', 'type': 'BACKGROUND', 'citation': 'Conklin LS, Damsker JM, Hoffman EP, Jusko WJ, Mavroudis PD, Schwartz BD, Mengle-Gaw LJ, Smith EC, Mah JK, Guglieri M, Nevo Y, Kuntz N, McDonald CM, Tulinius M, Ryan MM, Webster R, Castro D, Finkel RS, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, McCall JM, Hathout Y, Nagaraju K, van den Anker J, Ward LM, Ahmet A, Cornish MR, Clemens PR. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacol Res. 2018 Oct;136:140-150. doi: 10.1016/j.phrs.2018.09.007. Epub 2018 Sep 13.'}, {'pmid': '29883261', 'type': 'BACKGROUND', 'citation': 'Fiorillo AA, Tully CB, Damsker JM, Nagaraju K, Hoffman EP, Heier CR. Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone. Physiol Genomics. 2018 Sep 1;50(9):735-745. doi: 10.1152/physiolgenomics.00134.2017. Epub 2018 Jun 8.'}, {'pmid': '30166241', 'type': 'BACKGROUND', 'citation': 'Sreetama SC, Chandra G, Van der Meulen JH, Ahmad MM, Suzuki P, Bhuvanendran S, Nagaraju K, Hoffman EP, Jaiswal JK. Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit. Mol Ther. 2018 Sep 5;26(9):2231-2242. doi: 10.1016/j.ymthe.2018.07.021. Epub 2018 Aug 27.'}, {'pmid': '32592467', 'type': 'BACKGROUND', 'citation': 'Dang UJ, Ziemba M, Clemens PR, Hathout Y, Conklin LS; CINRG Vamorolone 002/003 Investigators; Hoffman EP. Serum biomarkers associated with baseline clinical severity in young steroid-naive Duchenne muscular dystrophy boys. Hum Mol Genet. 2020 Aug 29;29(15):2481-2495. doi: 10.1093/hmg/ddaa132.'}, {'pmid': '33617542', 'type': 'BACKGROUND', 'citation': 'Ziemba M, Barkhouse M, Uaesoontrachoon K, Giri M, Hathout Y, Dang UJ, Gordish-Dressman H, Nagaraju K, Hoffman EP. Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice. PLoS One. 2021 Feb 22;16(2):e0246507. doi: 10.1371/journal.pone.0246507. eCollection 2021.'}, {'pmid': '25313409', 'type': 'BACKGROUND', 'citation': 'Dadgar S, Wang Z, Johnston H, Kesari A, Nagaraju K, Chen YW, Hill DA, Partridge TA, Giri M, Freishtat RJ, Nazarian J, Xuan J, Wang Y, Hoffman EP. Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy. J Cell Biol. 2014 Oct 13;207(1):139-58. doi: 10.1083/jcb.201402079.'}, {'pmid': '24014378', 'type': 'BACKGROUND', 'citation': 'Heier CR, Damsker JM, Yu Q, Dillingham BC, Huynh T, Van der Meulen JH, Sali A, Miller BK, Phadke A, Scheffer L, Quinn J, Tatem K, Jordan S, Dadgar S, Rodriguez OC, Albanese C, Calhoun M, Gordish-Dressman H, Jaiswal JK, Connor EM, McCall JM, Hoffman EP, Reeves EK, Nagaraju K. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med. 2013 Oct;5(10):1569-85. doi: 10.1002/emmm.201302621. Epub 2013 Sep 9.'}, {'pmid': '23667681', 'type': 'BACKGROUND', 'citation': 'Damsker JM, Dillingham BC, Rose MC, Balsley MA, Heier CR, Watson AM, Stemmy EJ, Jurjus RA, Huynh T, Tatem K, Uaesoontrachoon K, Berry DM, Benton AS, Freishtat RJ, Hoffman EP, McCall JM, Gordish-Dressman H, Constant SL, Reeves EK, Nagaraju K. VBP15, a glucocorticoid analogue, is effective at reducing allergic lung inflammation in mice. PLoS One. 2013 May 7;8(5):e63871. doi: 10.1371/journal.pone.0063871. Print 2013.'}, {'pmid': '26511361', 'type': 'BACKGROUND', 'citation': 'Freishtat RJ, Nino G, Tsegaye Y, Alcala SE, Benton AS, Watson AM, Reeves EK, Haider SK, Damsker JM. Pharmacologically-induced mitotic synchrony in airway epithelial cells as a mechanism of action of anti-inflammatory drugs. Respir Res. 2015 Oct 29;16:132. doi: 10.1186/s12931-015-0293-4.'}, {'pmid': '25392236', 'type': 'BACKGROUND', 'citation': 'Dillingham BC, Knoblach SM, Many GM, Harmon BT, Mullen AM, Heier CR, Bello L, McCall JM, Hoffman EP, Connor EM, Nagaraju K, Reeves EKM, Damsker JM. VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis. Cell Mol Neurobiol. 2015 Apr;35(3):377-387. doi: 10.1007/s10571-014-0133-y. Epub 2014 Nov 13.'}, {'pmid': '27133900', 'type': 'BACKGROUND', 'citation': 'Garvin LM, Chen Y, Damsker JM, Rose MC. A novel dissociative steroid VBP15 reduces MUC5AC gene expression in airway epithelial cells but lacks the GRE mediated transcriptional properties of dexamethasone. Pulm Pharmacol Ther. 2016 Jun;38:17-26. doi: 10.1016/j.pupt.2016.04.004. Epub 2016 Apr 29.'}, {'pmid': '27261270', 'type': 'BACKGROUND', 'citation': 'Damsker JM, Conklin LS, Sadri S, Dillingham BC, Panchapakesan K, Heier CR, McCall JM, Sandler AD. VBP15, a novel dissociative steroid compound, reduces NFkappaB-induced expression of inflammatory cytokines in vitro and symptoms of murine trinitrobenzene sulfonic acid-induced colitis. Inflamm Res. 2016 Sep;65(9):737-43. doi: 10.1007/s00011-016-0956-8. Epub 2016 Jun 3.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000009136', 'term': 'Muscular Dystrophies'}, {'id': 'D000020388', 'term': 'Muscular Dystrophy, Duchenne'}], 'ancestors': [{'id': 'D000020966', 'term': 'Muscular Disorders, Atrophic'}, {'id': 'D000009135', 'term': 'Muscular Diseases'}, {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D000040181', 'term': 'Genetic Diseases, X-Linked'}], 'browseLeaves': [{'id': 'M12093', 'name': 'Muscular Dystrophies', 'asFound': 'Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'M22185', 'name': 'Muscular Dystrophy, Duchenne', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'M4589', 'name': 'Atrophy', 'relevance': 'LOW'}, {'id': 'M12092', 'name': 'Muscular Diseases', 'relevance': 'LOW'}, {'id': 'M22697', 'name': 'Muscular Disorders, Atrophic', 'relevance': 'LOW'}, {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M23686', 'name': 'Genetic Diseases, Inborn', 'relevance': 'LOW'}, {'id': 'M24877', 'name': 'Genetic Diseases, X-Linked', 'relevance': 'LOW'}, {'id': 'T3963', 'name': 'Muscular Dystrophy', 'asFound': 'Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'T698', 'name': 'Becker Muscular Dystrophy', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'T1945', 'name': 'Duchenne Muscular Dystrophy', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC16', 'name': 'Diseases and Abnormalities at or Before Birth'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05670730', 'orgStudyIdInfo': {'id': 'AOC 1044-CS1'}, 'organization': {'fullName': 'Avidity Biosciences, Inc.', 'class': 'INDUSTRY'}, 'briefTitle': 'Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping', 'officialTitle': 'A Phase 1/2, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Single and Multiple Ascending Doses of AOC 1044 Administered Intravenously to Healthy Adult Volunteers and Participants With DMD Mutations Amenable to Exon 44 Skipping', 'acronym': 'EXPLORE44'}, 'statusModule': {'statusVerifiedDate': '2024-02', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-11-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-03', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-03', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-12-06', 'studyFirstSubmitQcDate': '2023-01-02', 'studyFirstPostDateStruct': {'date': '2023-01-04', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-08', 'lastUpdatePostDateStruct': {'date': '2024-02-09', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Avidity Biosciences, Inc.', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'AOC 1044-CS1 (EXPLORE44) is a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of single and multiple ascending doses of AOC 1044 in healthy adult volunteers and participants with DMD mutations amenable to exon 44 skipping.\\n\\nPart A is a single dose design with multiple cohorts (dose levels) in healthy adult volunteers.\\n\\nPart B is a multiple-ascending dose design with 3 cohorts (dose levels) in participants with Duchenne.'}, 'conditionsModule': {'conditions': ['Duchenne Muscular Dystrophy', 'Exon 44'], 'keywords': ['EXPLORE44', 'Avidity Biosciences', 'Avidity', 'AOC 1044']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'interventionModelDescription': 'AOC 1044-CS1 (EXPLORE44) is a 2-part study:\\n\\nPart A: 5 cohorts with single ascending doses conducted in healthy adult volunteers\\n\\nPart B: 3 cohorts with multiple ascending doses in participants with DMD mutations amenable to exon 44 skipping', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 64, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'AOC 1044-CS1 Part A - Single Dose Levels 1-5', 'type': 'EXPERIMENTAL', 'description': 'AOC 1044 will be administered once.', 'interventionNames': ['Drug: AOC 1044']}, {'label': 'AOC 1044-CS1 Part A - Single Dose: Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Placebo will be administered once.', 'interventionNames': ['Drug: Placebo']}, {'label': 'AOC 1044-CS1 Part B - Multiple Ascending Dose Levels 1-3', 'type': 'EXPERIMENTAL', 'description': 'AOC 1044 will be administered three times.', 'interventionNames': ['Drug: AOC 1044']}, {'label': 'AOC 1044-CS1 Part B - Multiple Ascending Dose: Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Placebo will be administered three times.', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'AOC 1044', 'description': 'AOC 1044 will be administered via intravenous (IV) infusion', 'armGroupLabels': ['AOC 1044-CS1 Part A - Single Dose Levels 1-5', 'AOC 1044-CS1 Part B - Multiple Ascending Dose Levels 1-3']}, {'type': 'DRUG', 'name': 'Placebo', 'description': 'Placebo will be administered via intravenous (IV) infusion.', 'armGroupLabels': ['AOC 1044-CS1 Part A - Single Dose: Placebo', 'AOC 1044-CS1 Part B - Multiple Ascending Dose: Placebo'], 'otherNames': ['Saline']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of treatment-emergent adverse events (TEAEs)', 'timeFrame': 'Through study completion, up to Day 85 (Part A) or Day 169 (Part B)'}], 'secondaryOutcomes': [{'measure': 'Plasma pharmacokinetic (PK) parameters', 'description': 'Maximum plasma concentration (Cmax) of AOC 1044', 'timeFrame': 'Through Week 8 (Part A); Through Week 12 (Part B)'}, {'measure': 'Plasma pharmacokinetic (PK) parameters', 'description': 'Terminal half-life (T1/2) of AOC 1044', 'timeFrame': 'Through Week 8 (Part A); Through Week 12 (Part B)'}, {'measure': 'Plasma pharmacokinetic (PK) parameters', 'description': 'Area under the concentration-time curve (AUC) of AOC 1044', 'timeFrame': 'Through Week 8 (Part A); Through Week 12 (Part B)'}, {'measure': 'PMO44 levels in skeletal muscle tissue', 'timeFrame': 'Through Week 4 (Part A); Through Week 16 (Part B)'}, {'measure': 'Urine pharmacokinetic parameters', 'description': 'Fraction of PMO44 excreted in urine', 'timeFrame': 'Day 1-2 (0-24 hours after first dose) (Part A); Day 1-2 (0-24 hours after first dose) (Part B)'}, {'measure': 'Change from baseline in exon skipping as measured in skeletal muscle (Part B only)', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Absolute change from baseline in dystrophin protein level in skeletal muscle (Part B only)', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Percentage change from baseline in dystrophin protein level in skeletal muscle (Part B only)', 'timeFrame': 'Baseline, Week 16'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Part A:\\n\\nKey Inclusion Criteria:\\n\\n* Aged 18 to 55 years, inclusive, at the time of informed consent\\n* Body mass index (BMI) of 18.5 to 32.0 kg/m2\\n\\nKey Exclusion Criteria:\\n\\n* Clinically significant abnormalities in laboratory results, ECGs, or vitals\\n* Current or recent use of prescription or nonprescription drugs\\n* Positive drug/alcohol test at Screening or Day -1\\n* Elevated blood pressure (BP) \\\\>130/80 mmHg at Screening\\n* Participation in a clinical study in which an investigational product was received within 1 month of screening or 5 half-lives of the investigational product\\n* Blood or plasma donation within 16 weeks of planned AOC 1044 administration Note: Other protocol defined Inclusion/Exclusion criteria may apply\\n\\nPart B:\\n\\nKey Inclusion Criteria:\\n\\n* Aged 7 to 27 years, inclusive, at the time of informed consent\\n* Clinical diagnosis of DMD or clear onset of DMD symptoms at or before the age of 6 years\\n* Confirmation of DMD gene mutation amenable to exon 44 skipping\\n* Weight ≥ 23 kg\\n* Ambulatory or non-ambulatory\\n\\n  * Ambulatory participants: LVEF ≥50% and FVC≥50%\\n  * Non-ambulatory participants: LVEF ≥45% and FVC≥40%\\n* PUL 2.0 entry item A ≥3\\n* If on corticosteroids, stable dose for 30 days before screening and throughout the study\\n\\nKey Exclusion Criteria:\\n\\n* Biceps brachii muscles unsuitable for biopsy\\n* Serum hemoglobin \\\\< lower limit of normal\\n* Uncontrolled hypertension or diabetes\\n* Prior treatment with any cell or gene therapy\\n* Prior treatment with another exon 44 skipping agent within 6 months prior to informed consent\\n* Recently treated with an investigational drug\\n* History of multiple drug allergies', 'healthyVolunteers': True, 'sex': 'MALE', 'minimumAge': '7 Years', 'maximumAge': '55 Years', 'stdAges': ['CHILD', 'ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Avidity Biosciences, Inc.', 'role': 'CONTACT', 'phone': '858-771-7038', 'email': 'medinfo@aviditybio.com'}], 'overallOfficials': [{'name': 'Mark Stahl, MD, PhD', 'affiliation': 'Avidity Biosciences, Inc.', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': \"Arkansas Children's\", 'status': 'RECRUITING', 'city': 'Little Rock', 'state': 'Arkansas', 'zip': '72202', 'country': 'United States', 'contacts': [{'name': 'Ashley Bryan', 'role': 'CONTACT'}], 'geoPoint': {'lat': 34.74648, 'lon': -92.28959}}, {'facility': 'Stanford University', 'status': 'RECRUITING', 'city': 'Palo Alto', 'state': 'California', 'zip': '94304', 'country': 'United States', 'contacts': [{'name': 'Rabia Farooquee', 'role': 'CONTACT'}], 'geoPoint': {'lat': 37.44188, 'lon': -122.14302}}, {'facility': 'Rare Disease Research - Atlanta', 'status': 'RECRUITING', 'city': 'Atlanta', 'state': 'Georgia', 'zip': '30329', 'country': 'United States', 'contacts': [{'name': 'Laura Sutton', 'role': 'CONTACT'}], 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'facility': 'University of Massachusetts Chan Medical School', 'status': 'RECRUITING', 'city': 'Worcester', 'state': 'Massachusetts', 'zip': '01655', 'country': 'United States', 'contacts': [{'name': 'Sarah Figueira', 'role': 'CONTACT'}], 'geoPoint': {'lat': 42.26259, 'lon': -71.80229}}, {'facility': \"Gillette Children's\", 'status': 'RECRUITING', 'city': 'Saint Paul', 'state': 'Minnesota', 'zip': '55101', 'country': 'United States', 'contacts': [{'name': 'Laura Feldman', 'role': 'CONTACT'}], 'geoPoint': {'lat': 44.94441, 'lon': -93.09327}}, {'facility': \"Abigail Research Institute at Nationwide Children's Hospital\", 'status': 'RECRUITING', 'city': 'Columbus', 'state': 'Ohio', 'zip': '43215', 'country': 'United States', 'contacts': [{'name': 'Regina Flomo', 'role': 'CONTACT'}], 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'facility': 'Worldwide Clinical Trials (Part A only)', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'San Antonio', 'state': 'Texas', 'zip': '78217', 'country': 'United States', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000009136', 'term': 'Muscular Dystrophies'}, {'id': 'D000020388', 'term': 'Muscular Dystrophy, Duchenne'}], 'ancestors': [{'id': 'D000020966', 'term': 'Muscular Disorders, Atrophic'}, {'id': 'D000009135', 'term': 'Muscular Diseases'}, {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D000040181', 'term': 'Genetic Diseases, X-Linked'}], 'browseLeaves': [{'id': 'M12093', 'name': 'Muscular Dystrophies', 'asFound': 'Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'M22185', 'name': 'Muscular Dystrophy, Duchenne', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'M4589', 'name': 'Atrophy', 'relevance': 'LOW'}, {'id': 'M12092', 'name': 'Muscular Diseases', 'relevance': 'LOW'}, {'id': 'M22697', 'name': 'Muscular Disorders, Atrophic', 'relevance': 'LOW'}, {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M23686', 'name': 'Genetic Diseases, Inborn', 'relevance': 'LOW'}, {'id': 'M24877', 'name': 'Genetic Diseases, X-Linked', 'relevance': 'LOW'}, {'id': 'T3963', 'name': 'Muscular Dystrophy', 'asFound': 'Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'T698', 'name': 'Becker Muscular Dystrophy', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}, {'id': 'T1945', 'name': 'Duchenne Muscular Dystrophy', 'asFound': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC16', 'name': 'Diseases and Abnormalities at or Before Birth'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}]\n"
     ]
    }
   ],
   "source": [
    "#Within the disease “Duchenne Muscular Dystrophy”, what are common eligibility criteria?\n",
    "\n",
    "query = \"Duchenne Muscular Dystrophy\"\n",
    "result = fetch_studies(query)\n",
    "print(len(result['studies']))\n",
    "print(result['studies'])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "def find_eligable_studies(patient):\n",
    "    '''\n",
    "    Finds a list of studies for one patient based on his condition\n",
    "    '''\n",
    "    condition = patient['profile'].condition\n",
    "    eligable_studies = fetch_studies(condition)\n",
    "    amount_studies = len(eligable_studies['studies'])\n",
    "    return amount_studies, eligable_studies"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [],
   "source": [
    "amount_studies, studies = find_eligable_studies(patient_1)\n",
    "study1= studies['studies'][0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'eligibilityCriteria': '* INCLUSION CRITERIA:\\n\\nThe study population will consist of several subgroups of patients. An individual must meet one of the following subgroup inclusion criteria to participate in this study.\\n\\nSBMA subgroup:\\n\\n1. Male\\n2. Genetically confirmed SBMA\\n3. Able to travel to the NIH\\n4. Greater than 18 years old\\n\\nSBMA carriers:\\n\\n1. Female\\n2. Genetically confirmed SBMA heterozygote\\n3. Able to travel to the NIH\\n4. Greater than 18 years old\\n\\nOther motor neuron disease patients:\\n\\n1. Diagnosis of motor neuron disease other than SBMA (e.g.. amyotrophic lateral sclerosis (ALS), spinal muscular atrophy)\\n2. Able to travel to the NIH\\n3. Greater than 18 years old\\n4. . Male\\n\\nHealthy male control:\\n\\n1. Male\\n2. No history or diagnosis of liver disease\\n3. No history of SBMA or other motor neuron disease\\n4. Greater than 18 years old\\n5. No diagnosis of diabetes or insulin resistance\\n6. No history of alcohol abuse within the last 1 year\\n7. No history of hyperlipidemia (LDL \\\\< 195) or hypertriglyceridemia (TAG \\\\< 225)\\n\\nHealthy female control:\\n\\n1. Female\\n2. No history or diagnosis of liver disease\\n3. No history of SBMA or other motor neuron disease\\n4. Greater than 18 years old\\n5. No diagnosis of diabetes or insulin resistance\\n6. No history of alcohol abuse within the last 1 year\\n7. No history of hyperlipidemia (LDL \\\\< 195) or hypertriglyceridemia (TAG \\\\< 225)\\n\\nEXCLUSION CRITERIA:\\n\\n* Diagnosed with an acquired or inherited liver disease eg., hepatitis B, hepatitis C, HIV, autoimmune hepatitis, cholestatic liver disease, Wilson s disease, iron overload disease, alpha-1 antitrypsin deficiency, hepatocellular carcinoma, (hepatic neoplasm or metastasis, etc.) or injury except for fatty liver disease.\\n* Contraindications to MRI such as a contraindicated non-removable metal device (i.e. pacemaker, defibrillator, insulin pump, metal clips, non-removable jewelry) or claustrophobia.\\n* Currently pregnant or pregnant within the past 6 months. Pregnant women are excluded from the study because of the known associated abnormalities in liver function that can occur in this population. The long term effects of MRI on the developing fetus are unknown and would present a risk with participation.\\n\\nIn addition to the above criteria, the patients receiving a liver biopsy will need to meet the additional exclusion criteria below:\\n\\n* Coagulopathy (PT/PTT values that are prolonged \\\\>= 3 seconds from the upper limit of normal, including treatment with oral and parenteral anticoagulants), thrombocytopenia (\\\\< 70,000), abnormal bleeding time or platelet dysfunction.\\n* Taking anti-platelet agents for cardiovascular protection that cannot be safely stopped for the performance of the liver biopsy.\\n* Obesity, which is defined as a BMI\\\\>30 at the screenig visit.',\n",
       " 'healthyVolunteers': False,\n",
       " 'sex': 'ALL',\n",
       " 'minimumAge': '18 Years',\n",
       " 'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       " 'studyPopulation': 'We plan to enroll men with genetically confirmed SBMA, age-matched healthy control men, SBMA carrier women, age-matched healthy control women and males with other motor neuron disease patients as disease controls.',\n",
       " 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}"
      ]
     },
     "execution_count": 68,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "study1[0]['protocolSection']['eligibilityModule']['eligibilityCriteria']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [],
   "source": [
    "'''\n",
    "Based on one Patient and one Study, check the eligabilty of tha Patient:\n",
    "'''\n",
    "\n",
    "def get_study_info(study):\n",
    "    title = study['protocolSection']['identificationModule']['officialTitle']\n",
    "    info= f'''Title: {title}'''\n",
    "    try:\n",
    "        #description = study['protocolSection']['descriptionModule']['detailedDescription']\n",
    "        eligibilityCriteria = f\"eligibilityCriteria: {study['protocolSection']['eligibilityModule']['eligibilityCriteria']}\"\n",
    "        info += f'\\n{eligibilityCriteria}'\n",
    "    except:\n",
    "        pass\n",
    "    \n",
    "    try:\n",
    "        sex = f\"required sex: {study['protocolSection']['eligibilityModule']['sex']}\"\n",
    "        info += f'\\n{sex}'\n",
    "    except:\n",
    "        pass\n",
    "\n",
    "    try:\n",
    "        minimumAge = f\"required minimum Age: {study['protocolSection']['eligibilityModule']['minimumAge']}\"\n",
    "        info += f'\\n{minimumAge}'\n",
    "    except:\n",
    "        pass\n",
    "\n",
    "    return info\n",
    "\n",
    "def get_patient_info(patient):\n",
    "    condition = patient['profile'].condition\n",
    "    age = patient['profile'].age\n",
    "    description = patient['profile'].profile\n",
    "    gender = patient['profile'].gender\n",
    "    country = patient['profile'].country\n",
    "    info =  f'''condition: {condition} \\nage: {age} \\ndescription: {description} \\ngender: {gender} \\ncountry: {country}'''\n",
    "\n",
    "    return info\n",
    "\n",
    "def create_promt(patient, study):\n",
    "    study_info= get_study_info(study)\n",
    "    patient_info= get_patient_info(patient)\n",
    "    promt = f'''You are an expert doctor and you need to determine the eligibility of the patient for the given trail based on the information of the paitient and the train:\n",
    "Patient information\n",
    "{patient_info}\n",
    "Trial Information\n",
    "{study_info}\n",
    "Predict whether the patient is eligible/uneligible/uncertain\n",
    "Only return the category\n",
    "    '''\n",
    "    return promt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {},
   "outputs": [],
   "source": [
    "study4= studies['studies'][4]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "You are an expert doctor and you need to determine the eligibility of the patient for the given trail based on the information of the paitient and the train:\n",
      "Patient information\n",
      "condition: Amyotrophic Lateral Sclerosis \n",
      "age: 53 \n",
      "description: Histology: None\n",
      "Previous treatment: riluzole since two months\n",
      "Biomarkers: SOD1 mutation\n",
      "Tests: None\n",
      "Comorbidities: rheumatoid arthritis\n",
      "Other: None \n",
      "gender: Male \n",
      "country: France\n",
      "Trial Information\n",
      "Title: A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies\n",
      "eligibilityCriteria: Key Inclusion Criteria:\n",
      "\n",
      "1. Subject must be ≥16 years of age.\n",
      "2. Subject must:\n",
      "\n",
      "   • Have a confirmed diagnosis of R/R AML, R/R MDS, or R/R CMML not in blast crisis\n",
      "\n",
      "   AND\n",
      "\n",
      "   • Be an appropriate candidate for treatment with LDAC (Arm A) or decitabine (Arm B)\n",
      "3. Subject or their parent or legal guardian (when applicable) must be able to understand and be willing to sign an informed consent and, when applicable, subject must sign an assent form.\n",
      "4. Subject must be willing and able to comply with scheduled study visits and treatment plans.\n",
      "5. Subject must be willing to undergo all study procedures unless contraindicated due to medical risk.\n",
      "6. Subject must have an ECOG PS of ≤2.\n",
      "7. Subject must have a life expectancy of ≥3 months.\n",
      "8. Subject must have adequate hepatic function\n",
      "9. Subject must have adequate renal function\n",
      "10. Subject must have a WBC count ≤20×109/L\n",
      "11. Subject must have adequate cardiovascular, respiratory, and immune system function\n",
      "12. Subject must agree to abide by dietary and other considerations required during the study\n",
      "13. Subject must meet timing requirements with respect to prior therapy and surgery\n",
      "14. Toxicity related to prior therapy must have returned to Grade ≤2 by CTCAE by approximately 14 days before the start of study treatment\n",
      "15. Female subjects must be:\n",
      "\n",
      "    * postmenopausal; or\n",
      "    * permanently sterile, or, if sexually active with male partners, these partners must be azoospermic; or\n",
      "    * nonpregnant, nonlactating, and, if sexually active with fertile male partners, having agreed to use a highly effective method of contraception\n",
      "16. Male subjects must have documented azoospermia or, if fertile and sexually active, must agree to use a highly effective method of contraception with their partners of childbearing potential\n",
      "\n",
      "Key Exclusion Criteria:\n",
      "\n",
      "1. Subject is unable to provide informed consent and/or to follow protocol requirements.\n",
      "2. Subject:\n",
      "\n",
      "   * Has undergone chimeric antigen receptor T cell therapy or HSCT within 60 days of the first dose of study treatment OR\n",
      "   * Has clinically significant GVHD\n",
      "3. Subject has clinical symptoms suggesting active CNS leukemia or known CNS leukemia.\n",
      "4. Subject has an immediately life-threatening, severe complication(s) of advanced myeloid malignancy, such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation.\n",
      "5. Subject has other malignancy that may interfere with the diagnosis and/or treatment of advanced hematologic malignancies.\n",
      "6. Subject has active HBV or HCV infections; Subject has known positive HIV antibody results, or AIDS-related illness;\n",
      "7. Subject has an active severe infection that requires anti-infective therapy or has an unexplained temperature of \\>38.5°C during screening visits or on their first day of study treatment\n",
      "8. Subject has an uncontrolled intercurrent illness.\n",
      "9. Subject has QTcF \\>470 msec or other factors that increase the risk of QTc prolongation or arrhythmic events\n",
      "10. Subject has any other medical or psychological condition, deemed by the Investigator to be likely to interfere with a subject's ability to sign informed consent/assent, cooperate, or participate in the study.\n",
      "11. Subject has known allergies or hypersensitivities to:\n",
      "\n",
      "    * All subjects: components of the FHD-286 formulation\n",
      "    * Arm A: cytarabine or any of the excipients\n",
      "    * Arm B: decitabine or any of the excipients\n",
      "12. Subject is unable to tolerate the administration of oral medication or has GI dysfunction that would preclude adequate absorption, distribution, metabolism, or excretion of FHD-286.\n",
      "13. Subject is receiving any other investigational agents.\n",
      "14. At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed since last administration of a prior investigational drug at the start of study treatment. Exceptions include participation in any observational or nontherapeutic clinical trials.\n",
      "15. Subject is on medications classified as:\n",
      "\n",
      "    * Strong CYP3A inhibitors\n",
      "\n",
      "      - Triazole antifungal agents, including those classified as strong CYP3A inhibitors , are permitted.\n",
      "    * Strong CYP3A inducers\n",
      "    * Sensitive CYP3A substrates with narrow TIs\n",
      "16. Subject is on medications with narrow TIs that are sensitive P-gp or BCRP substrates and are administered orally or on medications classified as strong inhibitors of P-gp or BCRP.\n",
      "17. Administration of PPIs should be stopped or switched to another ARA 7 days before administration of FHD-286.\n",
      "18. Subject is requiring clinically significant or increasing doses of systemic steroid therapy or any other systemic immunosuppressive medication. Local or targeted steroid and immunosuppressive therapies are acceptable. Appropriate steroid replacement to manage endocrine toxicities resulting from prior anticancer systemic therapy is permitted.\n",
      "19. Subject has undergone any prior treatment with a BRG1/BRM inhibitor.\n",
      "20. Subject is pregnant or breastfeeding or is planning to become pregnant within 1 year of the start of study treatment.\n",
      "required sex: ALL\n",
      "required minimum Age: 16 Years\n",
      "Predict whether the patient is eligible/uneligible/uncertain\n",
      "Only return the category\n",
      "    \n"
     ]
    }
   ],
   "source": [
    "promt =create_promt(patient_1, study4)\n",
    "print(promt)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Call OpenAI Model\n",
    "from env_file import OPENAI_API_KEY\n",
    "\n",
    "client = OpenAI(api_key=OPENAI_API_KEY)\n",
    "\n",
    "def get_openAI_response(client, promt, model='gpt-4'):\n",
    "    \n",
    "  response = client.chat.completions.create(\n",
    "    model=model,\n",
    "    messages=[\n",
    "      {\"role\": \"user\", \"content\": promt},\n",
    "    ]\n",
    "  )\n",
    "  return response.choices[0].message.content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'uneligible'"
      ]
     },
     "execution_count": 93,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "output = get_openAI_response(client, promt, model='gpt-4')\n",
    "output"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "found 10 studies for                                                      profile\n",
      "age                                                       53\n",
      "condition                      Amyotrophic Lateral Sclerosis\n",
      "country                                               France\n",
      "gender                                                  Male\n",
      "profile    Histology: None\\nPrevious treatment: riluzole ...\n",
      "NCT05632757 is uncertain\n",
      "NCT05632757 is rejected!\n",
      "NCT05306457 is uneligible\n",
      "NCT05306457 is rejected!\n",
      "NCT05137665 is eligible\n",
      "NCT05137665 is saved!\n",
      "NCT05474235 is eligible\n",
      "NCT05474235 is saved!\n",
      "NCT04885374 is uneligible\n",
      "NCT04885374 is rejected!\n",
      "NCT05716074 is uncertain\n",
      "NCT05716074 is rejected!\n",
      "NCT05819931 is uncertain\n",
      "NCT05819931 is rejected!\n",
      "NCT06325865 is uncertain\n",
      "NCT06325865 is rejected!\n",
      "NCT02916966 is eligible\n",
      "NCT02916966 is saved!\n",
      "NCT05340660 is eligible\n",
      "NCT05340660 is saved!\n",
      "found 10 studies for                                                      profile\n",
      "age                                                       62\n",
      "condition                           Leukemia, Myeloid, Acute\n",
      "country                                              Belgium\n",
      "gender                                                  Male\n",
      "profile    Diagnosed with Acute Myeloid Leukemia\\nMale ag...\n",
      "NCT05673057 is eligible\n",
      "NCT05673057 is saved!\n",
      "NCT04691648 is uncertain\n",
      "NCT04691648 is rejected!\n",
      "NCT05431257 is Uncertain\n",
      "NCT05431257 is rejected!\n",
      "NCT05907057 is uneligible\n",
      "NCT05907057 is rejected!\n",
      "NCT04891757 is Uncertain\n",
      "NCT04891757 is rejected!\n",
      "NCT05832320 is uneligible\n",
      "NCT05832320 is rejected!\n",
      "NCT06268574 is Uncertain\n",
      "NCT06268574 is rejected!\n",
      "NCT05586074 is Uncertain\n",
      "NCT05586074 is rejected!\n",
      "NCT05881265 is uncertain\n",
      "NCT05881265 is rejected!\n",
      "NCT05014165 is uneligible\n",
      "NCT05014165 is rejected!\n",
      "found 10 studies for                                                      profile\n",
      "age                                                        6\n",
      "condition                       Muscular Dystrophy, Duchenne\n",
      "country    United Kingdom of Great Britain and Northern I...\n",
      "gender                                                  Male\n",
      "profile    Histology: None\\nPrevious treatment: Deflazaco...\n",
      "NCT05933057 is uneligible\n",
      "NCT05933057 is rejected!\n",
      "NCT04322357 is eligible\n",
      "NCT04322357 is saved!\n",
      "NCT05601986 is Eligible\n",
      "NCT05601986 is rejected!\n",
      "NCT04626674 is eligible\n",
      "NCT04626674 is saved!\n",
      "NCT06244082 is uneligible\n",
      "NCT06244082 is rejected!\n",
      "NCT03689660 is eligible\n",
      "NCT03689660 is saved!\n",
      "NCT02972580 is uneligible\n",
      "NCT02972580 is rejected!\n",
      "NCT06013839 is uneligible\n",
      "NCT06013839 is rejected!\n",
      "NCT05185622 is UNELIGIBLE\n",
      "NCT05185622 is rejected!\n",
      "NCT05670730 is uneligible\n",
      "NCT05670730 is rejected!\n"
     ]
    }
   ],
   "source": [
    "from collections import defaultdict\n",
    "\n",
    "eligable_studies_per_patient = defaultdict(lambda:[])\n",
    "for idx, patient in enumerate(patients):\n",
    "    #find eligable studies:\n",
    "    amount_studies, studies = find_eligable_studies(patient)\n",
    "    #studies_per_patient[patient] = studies['studies']\n",
    "    print(f'found {amount_studies} studies for {patient}')\n",
    "    for study in studies['studies']:\n",
    "        promt =create_promt(patient, study)\n",
    "        output = get_openAI_response(client, promt, model='gpt-4')\n",
    "        study_id = study['protocolSection']['identificationModule']['nctId']\n",
    "        print(f'{study_id} is {output}')\n",
    "        if output == 'eligible':\n",
    "            patient_name = f'Patient_{idx+1}'\n",
    "            eligable_studies_per_patient[patient_name].append(study)\n",
    "            print(f'{study_id} is saved!')\n",
    "        else:\n",
    "            print(f'{study_id} is rejected!')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "defaultdict(<function __main__.<lambda>()>,\n",
       "            {'Patient_1': [{'protocolSection': {'identificationModule': {'nctId': 'NCT05137665',\n",
       "                 'orgStudyIdInfo': {'id': '21-500-101-70-09'},\n",
       "                 'organization': {'fullName': 'Target ALS Foundation, Inc.',\n",
       "                  'class': 'OTHER'},\n",
       "                 'briefTitle': 'Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures',\n",
       "                 'officialTitle': 'Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At - Home Measures',\n",
       "                 'acronym': 'TALSLB'},\n",
       "                'statusModule': {'statusVerifiedDate': '2023-11',\n",
       "                 'overallStatus': 'RECRUITING',\n",
       "                 'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "                 'startDateStruct': {'date': '2021-01-01', 'type': 'ACTUAL'},\n",
       "                 'primaryCompletionDateStruct': {'date': '2031-12-31',\n",
       "                  'type': 'ESTIMATED'},\n",
       "                 'completionDateStruct': {'date': '2031-12-31',\n",
       "                  'type': 'ESTIMATED'},\n",
       "                 'studyFirstSubmitDate': '2021-11-16',\n",
       "                 'studyFirstSubmitQcDate': '2021-11-16',\n",
       "                 'studyFirstPostDateStruct': {'date': '2021-11-30',\n",
       "                  'type': 'ACTUAL'},\n",
       "                 'lastUpdateSubmitDate': '2023-11-13',\n",
       "                 'lastUpdatePostDateStruct': {'date': '2023-11-15',\n",
       "                  'type': 'ACTUAL'}},\n",
       "                'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "                 'leadSponsor': {'name': 'Target ALS Foundation, Inc.',\n",
       "                  'class': 'OTHER'}},\n",
       "                'oversightModule': {'oversightHasDmc': False,\n",
       "                 'isFdaRegulatedDrug': False,\n",
       "                 'isFdaRegulatedDevice': False},\n",
       "                'descriptionModule': {'briefSummary': 'Brief Summary: The goal of the study is to generate a biorepository of longitudinal blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 200 Amyotrophic Lateral Sclerosis (ALS) patients and 80 healthy controls from multiple sites, over a 5 year time frame. Additionally, speech measures will be collected on weekly basis at home for all participants. The measurements are performed using a speech recording application installed on their personal device. For a subset of both ALS and healthy participants, we will also collect at-home vital capacity on a weekly basis. It is expected that increased frequency data sampling of these outcome measures will help in better tracking of disease progression. Biofluids and clinical information are collected over a 20-month time frame for each individual enrolled in the research study. ALS participants will be coming to clinic for 5 study visits with a 4-month interval between visits. Healthy participants will be coming for 2 study visits with a 12-month interval between visits. These samples and clinical information will be stored in a de-identified manner and made available for investigators to use in future research studies.',\n",
       "                 'detailedDescription': 'An industry wide survey performed by Dr. Lyle Ostrow at Johns Hopkins University indicated that longitudinal bio-fluids linked to detailed clinical information are critical to continued drug development for amyotrophic lateral sclerosis (ALS), with CSF being the top biofluid often lacking in longitudinal sample biorepositories. There have been prior efforts for longitudinal collection of biofluids matched to clinical information (see https://cdmrp.army.mil/alsrp/resources/Biorepositories_biofluids_celllines for a listing of ALS biorepositories), but those sample sets are limited in size and quickly utilized by the research community. Based upon input from industry leaders, we propose the creation of a Target ALS longitudinal biofluids biorepository linked to patient genetic and clinical information.\\n\\nGiven the heterogeneous clinical and biologic nature of ALS, a repository of longitudinal samples linked to clinical and genetic information is essential to help identify and verify ALS biomarkers. Recent studies to identify ALS biomarkers have used longitudinal samples from either the sporadic patient population or from those that harbor genetic mutations known to cause ALS but are not yet symptomatic. Beyond exploring the relationship between known causative genes and candidate biomarkers, the Target ALS Postmortem Core has collected postmortem ALS tissue samples linked to whole genome sequencing information that have been valuable at finding new subtypes of ALS linked to transcriptomics profiles from the tissue samples. The current study utilizes medical centers participating in the Target ALS Postmortem Core to create a longitudinal biofluids repository from living patients and healthy controls. Given the impact of COVID-19 on ALS clinical research studies and clinical trials, all participants will participate in at home speech measures on a weekly basis and we will also enroll 100 ALS and 30 healthy control participants for at home measures of vital capacity that are completed once every two weeks. The added feature of these at home measures is to further evaluate the potential for at home measures in future clinical trials and ability to obtain enriched speech and vital capacity measures to correlate to downstream biomarker studies using biofluid or genetic data. There is a growing interest in the use of at home speech analytics to classify and monitor ALS patients, with recent studies indicating the value for these at home measures in both clinical research and clinical trial settings. Our study will not only expand upon these early findings but also include at home spirometry measures of vital capacity to evaluate the ability to obtain reliable vital capacity measures at home.\\n\\nOur proposed study will provide valuable longitudinal biofluids linked to clinical information, genetic data, at home speech and vital capacity measures for use in future research studies. These de-identified samples and clinical information will be available to investigators throughout the world to enhance ALS research and ultimately improved treatments for ALS. There is a long history of benefit for biorepositories with linked clinical data to be instrumental in research progress. Most studies that identify biomarkers or validate biomarkers for human diseases typically require banked samples that are linked to clinical information to determine sensitivity/specificity of the biomarker for that disease or to demonstrate change over course of disease.'},\n",
       "                'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis',\n",
       "                  'Movement Disorders',\n",
       "                  'Degenerative Disorder',\n",
       "                  'Motor Neuron Disease'],\n",
       "                 'keywords': ['Amyotrophic Lateral Sclerosis',\n",
       "                  'ALS Amyotrophic Lateral Sclerosis',\n",
       "                  'Target ALS',\n",
       "                  'Longitudinal Biofluids',\n",
       "                  'Barrow Neurological Institute',\n",
       "                  'New York Genome Center',\n",
       "                  'Biofluids Biorepository',\n",
       "                  'Genomic-wide association studies']},\n",
       "                'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "                 'patientRegistry': True,\n",
       "                 'targetDuration': '5 Years',\n",
       "                 'designInfo': {'observationalModel': 'OTHER',\n",
       "                  'timePerspective': 'OTHER'},\n",
       "                 'bioSpec': {'retention': 'SAMPLES_WITH_DNA',\n",
       "                  'description': \"Participating sites will label and freeze up to two blood tubes collected from each study participant for DNA extraction and analysis. DNA extraction will be done at Barrow Neurological Institute (BNI). DNA may be stored, used in genome-wide association studies (GWAS), whole genome sequencing, exome sequencing, or for any other known or as yet undiscovered DNA analysis applicable to understanding or targeting disease, with a particular emphasis on ALS. The whole genomic sequencing will be done at the New York Genome Center (NYGC). The information from these genetic studies may be made available to collaborators in academia, not-for-profit settings, or industry for appropriate research. Results of DNA testing from this study will not go into the participant's medical record.\"},\n",
       "                 'enrollmentInfo': {'count': 280, 'type': 'ESTIMATED'}},\n",
       "                'armsInterventionsModule': {'armGroups': [{'label': 'Amyotrophic Lateral Sclerosis ALS',\n",
       "                   'description': 'Amyotrophic Lateral Sclerosis (ALS): Clinical diagnosis of ALS requires the presence of UMN and LMN involvement in different body regions and evidence of progressive spread of symptoms or signs according to EEC. ALS clinic patients with suspected, possible, probable, probable-laboratory supported, or definite ALS will be included. ALS clinic participants with suspected, possible, probable, probable-laboratory supported, and definite Amyotrophic Lateral Sclerosis (ALS) according to revised El Escorial Criteria (EEC) will participate in 5 longitudinal visits; Screening/Baseline Visit 1, and four (4) follow-up visits which will occur at approximate 4-month intervals. Upon IRB approved consent, the study participant will undergo the assessments and bio-fluid collections at each visit as outlined in the Schedule of Events.'},\n",
       "                  {'label': 'Healthy',\n",
       "                   'description': 'Healthy participants (family or friends) will have a neurologic exam to confirm non-neurologic disease status and will participate in 2 longitudinal visits; Screening/baseline Visit 1, and one (1) follow-up which will occur at approximate 12-month interval. Upon IRB approved consent, the study participant will undergo the assessments and bio-fluid collections at each visit as outlined in the Schedule of Events.'}]},\n",
       "                'outcomesModule': {'primaryOutcomes': [{'measure': 'Biofluid Biorepository',\n",
       "                   'description': 'This project will create a biorepository of longitudinal biofluid samples, linked to clinical measures, and at home measures',\n",
       "                   'timeFrame': '+ 3.5 Years'}]},\n",
       "                'eligibilityModule': {'eligibilityCriteria': 'Inclusion ALS participants:\\n\\n1. Age 18 or older.\\n2. Ability to understand the purpose and risks of the study, provide informed consent and comply with trial procedures.\\n3. Diagnosis of ALS according to revised EEC, including suspected, possible, probable (+/- laboratory supported), and definite.\\n4. Vital capacity (VC) at least 50% predicted value for gender, height and age at screening\\n5. In the opinion of the study physician, able to tolerate study procedures, including lumbar puncture, for the duration of the study.\\n6. A Score of 2 or more on item one (SPEECH) of the ALSFRS-R scale.\\n7. Subjects medically able to undergo lumbar puncture (LP) as determined by the investigator 15 (i.e.: no bleeding disorder, allergy to local anesthetics, a skin infection at or near the LP site, or evidence of high intracranial pressure).\\n8. Access to a smartphone or tablet, and internet access at home.\\n\\nInclusion Healthy participants:\\n\\n1. Age 18 or older.\\n2. Capable of providing informed consent and complying with trial procedure.\\n3. No history of neurological disease, as determined by the investigator.\\n4. Individuals that harbor known genetic mutations that cause ALS yet are asymptomatic can also be enrolled in the Healthy participant cohort.\\n5. Access to a smartphone or tablet, and internet access at home.\\n\\nExclusion ALS and Healthy participants:\\n\\n1. Any known or suspected abnormal CSF pressure or intracranial/intraspinal tumors\\n2. Use of anticoagulant medication (eg. warfarin, dalteparin, enoxaparin, rivaroxaban, fondaparinux, dabigatran) that cannot be safely withheld until coagulation parameters have normalized prior to lumbar puncture and for up to a week following the lumbar puncture.\\n3. Blood dyscrasia, abnormal bleeding diathesis, or the use of dialysis for renal failure.\\n4. Clinical judgment of the Site Investigator that the participant would be unable to undergo multiple lumbar punctures.\\n5. Inability to perform at home speech measures using an app on a patient device (phone or iPad)\\n\\nIndividuals participating in other clinical research studies will be eligible to participate in this study. ALS patients on any currently approved therapies (riluzole, edaravone) are eligible to participate and continue their medications throughout this study.',\n",
       "                 'healthyVolunteers': True,\n",
       "                 'sex': 'ALL',\n",
       "                 'minimumAge': '18 Years',\n",
       "                 'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "                 'studyPopulation': 'Clinic patients, with suspected, possible, probable-laboratory supported, and definite Amyotrophic Lateral Sclerosis, (ALS) according to revised El Escorial Criteria (EEC). Healthy volunteers will be family or friends of Clinic patients with suspected, possible probable, probable laboratory supported and definite Amyotrophic Lateral Sclerosis (ALS) according to revised El Escorial Criteria (EEC).',\n",
       "                 'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "                'contactsLocationsModule': {'centralContacts': [{'name': 'Manish Raisinghani, MBBS PhD',\n",
       "                   'role': 'CONTACT',\n",
       "                   'phone': '332-333-4140',\n",
       "                   'email': 'manish.raisinghani@targetals.org'},\n",
       "                  {'name': 'Robert Bowser, PhD',\n",
       "                   'role': 'CONTACT',\n",
       "                   'phone': '602-406-8989',\n",
       "                   'email': 'robert.bowser@dignityhealth.org'}],\n",
       "                 'overallOfficials': [{'name': 'Manish J Raisinghani, MBBS PhD',\n",
       "                   'affiliation': 'Target ALS Foundation, Inc.',\n",
       "                   'role': 'STUDY_DIRECTOR'},\n",
       "                  {'name': 'Amy Easton, PhD',\n",
       "                   'affiliation': 'Target ALS Foundation, Inc.',\n",
       "                   'role': 'STUDY_DIRECTOR'}],\n",
       "                 'locations': [{'facility': 'Barrow Neurological Institute',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'Phoenix',\n",
       "                   'state': 'Arizona',\n",
       "                   'zip': '85013',\n",
       "                   'country': 'United States',\n",
       "                   'contacts': [{'name': 'Whitney Dailey, MS',\n",
       "                     'role': 'CONTACT',\n",
       "                     'phone': '602-406-7804',\n",
       "                     'phoneExt': '67804',\n",
       "                     'email': 'whitney.dailey@dignityhealth.org'},\n",
       "                    {'name': 'Lisa Butler, MPH',\n",
       "                     'role': 'CONTACT',\n",
       "                     'phone': '602-406-4217',\n",
       "                     'phoneExt': '64217',\n",
       "                     'email': 'lisa.butler@dignityhealth.org'},\n",
       "                    {'name': 'Shafeeq Ladha, MD',\n",
       "                     'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "                   'geoPoint': {'lat': 33.44838, 'lon': -112.07404}},\n",
       "                  {'facility': 'University of California San Diego',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'San Diego',\n",
       "                   'state': 'California',\n",
       "                   'zip': '92121',\n",
       "                   'country': 'United States',\n",
       "                   'contacts': [{'name': 'Gil Gutierrez',\n",
       "                     'role': 'CONTACT',\n",
       "                     'email': 'grg005@health.ucsd.edu'},\n",
       "                    {'name': 'John Ravits, MD',\n",
       "                     'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "                   'geoPoint': {'lat': 32.71533, 'lon': -117.15726}},\n",
       "                  {'facility': 'Georgetown University',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'Georgetown',\n",
       "                   'state': 'District of Columbia',\n",
       "                   'zip': '20007',\n",
       "                   'country': 'United States',\n",
       "                   'contacts': [{'name': 'Charles Carpenter',\n",
       "                     'role': 'CONTACT',\n",
       "                     'email': 'cjc357@georgetown.edu'},\n",
       "                    {'name': 'Luke Lovelace',\n",
       "                     'role': 'CONTACT',\n",
       "                     'email': 'll928@georgetwon.edu'},\n",
       "                    {'name': 'Brent Harris, MD',\n",
       "                     'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "                   'geoPoint': {'lat': 38.90483, 'lon': -77.06248}},\n",
       "                  {'facility': 'Mayo Clinic',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'Jacksonville',\n",
       "                   'state': 'Florida',\n",
       "                   'zip': '32224',\n",
       "                   'country': 'United States',\n",
       "                   'contacts': [{'name': 'Alexander Burch',\n",
       "                     'role': 'CONTACT',\n",
       "                     'email': 'burch.alexander@mayo.edu'},\n",
       "                    {'name': 'Bjorn Oskarsson, MD',\n",
       "                     'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "                   'geoPoint': {'lat': 30.33218, 'lon': -81.65565}},\n",
       "                  {'facility': 'Washington University',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'Saint Louis',\n",
       "                   'state': 'Missouri',\n",
       "                   'zip': '63110',\n",
       "                   'country': 'United States',\n",
       "                   'contacts': [{'name': 'Jeri Oranski',\n",
       "                     'role': 'CONTACT',\n",
       "                     'email': 'jerio@wustl.edu'},\n",
       "                    {'name': 'Jesse Markway',\n",
       "                     'role': 'CONTACT',\n",
       "                     'email': 'jessemarkway@wustl.edu'},\n",
       "                    {'name': 'Tim Miller, MD',\n",
       "                     'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "                    {'name': 'Cindy Ly, MD',\n",
       "                     'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "                   'geoPoint': {'lat': 38.62727, 'lon': -90.19789}},\n",
       "                  {'facility': 'Columbia University',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'New York',\n",
       "                   'state': 'New York',\n",
       "                   'zip': '10032',\n",
       "                   'country': 'United States',\n",
       "                   'contacts': [{'name': 'Ben Hoover',\n",
       "                     'role': 'CONTACT',\n",
       "                     'email': 'bnh2119@cumc.columbia.edu'},\n",
       "                    {'name': 'Sarah Griffen',\n",
       "                     'role': 'CONTACT',\n",
       "                     'email': 'sjg2220@cumc.columbia.edu'},\n",
       "                    {'name': 'Neil Schneider, MD',\n",
       "                     'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "                    {'name': 'Matt Harms, MD', 'role': 'SUB_INVESTIGATOR'}],\n",
       "                   'geoPoint': {'lat': 40.71427, 'lon': -74.00597}},\n",
       "                  {'facility': 'Temple University',\n",
       "                   'status': 'ACTIVE_NOT_RECRUITING',\n",
       "                   'city': 'Philadelphia',\n",
       "                   'state': 'Pennsylvania',\n",
       "                   'zip': '19140',\n",
       "                   'country': 'United States',\n",
       "                   'geoPoint': {'lat': 39.95233, 'lon': -75.16379}}]},\n",
       "                'referencesModule': {'references': [{'pmid': '21989244',\n",
       "                   'type': 'BACKGROUND',\n",
       "                   'citation': 'Bowser R, Turner MR, Shefner J. Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. Nat Rev Neurol. 2011 Oct 11;7(11):631-8. doi: 10.1038/nrneurol.2011.151.'},\n",
       "                  {'pmid': '30941088',\n",
       "                   'type': 'BACKGROUND',\n",
       "                   'citation': 'Chipika RH, Finegan E, Li Hi Shing S, Hardiman O, Bede P. Tracking a Fast-Moving Disease: Longitudinal Markers, Monitoring, and Clinical Trial Endpoints in ALS. Front Neurol. 2019 Mar 19;10:229. doi: 10.3389/fneur.2019.00229. eCollection 2019.'},\n",
       "                  {'pmid': '31432691',\n",
       "                   'type': 'BACKGROUND',\n",
       "                   'citation': 'Benatar M, Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, Malaspina A. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(7-8):538-548. doi: 10.1080/21678421.2019.1646769. Epub 2019 Aug 21.'},\n",
       "                  {'pmid': '32515902',\n",
       "                   'type': 'BACKGROUND',\n",
       "                   'citation': 'Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, Glass JD, Brown RH Jr, Ladha SS, Lacomis D, Harris JM, Scearce-Levie K, Ho C, Bowser R, Berry JD. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020 Jul;7(7):1103-1116. doi: 10.1002/acn3.51078. Epub 2020 Jun 9.'},\n",
       "                  {'pmid': '31665631',\n",
       "                   'type': 'BACKGROUND',\n",
       "                   'citation': 'Tam OH, Rozhkov NV, Shaw R, Kim D, Hubbard I, Fennessey S, Propp N; NYGC ALS Consortium; Fagegaltier D, Harris BT, Ostrow LW, Phatnani H, Ravits J, Dubnau J, Gale Hammell M. Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia. Cell Rep. 2019 Oct 29;29(5):1164-1177.e5. doi: 10.1016/j.celrep.2019.09.066.'},\n",
       "                  {'pmid': '32126556',\n",
       "                   'type': 'BACKGROUND',\n",
       "                   'citation': 'Vieira H, Costa N, Sousa T, Reis S, Coelho L. Voice-Based Classification of Amyotrophic Lateral Sclerosis: Where Are We and Where Are We Going? A Systematic Review. Neurodegener Dis. 2019;19(5-6):163-170. doi: 10.1159/000506259. Epub 2020 Mar 3.'},\n",
       "                  {'pmid': '32138555',\n",
       "                   'type': 'BACKGROUND',\n",
       "                   'citation': 'Barnett C, Green JR, Marzouqah R, Stipancic KL, Berry JD, Korngut L, Genge A, Shoesmith C, Briemberg H, Abrahao A, Kalra S, Zinman L, Yunusova Y. Reliability and validity of speech & pause measures during passage reading in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Feb;21(1-2):42-50. doi: 10.1080/21678421.2019.1697888. Epub 2019 Dec 6.'},\n",
       "                  {'pmid': '32515889',\n",
       "                   'type': 'BACKGROUND',\n",
       "                   'citation': 'Rutkove SB, Narayanaswami P, Berisha V, Liss J, Hahn S, Shelton K, Qi K, Pandeya S, Shefner JM. Improved ALS clinical trials through frequent at-home self-assessment: a proof of concept study. Ann Clin Transl Neurol. 2020 Jul;7(7):1148-1157. doi: 10.1002/acn3.51096. Epub 2020 Jun 9. Erratum In: Ann Clin Transl Neurol. 2021 Aug;8(8):1770.'},\n",
       "                  {'pmid': '23834161',\n",
       "                   'type': 'BACKGROUND',\n",
       "                   'citation': 'Quinn C, Macklin EA, Atassi N, Bowser R, Boylan K, Cudkowicz M, Fournier C, Ladha SS, Lacomis D, Berry J. Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):632-4. doi: 10.3109/21678421.2013.808227. Epub 2013 Jul 8. No abstract available.'},\n",
       "                  {'pmid': '16705110',\n",
       "                   'type': 'BACKGROUND',\n",
       "                   'citation': 'Schievink WI. Spontaneous spinal cerebrospinal fluid leaks and intracranial hypotension. JAMA. 2006 May 17;295(19):2286-96. doi: 10.1001/jama.295.19.2286.'}]},\n",
       "                'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "                 'description': 'These samples and clinical information will be stored in a de-identified manner and made available for investigators to use in future research studies.\\n\\nIt is expected to take approximately 5 years to complete all sample and data collection for the study. The first phase of the study will involve activating all sites participating in the study, and will take about 4 months to complete. The enrollment period is expected to be about 2-3.5 years. Active assessment for each subject will be for 16-18 months from the time of enrollment. After the end of active assessment period (5 years), the bio-samples and clinical information from the study will be made available for future research.',\n",
       "                 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR'],\n",
       "                 'timeFrame': 'Greater than 5+ Years',\n",
       "                 'accessCriteria': 'Access available using published manuscripts and stored biofluids using the BioLims Repository.',\n",
       "                 'url': 'http://targetals.org'}},\n",
       "               'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'},\n",
       "                'conditionBrowseModule': {'meshes': [{'id': 'D000016472',\n",
       "                   'term': 'Motor Neuron Disease'},\n",
       "                  {'id': 'D000000690',\n",
       "                   'term': 'Amyotrophic Lateral Sclerosis'},\n",
       "                  {'id': 'D000009069', 'term': 'Movement Disorders'},\n",
       "                  {'id': 'D000012598', 'term': 'Sclerosis'}],\n",
       "                 'ancestors': [{'id': 'D000010335',\n",
       "                   'term': 'Pathologic Processes'},\n",
       "                  {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'},\n",
       "                  {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "                  {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "                  {'id': 'D000013118', 'term': 'Spinal Cord Diseases'},\n",
       "                  {'id': 'D000002493',\n",
       "                   'term': 'Central Nervous System Diseases'},\n",
       "                  {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'},\n",
       "                  {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'},\n",
       "                  {'id': 'D000008659', 'term': 'Metabolic Diseases'}],\n",
       "                 'browseLeaves': [{'id': 'M15415',\n",
       "                   'name': 'Sclerosis',\n",
       "                   'asFound': 'Sclerosis',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M18879',\n",
       "                   'name': 'Motor Neuron Disease',\n",
       "                   'asFound': 'Motor Neuron Disease',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M4024',\n",
       "                   'name': 'Amyotrophic Lateral Sclerosis',\n",
       "                   'asFound': 'Amyotrophic Lateral Sclerosis',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M12029',\n",
       "                   'name': 'Movement Disorders',\n",
       "                   'asFound': 'Movement Disorders',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M21558',\n",
       "                   'name': 'Neurodegenerative Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M12411',\n",
       "                   'name': 'Neuromuscular Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M15915',\n",
       "                   'name': 'Spinal Cord Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M5742',\n",
       "                   'name': 'Central Nervous System Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M28759',\n",
       "                   'name': 'TDP-43 Proteinopathies',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M28747',\n",
       "                   'name': 'Proteostasis Deficiencies',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M11639',\n",
       "                   'name': 'Metabolic Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'T349',\n",
       "                   'name': 'Amyotrophic Lateral Sclerosis',\n",
       "                   'asFound': 'Amyotrophic Lateral Sclerosis',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'T4699',\n",
       "                   'name': 'Primary Lateral Sclerosis',\n",
       "                   'asFound': 'Lateral Sclerosis',\n",
       "                   'relevance': 'HIGH'}],\n",
       "                 'browseBranches': [{'abbrev': 'BC23',\n",
       "                   'name': 'Symptoms and General Pathology'},\n",
       "                  {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "                  {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "                  {'abbrev': 'BC18',\n",
       "                   'name': 'Nutritional and Metabolic Diseases'},\n",
       "                  {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "               'hasResults': False},\n",
       "              {'protocolSection': {'identificationModule': {'nctId': 'NCT05474235',\n",
       "                 'orgStudyIdInfo': {'id': '07-005711'},\n",
       "                 'secondaryIdInfos': [{'id': '5P01NS084974',\n",
       "                   'type': 'NIH',\n",
       "                   'link': 'https://reporter.nih.gov/quickSearch/5P01NS084974'}],\n",
       "                 'organization': {'fullName': 'Mayo Clinic', 'class': 'OTHER'},\n",
       "                 'briefTitle': 'Studies in Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Motor Neuron Disorders',\n",
       "                 'officialTitle': 'Clinical & Genetic Studies in ALS and Other Neurodegenerative Motor Neuron Disorders'},\n",
       "                'statusModule': {'statusVerifiedDate': '2023-08',\n",
       "                 'overallStatus': 'RECRUITING',\n",
       "                 'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "                 'startDateStruct': {'date': '2007-12', 'type': 'ACTUAL'},\n",
       "                 'primaryCompletionDateStruct': {'date': '2038-12',\n",
       "                  'type': 'ESTIMATED'},\n",
       "                 'completionDateStruct': {'date': '2038-12',\n",
       "                  'type': 'ESTIMATED'},\n",
       "                 'studyFirstSubmitDate': '2022-07-14',\n",
       "                 'studyFirstSubmitQcDate': '2022-07-22',\n",
       "                 'studyFirstPostDateStruct': {'date': '2022-07-26',\n",
       "                  'type': 'ACTUAL'},\n",
       "                 'lastUpdateSubmitDate': '2023-08-01',\n",
       "                 'lastUpdatePostDateStruct': {'date': '2023-08-02',\n",
       "                  'type': 'ACTUAL'}},\n",
       "                'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "                  'investigatorFullName': 'Bjorn E. Oskarsson',\n",
       "                  'investigatorTitle': 'Principal Investigator',\n",
       "                  'investigatorAffiliation': 'Mayo Clinic'},\n",
       "                 'leadSponsor': {'name': 'Mayo Clinic', 'class': 'OTHER'},\n",
       "                 'collaborators': [{'name': 'National Institute of Neurological Disorders and Stroke (NINDS)',\n",
       "                   'class': 'NIH'}]},\n",
       "                'oversightModule': {'oversightHasDmc': False,\n",
       "                 'isFdaRegulatedDrug': False,\n",
       "                 'isFdaRegulatedDevice': False},\n",
       "                'descriptionModule': {'briefSummary': 'The purpose of this study is to collect, from patients with sporadic and familial ALS and their family members, clinical data and blood samples for extraction of DNA, RNA, preparation of lymphocytes, plasma and serum to establish a repository for future investigations of genetic contributions to ALS pathogenesis. Blood samples for DNA extraction also would be collected from control subjects with no personal or family history of ALS phenotypes.'},\n",
       "                'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis']},\n",
       "                'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "                 'patientRegistry': False,\n",
       "                 'designInfo': {'observationalModel': 'CASE_CONTROL',\n",
       "                  'timePerspective': 'CROSS_SECTIONAL'},\n",
       "                 'enrollmentInfo': {'count': 3000, 'type': 'ESTIMATED'}},\n",
       "                'armsInterventionsModule': {'armGroups': [{'label': 'ALS or Suspected ALS Patient',\n",
       "                   'description': 'Subjects with clinical diagnosis of possible, laboratory-supported probable, probable or definite, ALS or diagnosis of a neurodegenerative disorder with evidence of ALS plus extramotor features or a blood relative (first, second or third degree) with history of ALS or neurodegenerative disorder with evidence of ALS plus extramotor features.'},\n",
       "                  {'label': 'Blood Relative of ALS Patient',\n",
       "                   'description': 'Subjects with family history (first, second or third degree blood relative) of ALS or other motor neuron disease.'},\n",
       "                  {'label': 'Healthy Control',\n",
       "                   'description': 'Subjects with no personal or family history (first, second or third degree blood relative) of ALS or other motor neuron disease'}]},\n",
       "                'outcomesModule': {'primaryOutcomes': [{'measure': 'Blood Collection',\n",
       "                   'description': 'Total number of blood samples collected',\n",
       "                   'timeFrame': '50 years'}]},\n",
       "                'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria\\n\\nALS or Suspected ALS Patient\\n\\n* Clinical diagnosis of possible, laboratory-supported probable, probable or definite ALS according to modified EL Escorial criteria, suspected ALS according to original El Escorial criteria, or diagnosis of a neurodegenerative disorder with evidence of ALS plus extramotor features; OR\\n* Blood relative (first, second or third degree) with history of ALS or neurodegenerative disorder with evidence of ALS plus extramotor features; OR:\\n\\n  * A clinical suspicion or referral for ALS;\\n  * \\\\> 18 years of age;\\n  * Willing and able to give signed informed consent or assent that has been approved by the Institutional Review Board (IRB).\\n\\nBlood Relative of ALS Patient\\n\\n* Family history (first, second or third degree blood relative) of ALS or other motor neuron disease;\\n* \\\\> 18 years of age;\\n* Willing and able to give signed informed consent that has been approved by the Institutional Review Board (IRB).\\n\\nHealthy Control\\n\\n* No personal or family history (first, second or third degree blood relative) of ALS or other motor neuron disease;\\n* \\\\> 18 years of age;\\n* No personal history of other neurodegenerative disease (i.e., Alzheimer disease, Parkinson disease);\\n* Willing and able to give signed informed consent that has been approved by the Institutional Review Board (IRB).\\n\\nExclusion Criteria:\\n\\nALS or Suspected Patient • Limited mental capacity rendering the subject unable to provide written informed consent or assent or comply with standard phlebotomy procedures.\\n\\nBlood Relative of ALS Patient\\n\\n• Limited mental capacity rendering the subject unable to provide written informed consent or comply with standard phlebotomy procedures.\\n\\nHealthy Control Subject\\n\\n* Personal or family history of dementia or other neurodegenerative disease (Parkinson disease, Alzheimer disease, etc.);\\n* MoCA score \\\\< 26;\\n* Limited mental capacity rendering the subject unable to provide written informed consent or comply with standard phlebotomy procedures.',\n",
       "                 'healthyVolunteers': True,\n",
       "                 'sex': 'ALL',\n",
       "                 'minimumAge': '18 Years',\n",
       "                 'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "                 'studyPopulation': 'Eligible subjects with ALS or suspected ALS or family history of ALS will be identified from patients seen in the Department of Neurology at Mayo Clinic Jacksonville. Inclusion criteria include standardized diagnostic criteria for ALS as used in ALS therapeutic trials and patients with clinically suspected ALS.',\n",
       "                 'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "                'contactsLocationsModule': {'overallOfficials': [{'name': 'Bjorn Oskarsson, MD',\n",
       "                   'affiliation': 'Mayo Clinic',\n",
       "                   'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "                 'locations': [{'facility': 'Mayo Clinic Florida',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'Jacksonville',\n",
       "                   'state': 'Florida',\n",
       "                   'zip': '32224',\n",
       "                   'country': 'United States',\n",
       "                   'contacts': [{'name': 'Alex Burch',\n",
       "                     'role': 'CONTACT',\n",
       "                     'phone': '904-953-4724',\n",
       "                     'email': 'burch.alexander@mayo.edu'}],\n",
       "                   'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}]}},\n",
       "               'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'},\n",
       "                'conditionBrowseModule': {'meshes': [{'id': 'D000016472',\n",
       "                   'term': 'Motor Neuron Disease'},\n",
       "                  {'id': 'D000000690',\n",
       "                   'term': 'Amyotrophic Lateral Sclerosis'},\n",
       "                  {'id': 'D000012598', 'term': 'Sclerosis'}],\n",
       "                 'ancestors': [{'id': 'D000010335',\n",
       "                   'term': 'Pathologic Processes'},\n",
       "                  {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'},\n",
       "                  {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "                  {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "                  {'id': 'D000013118', 'term': 'Spinal Cord Diseases'},\n",
       "                  {'id': 'D000002493',\n",
       "                   'term': 'Central Nervous System Diseases'},\n",
       "                  {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'},\n",
       "                  {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'},\n",
       "                  {'id': 'D000008659', 'term': 'Metabolic Diseases'}],\n",
       "                 'browseLeaves': [{'id': 'M15415',\n",
       "                   'name': 'Sclerosis',\n",
       "                   'asFound': 'Sclerosis',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M18879',\n",
       "                   'name': 'Motor Neuron Disease',\n",
       "                   'asFound': 'Lateral Sclerosis',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M4024',\n",
       "                   'name': 'Amyotrophic Lateral Sclerosis',\n",
       "                   'asFound': 'Amyotrophic Lateral Sclerosis',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M21558',\n",
       "                   'name': 'Neurodegenerative Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M12411',\n",
       "                   'name': 'Neuromuscular Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M15915',\n",
       "                   'name': 'Spinal Cord Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M5742',\n",
       "                   'name': 'Central Nervous System Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M28759',\n",
       "                   'name': 'TDP-43 Proteinopathies',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M28747',\n",
       "                   'name': 'Proteostasis Deficiencies',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M11639',\n",
       "                   'name': 'Metabolic Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'T349',\n",
       "                   'name': 'Amyotrophic Lateral Sclerosis',\n",
       "                   'asFound': 'Amyotrophic Lateral Sclerosis',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'T4699',\n",
       "                   'name': 'Primary Lateral Sclerosis',\n",
       "                   'asFound': 'Lateral Sclerosis',\n",
       "                   'relevance': 'HIGH'}],\n",
       "                 'browseBranches': [{'abbrev': 'BC23',\n",
       "                   'name': 'Symptoms and General Pathology'},\n",
       "                  {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "                  {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "                  {'abbrev': 'BC18',\n",
       "                   'name': 'Nutritional and Metabolic Diseases'},\n",
       "                  {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "               'hasResults': False},\n",
       "              {'protocolSection': {'identificationModule': {'nctId': 'NCT02916966',\n",
       "                 'orgStudyIdInfo': {'id': 'D06019'},\n",
       "                 'organization': {'fullName': 'Dartmouth-Hitchcock Medical Center',\n",
       "                  'class': 'OTHER'},\n",
       "                 'briefTitle': 'Environmental Exposure and Neurological Diseases Questionnaire',\n",
       "                 'officialTitle': 'Case-control and Population Questionnaire Studying Environmental Risk Factors and Neurological Diseases'},\n",
       "                'statusModule': {'statusVerifiedDate': '2023-09',\n",
       "                 'overallStatus': 'RECRUITING',\n",
       "                 'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "                 'startDateStruct': {'date': '2016-10', 'type': 'ACTUAL'},\n",
       "                 'primaryCompletionDateStruct': {'date': '2025-12',\n",
       "                  'type': 'ESTIMATED'},\n",
       "                 'completionDateStruct': {'date': '2025-12',\n",
       "                  'type': 'ESTIMATED'},\n",
       "                 'studyFirstSubmitDate': '2016-09-26',\n",
       "                 'studyFirstSubmitQcDate': '2016-09-27',\n",
       "                 'studyFirstPostDateStruct': {'date': '2016-09-28',\n",
       "                  'type': 'ESTIMATED'},\n",
       "                 'lastUpdateSubmitDate': '2023-09-05',\n",
       "                 'lastUpdatePostDateStruct': {'date': '2023-09-06',\n",
       "                  'type': 'ACTUAL'}},\n",
       "                'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "                  'investigatorFullName': 'Elijah W. Stommel',\n",
       "                  'investigatorTitle': 'Professor of Neurology',\n",
       "                  'investigatorAffiliation': 'Dartmouth-Hitchcock Medical Center'},\n",
       "                 'leadSponsor': {'name': 'Dartmouth-Hitchcock Medical Center',\n",
       "                  'class': 'OTHER'},\n",
       "                 'collaborators': [{'name': 'The Cleveland Clinic',\n",
       "                   'class': 'OTHER'}]},\n",
       "                'descriptionModule': {'briefSummary': 'The proposed research is particularly relevant to the National ALS Registry and public environmental health issues because it addresses the potential environmental causes of sporadic ALS. The research will develop an ALS surveillance program in Ohio that can be compared with the national and State-Metro Surveillance Programs of the National ALS Registry, and novel methodologies to determine the role of the cyanobacterial toxin, BMAA (beta-methylamino-L-alanine), and other environmental toxins/toxicants as risk factors for ALS. This work will advance the mission of the Centers for Disease Control Agency for Toxic Substances and Disease Registry (CDC ATSDR) National ALS Registry by offering data on ALS cases in Ohio that address public health concerns over the effects of chronic exposure to cyanobacterial blooms in Lake Erie.'},\n",
       "                'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis']},\n",
       "                'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "                 'patientRegistry': False,\n",
       "                 'designInfo': {'observationalModel': 'CASE_CONTROL',\n",
       "                  'timePerspective': 'PROSPECTIVE'},\n",
       "                 'enrollmentInfo': {'count': 2000, 'type': 'ESTIMATED'}},\n",
       "                'armsInterventionsModule': {'armGroups': [{'label': 'ALS Patients in Case-Control',\n",
       "                   'description': 'ALS patients enrolled by Cleveland Clinic Foundation (CCF)',\n",
       "                   'interventionNames': ['Other: Patient Registry']},\n",
       "                  {'label': 'Non-neurodegenerative patients in case control',\n",
       "                   'description': 'Non-neurodegenerative patients enrolled by CCF',\n",
       "                   'interventionNames': ['Other: Patient Registry']},\n",
       "                  {'label': 'Non-neurodegeneration population in population control',\n",
       "                   'description': 'Non-neurodegenerative general population enrolled by ABS mailing system from DHMC',\n",
       "                   'interventionNames': ['Other: Patient Registry']},\n",
       "                  {'label': 'ALS Patients in State of OH',\n",
       "                   'description': 'ALS registry of all cases in Ohio',\n",
       "                   'interventionNames': ['Other: Patient Registry']}],\n",
       "                 'interventions': [{'type': 'OTHER',\n",
       "                   'name': 'Patient Registry',\n",
       "                   'description': 'Patient Registry',\n",
       "                   'armGroupLabels': ['ALS Patients in Case-Control',\n",
       "                    'ALS Patients in State of OH',\n",
       "                    'Non-neurodegeneration population in population control',\n",
       "                    'Non-neurodegenerative patients in case control']}]},\n",
       "                'outcomesModule': {'primaryOutcomes': [{'measure': 'Questionnaire for Environmental Exposures, Toxins, and Neurological Disease',\n",
       "                   'timeFrame': '1 year'}]},\n",
       "                'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* ALS\\n* Non-neurodegenerative controls\\n* Can willingly give consent\\n* Over 18 years of age\\n\\nExclusion Criteria:\\n\\n* Cannot give consent\\n* Under 18 years of age',\n",
       "                 'healthyVolunteers': True,\n",
       "                 'sex': 'ALL',\n",
       "                 'minimumAge': '18 Years',\n",
       "                 'maximumAge': '80 Years',\n",
       "                 'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "                 'studyPopulation': '1. ALS patients in case-control at CCF\\n2. Non-neurodegenerative patients in case control at CCF\\n3. Non-neurodegenerative general population in Ohio\\n4. ALS patient registry in Ohio',\n",
       "                 'samplingMethod': 'PROBABILITY_SAMPLE'},\n",
       "                'contactsLocationsModule': {'centralContacts': [{'name': 'Elijah W Stommel, MD, PhD',\n",
       "                   'role': 'CONTACT',\n",
       "                   'phone': '866-894-8131',\n",
       "                   'email': 'neuroresearch@hitchcock.org'},\n",
       "                  {'name': 'Kathleen Sullivan',\n",
       "                   'role': 'CONTACT',\n",
       "                   'phone': '(603) 650-6496',\n",
       "                   'email': 'neuroresearch@hitchcock.org'}],\n",
       "                 'locations': [{'facility': 'Cleveland Clinic Foundation',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'Cleveland',\n",
       "                   'state': 'Ohio',\n",
       "                   'zip': '44195',\n",
       "                   'country': 'United States',\n",
       "                   'contacts': [{'name': 'Erik Pioro, MD, PhD',\n",
       "                     'role': 'CONTACT'}],\n",
       "                   'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}]}},\n",
       "               'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'},\n",
       "                'conditionBrowseModule': {'meshes': [{'id': 'D000016472',\n",
       "                   'term': 'Motor Neuron Disease'},\n",
       "                  {'id': 'D000000690',\n",
       "                   'term': 'Amyotrophic Lateral Sclerosis'},\n",
       "                  {'id': 'D000009422', 'term': 'Nervous System Diseases'}],\n",
       "                 'ancestors': [{'id': 'D000019636',\n",
       "                   'term': 'Neurodegenerative Diseases'},\n",
       "                  {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "                  {'id': 'D000013118', 'term': 'Spinal Cord Diseases'},\n",
       "                  {'id': 'D000002493',\n",
       "                   'term': 'Central Nervous System Diseases'},\n",
       "                  {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'},\n",
       "                  {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'},\n",
       "                  {'id': 'D000008659', 'term': 'Metabolic Diseases'}],\n",
       "                 'browseLeaves': [{'id': 'M15415',\n",
       "                   'name': 'Sclerosis',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M18879',\n",
       "                   'name': 'Motor Neuron Disease',\n",
       "                   'asFound': 'Lateral Sclerosis',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M4024',\n",
       "                   'name': 'Amyotrophic Lateral Sclerosis',\n",
       "                   'asFound': 'Amyotrophic Lateral Sclerosis',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M21558',\n",
       "                   'name': 'Neurodegenerative Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M12411',\n",
       "                   'name': 'Neuromuscular Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M15915',\n",
       "                   'name': 'Spinal Cord Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M5742',\n",
       "                   'name': 'Central Nervous System Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M28759',\n",
       "                   'name': 'TDP-43 Proteinopathies',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M28747',\n",
       "                   'name': 'Proteostasis Deficiencies',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M11639',\n",
       "                   'name': 'Metabolic Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'T349',\n",
       "                   'name': 'Amyotrophic Lateral Sclerosis',\n",
       "                   'asFound': 'Amyotrophic Lateral Sclerosis',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'T4699',\n",
       "                   'name': 'Primary Lateral Sclerosis',\n",
       "                   'relevance': 'LOW'}],\n",
       "                 'browseBranches': [{'abbrev': 'BC23',\n",
       "                   'name': 'Symptoms and General Pathology'},\n",
       "                  {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "                  {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "                  {'abbrev': 'BC18',\n",
       "                   'name': 'Nutritional and Metabolic Diseases'},\n",
       "                  {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "               'hasResults': False},\n",
       "              {'protocolSection': {'identificationModule': {'nctId': 'NCT05340660',\n",
       "                 'orgStudyIdInfo': {'id': 'BASEC Nr. 2021-01044'},\n",
       "                 'organization': {'fullName': 'Cantonal Hospital of St. Gallen',\n",
       "                  'class': 'OTHER'},\n",
       "                 'briefTitle': 'mGluR5 Imaging in ALS Using PET',\n",
       "                 'officialTitle': 'Metabotropic Glutamate Receptor 5 Imaging in Amyotrophic Lateral Sclerosis Using Positron Emission Tomography'},\n",
       "                'statusModule': {'statusVerifiedDate': '2022-04',\n",
       "                 'overallStatus': 'RECRUITING',\n",
       "                 'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "                 'startDateStruct': {'date': '2022-04', 'type': 'ESTIMATED'},\n",
       "                 'primaryCompletionDateStruct': {'date': '2022-10',\n",
       "                  'type': 'ESTIMATED'},\n",
       "                 'completionDateStruct': {'date': '2025-04',\n",
       "                  'type': 'ESTIMATED'},\n",
       "                 'studyFirstSubmitDate': '2022-03-29',\n",
       "                 'studyFirstSubmitQcDate': '2022-04-19',\n",
       "                 'studyFirstPostDateStruct': {'date': '2022-04-22',\n",
       "                  'type': 'ACTUAL'},\n",
       "                 'lastUpdateSubmitDate': '2022-04-19',\n",
       "                 'lastUpdatePostDateStruct': {'date': '2022-04-22',\n",
       "                  'type': 'ACTUAL'}},\n",
       "                'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR',\n",
       "                  'investigatorFullName': 'Nathalie Braun',\n",
       "                  'investigatorTitle': 'Principal Investigator',\n",
       "                  'investigatorAffiliation': 'Cantonal Hospital of St. Gallen'},\n",
       "                 'leadSponsor': {'name': 'Nathalie Braun', 'class': 'OTHER'},\n",
       "                 'collaborators': [{'name': 'University of Zurich',\n",
       "                   'class': 'OTHER'},\n",
       "                  {'name': 'ETH Zurich', 'class': 'OTHER'}]},\n",
       "                'oversightModule': {'oversightHasDmc': False,\n",
       "                 'isFdaRegulatedDrug': False,\n",
       "                 'isFdaRegulatedDevice': False},\n",
       "                'descriptionModule': {'briefSummary': 'In ALS models, it was shown that receptors, that bind an important messenger substance (glutamate) in the brain, are increased. In this research project, the investigators want to use a specific radioactive substance to find out whether these receptors are more detectable in people with ALS than in healthy people and increase over the course of the disease.',\n",
       "                 'detailedDescription': 'With this study, the investigators want to examine whether receptors (docking points on the surface of a nerve cell) that bind an important messenger substance in the brain (glutamate) are increased in patients with amyotrophic lateral sclerosis (ALS) as the disease progresses. Based on observations from ALS models, the investigators suspect that this increase in receptors contributes to the damage to the nerve cells in ALS.\\n\\nTo image these receptors, the investigators use a specific radioactive substance and imaging combining positron emission tomography (PET), magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI) of the brain and spinal cord.\\n\\nThe investigators will examine healthy people and ALS patients. The reason is that little is known about the receptor, even in healthy people. The investigators also do not know if and when the receptor is increasingly detectable in the course of the ALS disease. Only by comparing diseased and healthy people it can be determined if and when the receptor is built up in ALS patients. The investigators also hope to gain more information, e.g. about the distribution of receptors in the brain of healthy people compared to patients.'},\n",
       "                'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis'],\n",
       "                 'keywords': ['Receptor, Metabotropic Glutamate 5',\n",
       "                  'Brain / diagnostic imaging',\n",
       "                  'Positron-Emission Tomography / methods',\n",
       "                  'Radiopharmaceuticals / pharmacokinetics*',\n",
       "                  'PSS232',\n",
       "                  'Humans',\n",
       "                  'Adult']},\n",
       "                'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "                 'phases': ['NA'],\n",
       "                 'designInfo': {'allocation': 'NA',\n",
       "                  'interventionModel': 'SINGLE_GROUP',\n",
       "                  'primaryPurpose': 'BASIC_SCIENCE',\n",
       "                  'maskingInfo': {'masking': 'NONE'}},\n",
       "                 'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}},\n",
       "                'armsInterventionsModule': {'armGroups': [{'label': 'ALS Patient',\n",
       "                   'type': 'EXPERIMENTAL',\n",
       "                   'interventionNames': ['Radiation: [ 18 F]PSS232']}],\n",
       "                 'interventions': [{'type': 'RADIATION',\n",
       "                   'name': '[ 18 F]PSS232',\n",
       "                   'description': '\\\\[ 18 F\\\\]PSS232 for imaging metabotropic glutamate receptor subtype 5 and comparing expression of the receptor in healthy persons and ALS patients',\n",
       "                   'armGroupLabels': ['ALS Patient']}]},\n",
       "                'outcomesModule': {'primaryOutcomes': [{'measure': 'Change from baseline in [18F]PSS232 uptake in the brain and spinal cord in ALS patients at 6 months',\n",
       "                   'description': 'Difference of \\\\[18F\\\\]PSS232 uptake in the brain and spinal cord of ALS patients at baseline and day 180, as assessed by PET and MRI to allow morphological mapping.',\n",
       "                   'timeFrame': 'Baseline and 6 months'}],\n",
       "                 'secondaryOutcomes': [{'measure': 'Difference of [18F]PSS232 uptake in the brain and spinal cord between ALS patients and healthy, age and gender-matched subjects.',\n",
       "                   'description': 'Difference of \\\\[18F\\\\]PSS232 uptake in the brain and spinal cord of ALS patients and healthy subjects at baseline and day 180, as assessed by PET and MRI to allow morphological mapping',\n",
       "                   'timeFrame': '6 months'},\n",
       "                  {'measure': 'Correlation of change from baseline of [18F]PSS232 uptake with change from baseline of ALSFRS-R Score at day 180',\n",
       "                   'description': 'Change from baseline to day 180 in \\\\[18F\\\\]PSS232 uptake in the brain and spinal cord in ALS patients will be correlated to change from baseline to 180d in the ALS Functional Rating Scale (ALSFRS-R), evaluating bulbar, respiratory, upper limb and lower limb function with a total score of 48 (minimal value 0, maximal value 48, higher scores mean a better outcome).',\n",
       "                   'timeFrame': '6 months'},\n",
       "                  {'measure': 'Correlation of change from baseline of [18F]PSS232 uptake with change from baseline of respiratory function, as measuerd by slow vital capacity (sVC) and sniff nasal inspiratory pressure (SNIP) at day 180',\n",
       "                   'description': 'Change from baseline to day 180 in \\\\[18F\\\\]PSS232 uptake in the brain and spinal cord in ALS patients will be correlated to change from baseline to 180d in respiratory function, as measured by slow vital capacity (sVC) and sniff nasal inspiratory pressure (SNIP).',\n",
       "                   'timeFrame': '6 months'},\n",
       "                  {'measure': 'Correlation of change from baseline of [18F]PSS232 uptake with change from baseline of ECAS at day 180',\n",
       "                   'description': 'Change from baseline to day 180 in \\\\[18F\\\\]PSS232 uptake in the brain and spinal cord in ALS patients will be correlated to change from baseline to 180d in cognitive and behavioral function, as assessed by Edinburgh cognitive and behavioral ALS Screen (ECAS, minimal value 0, maximal value 136, higher scores mean a better outcome).',\n",
       "                   'timeFrame': '6 months'}]},\n",
       "                'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Clinically probable, probable laboratory supported, or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria (EEC) (45)\\n* Disease duration ≤18 months\\n* Pre-study ALSFRS-R progression between disease onset and screening of - 0.4 points/month or worse (calculated by ALSFRS -R total score decline form 48 divided by the months since onset of ALS symptoms)\\n* Upright slow vital capacity (sVC) ≥65 % of normal (best of three measurements)\\n\\nExclusion Criteria :\\n\\n* Previous participation in another clinical study involving trial medication within the preceding 12 weeks\\n* History or presence of significant psychiatric disease, such as depression, evaluated with the ALS depression questionnaire (ADI-12) ≥ 23 (43) since depression has an impact on mGluR5 expression (44)\\n* Use of tobacco, including cigarettes, smokeless tobacco, cigars, and pipes; Ex- smoker having quit smoking ≥ 2 years',\n",
       "                 'healthyVolunteers': True,\n",
       "                 'sex': 'ALL',\n",
       "                 'minimumAge': '18 Years',\n",
       "                 'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "                'contactsLocationsModule': {'centralContacts': [{'name': 'Nathalie Braun, MD, PhD',\n",
       "                   'role': 'CONTACT',\n",
       "                   'phone': '+41 71 494 35 81',\n",
       "                   'email': 'nathalie.braun@kssg.ch'},\n",
       "                  {'name': 'Zylfije Dibrani',\n",
       "                   'role': 'CONTACT',\n",
       "                   'phone': '+41 71 494 35 81',\n",
       "                   'email': 'Zylfije.Dibrani@kssg.ch'}],\n",
       "                 'overallOfficials': [{'name': 'Nathalie Braun, MD, PhD',\n",
       "                   'affiliation': 'Neuromuscular Center/ALS Clinic, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland',\n",
       "                   'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "                 'locations': [{'facility': 'Neuromuscular Center/ALS Clinic, Cantonal Hospital St. Gallen',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'St. Gallen',\n",
       "                   'zip': '9007',\n",
       "                   'country': 'Switzerland',\n",
       "                   'contacts': [{'name': 'Nathalie Braun, MD, PhD',\n",
       "                     'role': 'CONTACT',\n",
       "                     'phone': '+41714943581',\n",
       "                     'email': 'nathalie.braun@kssg.ch'},\n",
       "                    {'name': 'Zylifije Dibrani',\n",
       "                     'role': 'CONTACT',\n",
       "                     'phone': '+41714943581',\n",
       "                     'email': 'zylfije.dibrani@kssg.ch'},\n",
       "                    {'name': 'Nathalie Braun, MD, PhD',\n",
       "                     'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "                   'geoPoint': {'lat': 47.42391, 'lon': 9.37477}}]}},\n",
       "               'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'},\n",
       "                'conditionBrowseModule': {'meshes': [{'id': 'D000016472',\n",
       "                   'term': 'Motor Neuron Disease'},\n",
       "                  {'id': 'D000000690',\n",
       "                   'term': 'Amyotrophic Lateral Sclerosis'},\n",
       "                  {'id': 'D000012598', 'term': 'Sclerosis'}],\n",
       "                 'ancestors': [{'id': 'D000010335',\n",
       "                   'term': 'Pathologic Processes'},\n",
       "                  {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'},\n",
       "                  {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "                  {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "                  {'id': 'D000013118', 'term': 'Spinal Cord Diseases'},\n",
       "                  {'id': 'D000002493',\n",
       "                   'term': 'Central Nervous System Diseases'},\n",
       "                  {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'},\n",
       "                  {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'},\n",
       "                  {'id': 'D000008659', 'term': 'Metabolic Diseases'}],\n",
       "                 'browseLeaves': [{'id': 'M15415',\n",
       "                   'name': 'Sclerosis',\n",
       "                   'asFound': 'Sclerosis',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M18879',\n",
       "                   'name': 'Motor Neuron Disease',\n",
       "                   'asFound': 'Lateral Sclerosis',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M4024',\n",
       "                   'name': 'Amyotrophic Lateral Sclerosis',\n",
       "                   'asFound': 'Amyotrophic Lateral Sclerosis',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M21558',\n",
       "                   'name': 'Neurodegenerative Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M12411',\n",
       "                   'name': 'Neuromuscular Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M15915',\n",
       "                   'name': 'Spinal Cord Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M5742',\n",
       "                   'name': 'Central Nervous System Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M28759',\n",
       "                   'name': 'TDP-43 Proteinopathies',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M28747',\n",
       "                   'name': 'Proteostasis Deficiencies',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M11639',\n",
       "                   'name': 'Metabolic Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'T349',\n",
       "                   'name': 'Amyotrophic Lateral Sclerosis',\n",
       "                   'asFound': 'Amyotrophic Lateral Sclerosis',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'T4699',\n",
       "                   'name': 'Primary Lateral Sclerosis',\n",
       "                   'asFound': 'Lateral Sclerosis',\n",
       "                   'relevance': 'HIGH'}],\n",
       "                 'browseBranches': [{'abbrev': 'BC23',\n",
       "                   'name': 'Symptoms and General Pathology'},\n",
       "                  {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "                  {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "                  {'abbrev': 'BC18',\n",
       "                   'name': 'Nutritional and Metabolic Diseases'},\n",
       "                  {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "                'interventionBrowseModule': {'browseLeaves': [{'id': 'M21258',\n",
       "                   'name': 'Radiopharmaceuticals',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'T5', 'name': 'Glutamic Acid', 'relevance': 'LOW'}],\n",
       "                 'browseBranches': [{'abbrev': 'All',\n",
       "                   'name': 'All Drugs and Chemicals'},\n",
       "                  {'abbrev': 'AA', 'name': 'Amino Acids'}]}},\n",
       "               'hasResults': False}],\n",
       "             'Patient_2': [{'protocolSection': {'identificationModule': {'nctId': 'NCT05673057',\n",
       "                 'orgStudyIdInfo': {'id': 'MP0533-CP101'},\n",
       "                 'secondaryIdInfos': [{'id': '2022-002432-31',\n",
       "                   'type': 'EUDRACT_NUMBER'}],\n",
       "                 'organization': {'fullName': 'Molecular Partners AG',\n",
       "                  'class': 'INDUSTRY'},\n",
       "                 'briefTitle': 'Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome',\n",
       "                 'officialTitle': 'A Phase 1/2a, First-in-human, Open-label, Multicenter, Dose Escalation Study of MP0533 in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)'},\n",
       "                'statusModule': {'statusVerifiedDate': '2024-01',\n",
       "                 'overallStatus': 'RECRUITING',\n",
       "                 'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "                 'startDateStruct': {'date': '2022-12-29', 'type': 'ACTUAL'},\n",
       "                 'primaryCompletionDateStruct': {'date': '2025-12',\n",
       "                  'type': 'ESTIMATED'},\n",
       "                 'completionDateStruct': {'date': '2027-12',\n",
       "                  'type': 'ESTIMATED'},\n",
       "                 'studyFirstSubmitDate': '2022-12-14',\n",
       "                 'studyFirstSubmitQcDate': '2023-01-04',\n",
       "                 'studyFirstPostDateStruct': {'date': '2023-01-06',\n",
       "                  'type': 'ACTUAL'},\n",
       "                 'lastUpdateSubmitDate': '2024-01-23',\n",
       "                 'lastUpdatePostDateStruct': {'date': '2024-01-24',\n",
       "                  'type': 'ACTUAL'}},\n",
       "                'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "                 'leadSponsor': {'name': 'Molecular Partners AG',\n",
       "                  'class': 'INDUSTRY'}},\n",
       "                'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "                 'isFdaRegulatedDevice': False},\n",
       "                'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of MP0533 in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)'},\n",
       "                'conditionsModule': {'conditions': ['Leukemia',\n",
       "                  'Relapsed',\n",
       "                  'Myeloid',\n",
       "                  'Acute'],\n",
       "                 'keywords': ['DARPin',\n",
       "                  'CD33',\n",
       "                  'CD123',\n",
       "                  'CD70',\n",
       "                  'T-cell/CD3 engager',\n",
       "                  'multispecific']},\n",
       "                'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "                 'phases': ['PHASE1', 'PHASE2'],\n",
       "                 'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "                  'interventionModel': 'SEQUENTIAL',\n",
       "                  'primaryPurpose': 'TREATMENT',\n",
       "                  'maskingInfo': {'masking': 'NONE'}},\n",
       "                 'enrollmentInfo': {'count': 70, 'type': 'ESTIMATED'}},\n",
       "                'armsInterventionsModule': {'armGroups': [{'label': 'Dose escalation',\n",
       "                   'type': 'EXPERIMENTAL',\n",
       "                   'interventionNames': ['Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)']},\n",
       "                  {'label': 'Dose expansion',\n",
       "                   'type': 'EXPERIMENTAL',\n",
       "                   'interventionNames': ['Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)']}],\n",
       "                 'interventions': [{'type': 'DRUG',\n",
       "                   'name': 'MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)',\n",
       "                   'description': 'Phase 1 comprises the dose-escalation part of the study and is designed to determine the recommended phase 2a dose regimen (RP2D-R) and/or the maximum tolerated dose-regimen (MTD-R) for MP0533 monotherapy.\\n\\nOnce the RP2D-R or MTD-R has been selected based on the dose escalation part, the study will proceed into the phase 2 expansion part and up to 30 additional patients will be treated.',\n",
       "                   'armGroupLabels': ['Dose escalation', 'Dose expansion'],\n",
       "                   'otherNames': ['DARPin']}]},\n",
       "                'outcomesModule': {'primaryOutcomes': [{'measure': 'Phase 1 dose escalation: Recommended Phase 2 Dose Regimen and/or Maximum Tolerated Dose Regimen',\n",
       "                   'description': 'Incidence of dose limiting toxicities, assessment of toxicity/safety, pharmacokinetic and efficacy parameters',\n",
       "                   'timeFrame': 'from start of treatment to end of first cycle (day 1 - 28)'},\n",
       "                  {'measure': 'Phase 2 dose extension: Overall Response Rate',\n",
       "                   'description': 'Best overall response of complete remission (CR), complete remission with partial hematological recovery (CRh), complete remission with incomplete hematological recovery (CRi), morphologic leukemia-free state (MLFS) and partial remission (PR) according to the European LeukemiaNet (ELN) response criteria 2022',\n",
       "                   'timeFrame': 'throughout the study (on average 3 months)'}],\n",
       "                 'secondaryOutcomes': [{'measure': 'Serum Concentration-time profiles',\n",
       "                   'description': 'Determination of PK parameters including (but not limited to) maximum serum concentration (Cmax)',\n",
       "                   'timeFrame': 'throughout the study (on average 1 year)'},\n",
       "                  {'measure': 'Serum Concentration-time profiles',\n",
       "                   'description': 'Determination of PK parameters including (but not limited to) time at Cmax (Tmax)',\n",
       "                   'timeFrame': 'throughout the study (on average 1 year)'},\n",
       "                  {'measure': 'Serum Concentration-time profiles',\n",
       "                   'description': 'Determination of PK parameters including (but not limited to) minimal serum concentration (Cmin)',\n",
       "                   'timeFrame': 'throughout the study (on average 1 year)'},\n",
       "                  {'measure': 'Area under the concentration-time curve (AUC)',\n",
       "                   'description': 'Pharmacokinetic (PK) analysis of MP0533',\n",
       "                   'timeFrame': 'throughout the study (on average 1 year)'},\n",
       "                  {'measure': 'Total Clearance (CL)',\n",
       "                   'description': 'PK analysis of MP0533',\n",
       "                   'timeFrame': 'throughout the study (on average 1 year)'},\n",
       "                  {'measure': 'Volume of distribution (Vd)',\n",
       "                   'description': 'PK analysis of MP0533',\n",
       "                   'timeFrame': 'throughout the study (on average 1 year)'},\n",
       "                  {'measure': 'Half-life (t1/2)',\n",
       "                   'description': 'PK analysis of MP0533',\n",
       "                   'timeFrame': 'throughout the study (on average 1 year)'},\n",
       "                  {'measure': 'Incidence of adverse events (AEs) as a measure of safety',\n",
       "                   'description': 'Type, incidence and severity of AEs according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0',\n",
       "                   'timeFrame': 'throughout the study (on average 1 year)'},\n",
       "                  {'measure': 'Event free survival (EFS)',\n",
       "                   'description': 'time from the date of first study treatment administration to the date of treatment failure, hematologic relapse from CR/CRh/CRi or death from any cause',\n",
       "                   'timeFrame': 'throughout the study (on average 1 year)'},\n",
       "                  {'measure': 'Duration of response (DoR)',\n",
       "                   'description': 'time from the start date of CR, CRh, CRi, MLFS or PR to relapse or death',\n",
       "                   'timeFrame': 'throughout the study (on average 1 year)'},\n",
       "                  {'measure': 'Overall survival (OS)',\n",
       "                   'description': 'time from the date of first study treatment administration to the date of death',\n",
       "                   'timeFrame': 'throughout the study (up to 3 years)'}]},\n",
       "                'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Has signed and dated written informed consent prior to performing any study procedure, including screening\\n* Diagnosis of AML or MDS/AML according to the ELN, refractory or relapsed to pretreatment with hypomethylating agents (HMA) (with or without venetoclax), induction chemotherapy or allogeneic hematopoietic cell transplantation (HCT)\\n* Age ≥18 years old on the day of signing informed consent\\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 2\\n* Anticipated life expectancy ≥ 12 weeks by investigator judgement\\n* Adequate renal and hepatic function:\\n* Is using highly effective contraception, for females of childbearing potential and for men\\n\\nExclusion Criteria:\\n\\n* Allogeneic HCT within the last 3 months\\n* Active GvHD requiring immune-suppressive therapy\\n* Use of immunosuppressive drugs\\n* Symptoms of leukostasis (prior hydroxyurea allowed)\\n* Clinical signs of AML in the central nervous system\\n* Major surgery within 28 days prior to start of study medication\\n* Other malignancy requiring active therapy, but adjuvant endocrine therapy is allowed\\n* Any active infection requiring the use of parenteral antimicrobial agents or that is grade \\\\>2\\n* Treatment with investigational agents and/or agents targeting CD33, CD123 or CD70 within 4 weeks prior to start of trial medication\\n* Left ventricular ejection fraction of \\\\< 50% on echocardiographic exam at screening\\n* History or evidence of clinically significant cardiovascular disease\\n* Pulmonary disease with clinically relevant hypoxia\\n* Concurrent enrolment in another clinical trial, unless it is an observational (non-interventional) study or it is the follow-up period of an interventional study\\n* Known hypersensitivity to any of the excipients of the investigational medicinal product (IMP), i.e. finished MP0533 drug',\n",
       "                 'healthyVolunteers': False,\n",
       "                 'sex': 'ALL',\n",
       "                 'minimumAge': '18 Years',\n",
       "                 'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "                'contactsLocationsModule': {'centralContacts': [{'name': 'Medical DirectorG MPAG',\n",
       "                   'role': 'CONTACT',\n",
       "                   'phone': '+41 44 755 77 00',\n",
       "                   'email': 'info@molecularpartners.com'}],\n",
       "                 'locations': [{'facility': 'CHU Bordeaux',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'Bordeaux',\n",
       "                   'country': 'France',\n",
       "                   'geoPoint': {'lat': 44.84044, 'lon': -0.5805}},\n",
       "                  {'facility': 'AP-HP Hôpital Saint-Louis',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'Paris',\n",
       "                   'zip': '75010',\n",
       "                   'country': 'France',\n",
       "                   'geoPoint': {'lat': 48.85341, 'lon': 2.3488}},\n",
       "                  {'facility': 'IUCT Oncopole',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'Toulouse',\n",
       "                   'country': 'France',\n",
       "                   'geoPoint': {'lat': 43.60426, 'lon': 1.44367}},\n",
       "                  {'facility': 'Vilnius University Hospital Santaros Klinikos',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'Vilnius',\n",
       "                   'country': 'Lithuania',\n",
       "                   'geoPoint': {'lat': 54.68916, 'lon': 25.2798}},\n",
       "                  {'facility': 'Amsterdam UMC - Locatie VUmc',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'Amsterdam',\n",
       "                   'country': 'Netherlands',\n",
       "                   'geoPoint': {'lat': 52.37403, 'lon': 4.88969}},\n",
       "                  {'facility': 'Groningen UMC',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'Groningen',\n",
       "                   'country': 'Netherlands',\n",
       "                   'geoPoint': {'lat': 53.21917, 'lon': 6.56667}},\n",
       "                  {'facility': 'Erasmus MC',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'Rotterdam',\n",
       "                   'country': 'Netherlands',\n",
       "                   'geoPoint': {'lat': 51.9225, 'lon': 4.47917}},\n",
       "                  {'facility': 'Inselspital, Universitaetsspital Bern',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'Bern',\n",
       "                   'zip': '3010',\n",
       "                   'country': 'Switzerland',\n",
       "                   'geoPoint': {'lat': 46.94809, 'lon': 7.44744}},\n",
       "                  {'facility': 'Universitaetsspital Zuerich',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'Zuerich',\n",
       "                   'zip': '8006',\n",
       "                   'country': 'Switzerland',\n",
       "                   'geoPoint': {'lat': 47.36667, 'lon': 8.54999}}]}},\n",
       "               'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'},\n",
       "                'conditionBrowseModule': {'meshes': [{'id': 'D000007938',\n",
       "                   'term': 'Leukemia'},\n",
       "                  {'id': 'D000015470', 'term': 'Leukemia, Myeloid, Acute'},\n",
       "                  {'id': 'D000011289', 'term': 'Preleukemia'},\n",
       "                  {'id': 'D000009190', 'term': 'Myelodysplastic Syndromes'}],\n",
       "                 'ancestors': [{'id': 'D000009370',\n",
       "                   'term': 'Neoplasms by Histologic Type'},\n",
       "                  {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "                  {'id': 'D000006402', 'term': 'Hematologic Diseases'},\n",
       "                  {'id': 'D000007951', 'term': 'Leukemia, Myeloid'},\n",
       "                  {'id': 'D000001855', 'term': 'Bone Marrow Diseases'},\n",
       "                  {'id': 'D000011230', 'term': 'Precancerous Conditions'}],\n",
       "                 'browseLeaves': [{'id': 'M16355',\n",
       "                   'name': 'Syndrome',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M10945',\n",
       "                   'name': 'Leukemia',\n",
       "                   'asFound': 'Leukemia',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M10955',\n",
       "                   'name': 'Leukemia, Myeloid',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M18127',\n",
       "                   'name': 'Leukemia, Myeloid, Acute',\n",
       "                   'asFound': 'Acute Myeloid Leukemia',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M14164',\n",
       "                   'name': 'Preleukemia',\n",
       "                   'asFound': 'Myelodysplastic Syndrome',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M12145',\n",
       "                   'name': 'Myelodysplastic Syndromes',\n",
       "                   'asFound': 'Myelodysplastic Syndrome',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M12315',\n",
       "                   'name': 'Neoplasms by Histologic Type',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M9490',\n",
       "                   'name': 'Hematologic Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M5134',\n",
       "                   'name': 'Bone Marrow Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M14111',\n",
       "                   'name': 'Precancerous Conditions',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'T3995',\n",
       "                   'name': 'Myeloid Leukemia',\n",
       "                   'asFound': 'Myeloid Leukemia',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'T182',\n",
       "                   'name': 'Acute Myeloid Leukemia',\n",
       "                   'asFound': 'Acute Myeloid Leukemia',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'T188',\n",
       "                   'name': 'Acute Non Lymphoblastic Leukemia',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'T3993',\n",
       "                   'name': 'Myelodysplastic Syndromes',\n",
       "                   'asFound': 'Myelodysplastic Syndrome',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'T170',\n",
       "                   'name': 'Acute Graft Versus Host Disease',\n",
       "                   'relevance': 'LOW'}],\n",
       "                 'browseBranches': [{'abbrev': 'BC23',\n",
       "                   'name': 'Symptoms and General Pathology'},\n",
       "                  {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "                  {'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "                  {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'},\n",
       "                  {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "               'hasResults': False}],\n",
       "             'Patient_3': [{'protocolSection': {'identificationModule': {'nctId': 'NCT04322357',\n",
       "                 'orgStudyIdInfo': {'id': 'IRB201901339'},\n",
       "                 'secondaryIdInfos': [{'id': 'MD 180023',\n",
       "                   'type': 'OTHER_GRANT',\n",
       "                   'domain': 'U.S. Army Medical Research and Development Command'},\n",
       "                  {'id': 'OCR27142', 'type': 'OTHER', 'domain': 'UF OnCore'}],\n",
       "                 'organization': {'fullName': 'University of Florida',\n",
       "                  'class': 'OTHER'},\n",
       "                 'briefTitle': 'Twice Weekly Steroids and Exercise as Therapy for DMD',\n",
       "                 'officialTitle': 'Impact and Interplay of Corticosteroid Regimen and Exercise Training on DMD Muscle Function'},\n",
       "                'statusModule': {'statusVerifiedDate': '2024-01',\n",
       "                 'overallStatus': 'RECRUITING',\n",
       "                 'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "                 'startDateStruct': {'date': '2020-07-30', 'type': 'ACTUAL'},\n",
       "                 'primaryCompletionDateStruct': {'date': '2024-10-07',\n",
       "                  'type': 'ESTIMATED'},\n",
       "                 'completionDateStruct': {'date': '2025-10-07',\n",
       "                  'type': 'ESTIMATED'},\n",
       "                 'studyFirstSubmitDate': '2020-03-24',\n",
       "                 'studyFirstSubmitQcDate': '2020-03-24',\n",
       "                 'studyFirstPostDateStruct': {'date': '2020-03-26',\n",
       "                  'type': 'ACTUAL'},\n",
       "                 'lastUpdateSubmitDate': '2024-01-30',\n",
       "                 'lastUpdatePostDateStruct': {'date': '2024-01-31',\n",
       "                  'type': 'ACTUAL'}},\n",
       "                'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "                 'leadSponsor': {'name': 'University of Florida',\n",
       "                  'class': 'OTHER'},\n",
       "                 'collaborators': [{'name': 'U.S. Army Medical Research and Development Command',\n",
       "                   'class': 'FED'}]},\n",
       "                'oversightModule': {'oversightHasDmc': True,\n",
       "                 'isFdaRegulatedDrug': True,\n",
       "                 'isFdaRegulatedDevice': False},\n",
       "                'descriptionModule': {'briefSummary': 'The study team will determine the potential of low dose twice weekly prednisone and whether exercise training can synergize to delay disease progression and improve muscle strength/physical function in boys with Duchenne muscular dystrophy (DMD). Current standard of care (daily prednisone) is associated with adverse side effects. Evidence from DMD mouse models suggest that weekly dosing provides same efficacy without side effects. Appropriate exercise may also benefit but this area has not been adequately explored.'},\n",
       "                'conditionsModule': {'conditions': ['Duchenne Muscular Dystrophy (DMD)'],\n",
       "                 'keywords': ['steroid side effects, low dose steroid regimen, exercise training therapy']},\n",
       "                'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "                 'phases': ['PHASE2'],\n",
       "                 'designInfo': {'allocation': 'RANDOMIZED',\n",
       "                  'interventionModel': 'PARALLEL',\n",
       "                  'primaryPurpose': 'SUPPORTIVE_CARE',\n",
       "                  'maskingInfo': {'masking': 'NONE'}},\n",
       "                 'enrollmentInfo': {'count': 89, 'type': 'ESTIMATED'}},\n",
       "                'armsInterventionsModule': {'armGroups': [{'label': 'Daily Glucocorticoid (GC)',\n",
       "                   'type': 'NO_INTERVENTION',\n",
       "                   'description': 'Existing data from age-matched, ambulatory, on daily GC therapy, and similar exclusion criteria will be selected from the ImagingDMD database to serve as a historical control.'},\n",
       "                  {'label': 'Twice weekly glucocorticoid with or without exercise',\n",
       "                   'type': 'ACTIVE_COMPARATOR',\n",
       "                   'description': 'Patients will be randomized to one of 2 groups:\\n\\n* Twice weekly prednisone alone for 12 months\\n* Twice weekly prednisone for 6 months followed by twice weekly prednisone plus 6 months of structured, supervised and home-based exercise training.',\n",
       "                   'interventionNames': ['Drug: Prednisone']},\n",
       "                  {'label': 'Daily glucocorticoid with exercise',\n",
       "                   'type': 'ACTIVE_COMPARATOR',\n",
       "                   'description': 'Patients on daily glucocorticoids will undergo 6 months of structured, supervised and home-based exercise training.',\n",
       "                   'interventionNames': ['Drug: Prednisone',\n",
       "                    'Behavioral: In-home Exercise Training',\n",
       "                    'Drug: Prednisone plus exercise']}],\n",
       "                 'interventions': [{'type': 'DRUG',\n",
       "                   'name': 'Prednisone',\n",
       "                   'description': 'A 12-month treatment period with twice weekly, low-dose prednisone (dose of 0.75 mg/kg per day).',\n",
       "                   'armGroupLabels': ['Daily glucocorticoid with exercise',\n",
       "                    'Twice weekly glucocorticoid with or without exercise'],\n",
       "                   'otherNames': ['Glucocorticoid (GC)']},\n",
       "                  {'type': 'BEHAVIORAL',\n",
       "                   'name': 'In-home Exercise Training',\n",
       "                   'description': 'For boys on current standard of care (daily glucocorticoid use), 6-months in-home, remotely supervised exercise training program involving a combination of aerobic and isometric leg strength exercises.',\n",
       "                   'armGroupLabels': ['Daily glucocorticoid with exercise']},\n",
       "                  {'type': 'DRUG',\n",
       "                   'name': 'Prednisone plus exercise',\n",
       "                   'description': 'Twice weekly prednisone for 6 months followed by twice weekly prednisone plus exercise for 6 months.',\n",
       "                   'armGroupLabels': ['Daily glucocorticoid with exercise']}]},\n",
       "                'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in BMI',\n",
       "                   'description': 'Participant body mass index change (weight and height will be combined to report BMI in kg/m\\\\^2) over the course of one year',\n",
       "                   'timeFrame': 'Baseline up to 12 months'}]},\n",
       "                'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Diagnosis of DMD confirmed by 1) clinical history with features before the age of five, 2) physical examination, 3) elevated serum creatine kinase level and 4) absence of dystrophin expression, as determined by immunostain or Western blot (\\\\<2%) and/or DNA confirmation of dystrophin mutation.\\n* Age 5.0 to 9 years: a lower age limit of 5.0 years is selected as children younger than that are likely unable to cooperate and comply with all of the exercise measures as needed. An upper age limit of 9 years has been set as boys with DMD tend to reach a rapid progression into a late ambulatory phase soon after this age.\\n* Ambulatory at the time of the first visit, defined as the ability to walk for at least 100 m without an external assistive device and able to climb four stairs.\\n* Aim 1 only: GC-naïve at baseline (and prior 6 months)\\n* Aim 2 only: on stable daily GC regimen for 6 months prior to baseline\\n\\nExclusion Criteria:\\n\\n* Contraindication to an MR examination (e.g. aneurysm clip, severe claustrophobia, magnetic implants)\\n* Presence of unstable medical problems, significant concomitant illness including cardiomyopathy or cardiac conduction abnormalities\\n* Presence of a secondary condition that impacts muscle function or muscle metabolism (e.g. myasthenia gravis, endocrine disorder, mitochondrial disease)\\n* Presence of a secondary condition leading to developmental delay or impaired motor control (e.g. cerebral palsy)\\n* Presence of an unstable medical condition (e.g. uncontrolled seizure disorder)\\n* Behavioral problems causing an inability to cooperate during testing or understand exercise instruction\\n* Participation in other forms of drug or gene therapy during the period of the study',\n",
       "                 'healthyVolunteers': False,\n",
       "                 'sex': 'MALE',\n",
       "                 'minimumAge': '5 Years',\n",
       "                 'maximumAge': '9 Years',\n",
       "                 'stdAges': ['CHILD']},\n",
       "                'contactsLocationsModule': {'centralContacts': [{'name': 'Tanja Taivassalo, PhD',\n",
       "                   'role': 'CONTACT',\n",
       "                   'phone': '(352) 294-8748',\n",
       "                   'email': 'ttaivassalo@ufl.edu'}],\n",
       "                 'overallOfficials': [{'name': 'Tanja Taivassalo, MD',\n",
       "                   'affiliation': 'University of Florida',\n",
       "                   'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "                 'locations': [{'facility': 'University of Florida',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'Gainesville',\n",
       "                   'state': 'Florida',\n",
       "                   'zip': '32610',\n",
       "                   'country': 'United States',\n",
       "                   'contacts': [{'name': 'Tanja Taivassalo',\n",
       "                     'role': 'CONTACT',\n",
       "                     'phone': '352-294-8748',\n",
       "                     'email': 'ttaivassalo@ufl.edu'},\n",
       "                    {'name': 'Tanja Taivassalo',\n",
       "                     'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "                   'geoPoint': {'lat': 29.65163, 'lon': -82.32483}}]},\n",
       "                'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "               'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'},\n",
       "                'conditionBrowseModule': {'meshes': [{'id': 'D000009136',\n",
       "                   'term': 'Muscular Dystrophies'},\n",
       "                  {'id': 'D000020388',\n",
       "                   'term': 'Muscular Dystrophy, Duchenne'}],\n",
       "                 'ancestors': [{'id': 'D000020966',\n",
       "                   'term': 'Muscular Disorders, Atrophic'},\n",
       "                  {'id': 'D000009135', 'term': 'Muscular Diseases'},\n",
       "                  {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'},\n",
       "                  {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "                  {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "                  {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'},\n",
       "                  {'id': 'D000040181', 'term': 'Genetic Diseases, X-Linked'}],\n",
       "                 'browseLeaves': [{'id': 'M12093',\n",
       "                   'name': 'Muscular Dystrophies',\n",
       "                   'asFound': 'Muscular Dystrophy',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M22185',\n",
       "                   'name': 'Muscular Dystrophy, Duchenne',\n",
       "                   'asFound': 'Duchenne Muscular Dystrophy (DMD)',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M4589', 'name': 'Atrophy', 'relevance': 'LOW'},\n",
       "                  {'id': 'M12092',\n",
       "                   'name': 'Muscular Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M22697',\n",
       "                   'name': 'Muscular Disorders, Atrophic',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M12097',\n",
       "                   'name': 'Musculoskeletal Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M12411',\n",
       "                   'name': 'Neuromuscular Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M23686',\n",
       "                   'name': 'Genetic Diseases, Inborn',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M24877',\n",
       "                   'name': 'Genetic Diseases, X-Linked',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'T3963',\n",
       "                   'name': 'Muscular Dystrophy',\n",
       "                   'asFound': 'Muscular Dystrophy',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'T698',\n",
       "                   'name': 'Becker Muscular Dystrophy',\n",
       "                   'asFound': 'Duchenne Muscular Dystrophy (DMD)',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'T1945',\n",
       "                   'name': 'Duchenne Muscular Dystrophy',\n",
       "                   'asFound': 'Duchenne Muscular Dystrophy',\n",
       "                   'relevance': 'HIGH'}],\n",
       "                 'browseBranches': [{'abbrev': 'BC05',\n",
       "                   'name': 'Musculoskeletal Diseases'},\n",
       "                  {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "                  {'abbrev': 'BC16',\n",
       "                   'name': 'Diseases and Abnormalities at or Before Birth'},\n",
       "                  {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "                  {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "                  {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "                'interventionBrowseModule': {'meshes': [{'id': 'D000011241',\n",
       "                   'term': 'Prednisone'},\n",
       "                  {'id': 'D000005938', 'term': 'Glucocorticoids'}],\n",
       "                 'ancestors': [{'id': 'D000000893',\n",
       "                   'term': 'Anti-Inflammatory Agents'},\n",
       "                  {'id': 'D000006728', 'term': 'Hormones'},\n",
       "                  {'id': 'D000006730',\n",
       "                   'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'},\n",
       "                  {'id': 'D000045505',\n",
       "                   'term': 'Physiological Effects of Drugs'},\n",
       "                  {'id': 'D000018931',\n",
       "                   'term': 'Antineoplastic Agents, Hormonal'},\n",
       "                  {'id': 'D000000970', 'term': 'Antineoplastic Agents'}],\n",
       "                 'browseLeaves': [{'id': 'M14121',\n",
       "                   'name': 'Prednisone',\n",
       "                   'asFound': 'Usual',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M9047',\n",
       "                   'name': 'Glucocorticoids',\n",
       "                   'asFound': 'After treatment',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M4217',\n",
       "                   'name': 'Anti-Inflammatory Agents',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'},\n",
       "                  {'id': 'M9788',\n",
       "                   'name': 'Hormone Antagonists',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M20966',\n",
       "                   'name': 'Antineoplastic Agents, Hormonal',\n",
       "                   'relevance': 'LOW'}],\n",
       "                 'browseBranches': [{'abbrev': 'Infl',\n",
       "                   'name': 'Anti-Inflammatory Agents'},\n",
       "                  {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "                  {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "               'hasResults': False},\n",
       "              {'protocolSection': {'identificationModule': {'nctId': 'NCT04626674',\n",
       "                 'orgStudyIdInfo': {'id': 'SRP-9001-103'},\n",
       "                 'organization': {'fullName': 'Sarepta Therapeutics, Inc.',\n",
       "                  'class': 'INDUSTRY'},\n",
       "                 'briefTitle': 'A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)',\n",
       "                 'officialTitle': 'An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression From SRP-9001 in Subjects With Duchenne Muscular Dystrophy (ENDEAVOR)',\n",
       "                 'acronym': 'ENDEAVOR'},\n",
       "                'statusModule': {'statusVerifiedDate': '2023-07',\n",
       "                 'overallStatus': 'ENROLLING_BY_INVITATION',\n",
       "                 'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "                 'startDateStruct': {'date': '2020-11-23', 'type': 'ACTUAL'},\n",
       "                 'primaryCompletionDateStruct': {'date': '2024-11-30',\n",
       "                  'type': 'ESTIMATED'},\n",
       "                 'completionDateStruct': {'date': '2026-07-31',\n",
       "                  'type': 'ESTIMATED'},\n",
       "                 'studyFirstSubmitDate': '2020-11-06',\n",
       "                 'studyFirstSubmitQcDate': '2020-11-06',\n",
       "                 'studyFirstPostDateStruct': {'date': '2020-11-12',\n",
       "                  'type': 'ACTUAL'},\n",
       "                 'lastUpdateSubmitDate': '2023-07-28',\n",
       "                 'lastUpdatePostDateStruct': {'date': '2023-08-01',\n",
       "                  'type': 'ACTUAL'}},\n",
       "                'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "                 'leadSponsor': {'name': 'Sarepta Therapeutics, Inc.',\n",
       "                  'class': 'INDUSTRY'},\n",
       "                 'collaborators': [{'name': 'Hoffmann-La Roche',\n",
       "                   'class': 'INDUSTRY'}]},\n",
       "                'oversightModule': {'oversightHasDmc': True,\n",
       "                 'isFdaRegulatedDrug': True,\n",
       "                 'isFdaRegulatedDevice': False},\n",
       "                'descriptionModule': {'briefSummary': 'This is an open-label gene transfer therapy study evaluating the safety of and expression from delandistrogene moxeparvovec in participants with DMD. The maximum participant duration for this study is 156 weeks.'},\n",
       "                'conditionsModule': {'conditions': ['Muscular Dystrophy, Duchenne'],\n",
       "                 'keywords': ['Duchenne Muscular Dystrophy',\n",
       "                  'Gene-Delivery',\n",
       "                  'DMD',\n",
       "                  'Ambulatory Non-ambulatory',\n",
       "                  'Pediatric',\n",
       "                  'Dystrophin']},\n",
       "                'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "                 'phases': ['PHASE1'],\n",
       "                 'designInfo': {'allocation': 'NA',\n",
       "                  'interventionModel': 'SINGLE_GROUP',\n",
       "                  'primaryPurpose': 'TREATMENT',\n",
       "                  'maskingInfo': {'masking': 'NONE'}},\n",
       "                 'enrollmentInfo': {'count': 58, 'type': 'ESTIMATED'}},\n",
       "                'armsInterventionsModule': {'armGroups': [{'label': 'Delandistrogene Moxeparvovec',\n",
       "                   'type': 'EXPERIMENTAL',\n",
       "                   'description': 'Participants will receive a single intravenous (IV) infusion of delandistrogene moxeparvovec on Day 1.',\n",
       "                   'interventionNames': ['Genetic: delandistrogene moxeparvovec']}],\n",
       "                 'interventions': [{'type': 'GENETIC',\n",
       "                   'name': 'delandistrogene moxeparvovec',\n",
       "                   'description': 'Single IV infusion of delandistrogene moxeparvovec',\n",
       "                   'armGroupLabels': ['Delandistrogene Moxeparvovec'],\n",
       "                   'otherNames': ['SRP-9001',\n",
       "                    'delandistrogene moxeparvovec-rokl',\n",
       "                    'ELEVIDYS']}]},\n",
       "                'outcomesModule': {'primaryOutcomes': [{'measure': 'Part 1: Change from Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Expression at Week 12, as Measured by Western Blot',\n",
       "                   'timeFrame': 'Baseline, Week 12'},\n",
       "                  {'measure': 'Part 1: Quantity of Delandistrogene Moxeparvovec Dystrophin Expression at Week 12 as Measured by Western Blot',\n",
       "                   'timeFrame': 'Week 12'}],\n",
       "                 'secondaryOutcomes': [{'measure': 'Vector Shedding, Measured in Urine, Saliva, and Stool Samples Post-Infusion',\n",
       "                   'timeFrame': 'Day 1 up to Week 104'},\n",
       "                  {'measure': 'Level of Antibody Titers to Recombinant Adeno-Associated Virus Serotype rh74 (rAAVrh74)',\n",
       "                   'timeFrame': 'Day 2 up to Week 156'},\n",
       "                  {'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) of Special Interest',\n",
       "                   'timeFrame': 'Baseline up to Week 156'},\n",
       "                  {'measure': 'Change from Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression at Week 12, as Measured by Immunofluorescence (IF) Fiber Intensity',\n",
       "                   'timeFrame': 'Baseline, Week 12'},\n",
       "                  {'measure': 'Change from Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression at Week 12, as Measured by IF Percent Dystrophin Positive Fibers (PDPF)',\n",
       "                   'timeFrame': 'Baseline, Week 12'},\n",
       "                  {'measure': 'Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression at Week 12 as Measured by IF Fiber Intensity:',\n",
       "                   'timeFrame': 'Week 12'},\n",
       "                  {'measure': 'Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression at Week 12 as Measured by IF PDPF',\n",
       "                   'timeFrame': 'Week 12'}]},\n",
       "                'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* For Cohorts 1-7: Has a definitive diagnosis of DMD based on documented clinical findings and prior genetic testing.\\n* Cohort 1: Is ambulatory, and ≥4 to \\\\<8 years of age at the time of Screening.\\n* Cohort 2: Is ambulatory, and ≥8 to \\\\<18 years of age at the time of Screening.\\n* Cohort 3: Non-ambulatory per protocol specified criteria at the time of Screening.\\n* Cohort 4: Is ambulatory and ≥3 to \\\\<4 years of age at the time of Screening.\\n* Cohort 5a: Is ambulatory and ≥4 to \\\\<9 years of age.\\n* Cohort 5b: Non-ambulatory per protocol specified criteria at the time of Screening.\\n* Cohort 6: Is ambulatory, and ≥2 to \\\\<3 years of age at the time of Screening.\\n* Cohort 7: Non-ambulatory per protocol-specified criteria at the time of Screening.\\n* Ability to cooperate with motor assessment testing.\\n* Cohorts 1, 2, 3, 5, and 7 only: Stable dose equivalent of oral glucocorticoids for at least 12 weeks before screening and the dose is expected to remain constant (except for modifications to accommodate changes in weight) throughout the first year of the study.\\n* Cohorts 4 and 6: Do not yet require use of chronic steroids for treatment of their DMD, in the opinion of the Investigator, and are not receiving steroids at the time of Screening.\\n* rAAVrh74 antibody titers are not elevated as per protocol-specified requirements.\\n* Genetic mutation inclusion criteria vary by cohort.\\n\\nExclusion Criteria:\\n\\n* Has a concomitant illness, autoimmune disease, chronic drug treatment, and/or cognitive delay/impairment that in the opinion of the Investigator creates unnecessary risks for gene transfer.\\n* Exposure to gene therapy, investigational medication, or any treatment designed to increase dystrophin expression within protocol-specified time limits.\\n* Abnormality in protocol-specified diagnostic evaluations or laboratory tests.\\n\\nOther inclusion/exclusion criteria apply.',\n",
       "                 'healthyVolunteers': False,\n",
       "                 'sex': 'MALE',\n",
       "                 'minimumAge': '2 Years',\n",
       "                 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT']},\n",
       "                'contactsLocationsModule': {'overallOfficials': [{'name': 'Medical Director',\n",
       "                   'affiliation': 'Sarepta Therapeutics, Inc.',\n",
       "                   'role': 'STUDY_DIRECTOR'}],\n",
       "                 'locations': [{'facility': 'Stanford University',\n",
       "                   'city': 'Palo Alto',\n",
       "                   'state': 'California',\n",
       "                   'zip': '94304',\n",
       "                   'country': 'United States',\n",
       "                   'geoPoint': {'lat': 37.44188, 'lon': -122.14302}},\n",
       "                  {'facility': 'University of California, Davis',\n",
       "                   'city': 'Sacramento',\n",
       "                   'state': 'California',\n",
       "                   'zip': '95616',\n",
       "                   'country': 'United States',\n",
       "                   'geoPoint': {'lat': 38.58157, 'lon': -121.4944}},\n",
       "                  {'facility': 'Washington University in St. Louis',\n",
       "                   'city': 'Saint Louis',\n",
       "                   'state': 'Missouri',\n",
       "                   'zip': '21205',\n",
       "                   'country': 'United States',\n",
       "                   'geoPoint': {'lat': 38.62727, 'lon': -90.19789}},\n",
       "                  {'facility': \"Nationwide Children's Hospital\",\n",
       "                   'city': 'Columbus',\n",
       "                   'state': 'Ohio',\n",
       "                   'zip': '43205',\n",
       "                   'country': 'United States',\n",
       "                   'geoPoint': {'lat': 39.96118, 'lon': -82.99879}},\n",
       "                  {'facility': \"Children's Hospital of The King's Daughters\",\n",
       "                   'city': 'Norfolk',\n",
       "                   'state': 'Virginia',\n",
       "                   'zip': '23507',\n",
       "                   'country': 'United States',\n",
       "                   'geoPoint': {'lat': 36.84681, 'lon': -76.28522}}]}},\n",
       "               'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'},\n",
       "                'conditionBrowseModule': {'meshes': [{'id': 'D000009136',\n",
       "                   'term': 'Muscular Dystrophies'},\n",
       "                  {'id': 'D000020388',\n",
       "                   'term': 'Muscular Dystrophy, Duchenne'}],\n",
       "                 'ancestors': [{'id': 'D000020966',\n",
       "                   'term': 'Muscular Disorders, Atrophic'},\n",
       "                  {'id': 'D000009135', 'term': 'Muscular Diseases'},\n",
       "                  {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'},\n",
       "                  {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "                  {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "                  {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'},\n",
       "                  {'id': 'D000040181', 'term': 'Genetic Diseases, X-Linked'}],\n",
       "                 'browseLeaves': [{'id': 'M12093',\n",
       "                   'name': 'Muscular Dystrophies',\n",
       "                   'asFound': 'Muscular Dystrophy',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M22185',\n",
       "                   'name': 'Muscular Dystrophy, Duchenne',\n",
       "                   'asFound': 'Muscular Dystrophy, Duchenne',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M4589', 'name': 'Atrophy', 'relevance': 'LOW'},\n",
       "                  {'id': 'M12092',\n",
       "                   'name': 'Muscular Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M22697',\n",
       "                   'name': 'Muscular Disorders, Atrophic',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M12097',\n",
       "                   'name': 'Musculoskeletal Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M12411',\n",
       "                   'name': 'Neuromuscular Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M23686',\n",
       "                   'name': 'Genetic Diseases, Inborn',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M24877',\n",
       "                   'name': 'Genetic Diseases, X-Linked',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'T3963',\n",
       "                   'name': 'Muscular Dystrophy',\n",
       "                   'asFound': 'Muscular Dystrophy',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'T698',\n",
       "                   'name': 'Becker Muscular Dystrophy',\n",
       "                   'asFound': 'Duchenne',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'T1945',\n",
       "                   'name': 'Duchenne Muscular Dystrophy',\n",
       "                   'asFound': 'Duchenne Muscular Dystrophy',\n",
       "                   'relevance': 'HIGH'}],\n",
       "                 'browseBranches': [{'abbrev': 'BC05',\n",
       "                   'name': 'Musculoskeletal Diseases'},\n",
       "                  {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "                  {'abbrev': 'BC16',\n",
       "                   'name': 'Diseases and Abnormalities at or Before Birth'},\n",
       "                  {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "                  {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "                  {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "               'hasResults': False},\n",
       "              {'protocolSection': {'identificationModule': {'nctId': 'NCT03689660',\n",
       "                 'orgStudyIdInfo': {'id': 'Merve Kurt'},\n",
       "                 'organization': {'fullName': 'Dokuz Eylul University',\n",
       "                  'class': 'OTHER'},\n",
       "                 'briefTitle': 'Feasibility of Virtual Reality in Children With Neuromuscular Disease, Effectiveness of Virtual Reality and Biofeedback',\n",
       "                 'officialTitle': 'The Feasibility of Virtual Reality in Children With Neuromuscular Disease and the Effectiveness of Virtual Reality and Biofeedback Training on Functional Levels of Children With Neuromuscular Disease'},\n",
       "                'statusModule': {'statusVerifiedDate': '2022-06',\n",
       "                 'overallStatus': 'RECRUITING',\n",
       "                 'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "                 'startDateStruct': {'date': '2019-02-01', 'type': 'ACTUAL'},\n",
       "                 'primaryCompletionDateStruct': {'date': '2023-05-01',\n",
       "                  'type': 'ESTIMATED'},\n",
       "                 'completionDateStruct': {'date': '2023-10-01',\n",
       "                  'type': 'ESTIMATED'},\n",
       "                 'studyFirstSubmitDate': '2018-09-26',\n",
       "                 'studyFirstSubmitQcDate': '2018-09-26',\n",
       "                 'studyFirstPostDateStruct': {'date': '2018-09-28',\n",
       "                  'type': 'ACTUAL'},\n",
       "                 'lastUpdateSubmitDate': '2022-06-16',\n",
       "                 'lastUpdatePostDateStruct': {'date': '2022-06-22',\n",
       "                  'type': 'ACTUAL'}},\n",
       "                'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR',\n",
       "                  'investigatorFullName': 'Merve Kurt',\n",
       "                  'investigatorTitle': 'Research Assistant',\n",
       "                  'investigatorAffiliation': 'Dokuz Eylul University'},\n",
       "                 'leadSponsor': {'name': 'Merve Kurt', 'class': 'OTHER'}},\n",
       "                'oversightModule': {'oversightHasDmc': True,\n",
       "                 'isFdaRegulatedDrug': False,\n",
       "                 'isFdaRegulatedDevice': False},\n",
       "                'descriptionModule': {'briefSummary': 'Our study is a randomized controlled study and the subjects included in the study will be divided into three groups as virtual reality training, biofeedback training, and conventional rehabilitation.',\n",
       "                 'detailedDescription': 'We have 3 purposes:\\n\\n1. Determine the feasibility of virtual reality training in children with neuromuscular disease.\\n2. To determine the effect of virtual reality, biofeedback training, and conventional rehabilitation on functional levels and balances of children with neuromuscular disease.\\n3. To compare the motivation of children with neuromuscular disease to virtual reality, biofeedback training, and conventional rehabilitation.'},\n",
       "                'conditionsModule': {'conditions': ['Neuromuscular Disease',\n",
       "                  'Duchenne Muscular Dystrophy',\n",
       "                  'Spinal Muscular Atrophy',\n",
       "                  'Virtual Reality',\n",
       "                  'Biofeedback'],\n",
       "                 'keywords': ['motivation',\n",
       "                  'neuromuscular disease',\n",
       "                  'duchenne muscular dystrophy',\n",
       "                  'spinal Muscular Atrophy',\n",
       "                  'virtual reality',\n",
       "                  'biofeedback training']},\n",
       "                'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "                 'phases': ['NA'],\n",
       "                 'designInfo': {'allocation': 'RANDOMIZED',\n",
       "                  'interventionModel': 'PARALLEL',\n",
       "                  'primaryPurpose': 'TREATMENT',\n",
       "                  'maskingInfo': {'masking': 'SINGLE',\n",
       "                   'maskingDescription': 'Nope',\n",
       "                   'whoMasked': ['OUTCOMES_ASSESSOR']}},\n",
       "                 'enrollmentInfo': {'count': 24, 'type': 'ESTIMATED'}},\n",
       "                'armsInterventionsModule': {'armGroups': [{'label': 'Virtual Reality Training',\n",
       "                   'type': 'EXPERIMENTAL',\n",
       "                   'description': 'Virtual reality treatment will be applied during the 12 weeks. The training will consist of three sessions per week and 30 minutes per session.',\n",
       "                   'interventionNames': ['Other: Virtual Reality Training']},\n",
       "                  {'label': 'Biofeedback Training',\n",
       "                   'type': 'EXPERIMENTAL',\n",
       "                   'description': 'Biofeedback training will be applied during the 12 weeks. The training will consist of three sessions per week and 30 minutes per session.',\n",
       "                   'interventionNames': ['Other: Biofeedback Training']},\n",
       "                  {'label': 'Conventional Rehabilitation',\n",
       "                   'type': 'OTHER',\n",
       "                   'description': 'Participants will continue this rehabilitation program if they are already getting rehabilitation in a rehabilitation center. If they do not participate in any rehabilitation program, they will be included in the conventional rehabilitation program by us.',\n",
       "                   'interventionNames': ['Other: Conventional rehabilitation']}],\n",
       "                 'interventions': [{'type': 'OTHER',\n",
       "                   'name': 'Virtual Reality Training',\n",
       "                   'description': 'Participants will be given a game-based workout program that includes balance and weight transfers using the XBOX Kinect ™ device in a low-to-medium intensity for 3 weeks, 3 days a week, 30 minutes per day.',\n",
       "                   'armGroupLabels': ['Virtual Reality Training']},\n",
       "                  {'type': 'OTHER',\n",
       "                   'name': 'Biofeedback Training',\n",
       "                   'description': 'biofeedback training will be applied to participants in 10-minute sessions with 10 seconds of voluntary contraction and 15 seconds of rest at each session. Training will last 12 weeks.',\n",
       "                   'armGroupLabels': ['Biofeedback Training']},\n",
       "                  {'type': 'OTHER',\n",
       "                   'name': 'Conventional rehabilitation',\n",
       "                   'description': 'Participants will receive a 12-week conventional rehabilitation program.',\n",
       "                   'armGroupLabels': ['Conventional Rehabilitation']}]},\n",
       "                'outcomesModule': {'primaryOutcomes': [{'measure': 'The Motor Function Measure-32',\n",
       "                   'description': 'MFM-32 is a scale developed to evaluate motor functions of children and adults with neuromuscular disease. The scale can be used to evaluate both in children with and without walking problems.The MFM-32 consists of 32 items. Each item is answered with a 4-point likert scale (0 = cannot initiate the exercise or maintain its starting position, 1 = partially completes the exercise, 2 = completes exercises with compensations, slowly or roughly, 3 = completes the exercise in the standard pattern). The scale can be used for the evaluation of individuals aged between 6 and 60 years.',\n",
       "                   'timeFrame': '30 minutes'},\n",
       "                  {'measure': 'Pediatric Functional Independence Measure',\n",
       "                   'description': 'WeeFIM consists of 18 items divided into 6 sub-scales (self-care, sphincter control, mobility, locomotion, communication, social communication). Each item is scored from 1 to 7. A higher score indicates a better functional level.',\n",
       "                   'timeFrame': '5 minutes'},\n",
       "                  {'measure': 'Balance Master System',\n",
       "                   'description': 'The static and dynamic balance evaluated using the Balance Master System ver. 8.1. (NeuroCom International Inc. Clackamas, OR, USA) force platform system which has multiple testing protocols designed to examine balance. The system includes a computer linked force plate that records data with the aid of crystal transducers.',\n",
       "                   'timeFrame': '20 minutes'},\n",
       "                  {'measure': 'Vignos Scale',\n",
       "                   'description': 'The Vignos Scale has been developed to evaluate the lower extremity functions. The scale allows the lower extremity functions to be scored between 1 (can walk and climb stairs without help) and -10 (bed dependent).',\n",
       "                   'timeFrame': '2 Minutes'},\n",
       "                  {'measure': 'Feasibility of Virtual Reality',\n",
       "                   'description': 'The feasibility of virtual reality will be examined by laboratory tests. Laboratory tests to be carried out are as follows: Creatine Kinase, Lactate Dehydrogenase (LDH), Myoglobin, Serum Electrolytes, C-Reactive Protein levels. These are agents that are indicative of muscle destruction or inflammation. Will be evaluated in order to follow muscle destruction.',\n",
       "                   'timeFrame': '1 Minutes'},\n",
       "                  {'measure': 'Pediatric Motivation Scale',\n",
       "                   'description': \"The PMOT is recommended for assessing motivation to rehabilitation program in children aged 8 to 18 years. It comprises six subscales (effort-importance, interest-enjoyment, competence, relatedness, autonomy, and value-usefulness) with total 21 items. While the 19 items of the scale are answered with a 6-point smiley face scale (1 = absolutely false, 6 = absolutely correct), there are 2 open-ended questions on the scale. The high scores in each sub-scales indicate that the child's motivation in that sub-section is high. A higher total score indicates that the motivation is intrinsically arranged and that the child has a high motivation. From this point of view, the scale gives information about both the type of motivation and the amount of motivation of the child.\",\n",
       "                   'timeFrame': '5 Minutes'},\n",
       "                  {'measure': 'Visual Analog Scale',\n",
       "                   'description': 'Visual Analog Scale will be applied to evaluate muscle pain. It has a fixed line between two end adjectives of 100 mm length. The end adjectives in our study will be \"no pain\" and \"too much pain\".',\n",
       "                   'timeFrame': '1 Minute'}],\n",
       "                 'secondaryOutcomes': [{'measure': 'Pediatric Functional Reaching Test',\n",
       "                   'description': 'For the Pediatric Functional Reach test, children will be asked to raise their arms 90o in an upright posture position, extending to the maximum possible distance in three directions, forward, right, and left. Reach distances will be measured by pointing the wall with the end point of the third finger, and distances; \"start\", \"final\" and \"difference\" will be determined in cm using tape measure.',\n",
       "                   'timeFrame': '1 Minute'},\n",
       "                  {'measure': 'Fall Frequency',\n",
       "                   'description': \"The frequency of the fall will be questioned with a chart created by the researchers. The family will be asked to record the children's each fall a week before the study and a week after the treatment.\",\n",
       "                   'timeFrame': '1 Minute'},\n",
       "                  {'measure': 'Muscle Strength Test with Hand Held Dinamometer',\n",
       "                   'description': 'Upper and lower limb muscles strength will be evaluated with hand held dinamometer device. This device allows recording of muscle strength in kilograms.',\n",
       "                   'timeFrame': '20 minutes'},\n",
       "                  {'measure': 'Timed Up Go Test',\n",
       "                   'description': 'For the time up go test, children will be asked to walk with two walking cones at a distance of 10 meters, at normal walking speeds, and the elapsed time will be recorded in seconds.',\n",
       "                   'timeFrame': '2 Minutes'},\n",
       "                  {'measure': 'Stair Climb Test',\n",
       "                   'description': 'Children will be asked to climb up and down as quickly as they can, without running the steps, on a ladder of 16-20 cm height and 8-14 steps and the elapsed time will be recorded in seconds.',\n",
       "                   'timeFrame': '2 Minutes'},\n",
       "                  {'measure': 'T-shirt Wear Remove Test',\n",
       "                   'description': 'For the T-shirt pull-out test, the children will be asked to wear a T-Shirt in the sitting position as soon as possible and the elapsed time will be recorded in seconds; then they will be asked to remove the T-Shirt as soon as possible and the elapsed time will be recorded in seconds.',\n",
       "                   'timeFrame': '2 Minutes'},\n",
       "                  {'measure': 'Stand Up from Supine Position Test',\n",
       "                   'description': 'From the supine position to stand up, children will be asked to lie on the back of the body, the arms next to the body, the legs as closed as possible, and the head on the midline on a mat. Then, from this position, they will be asked to stand as soon as possible and the elapsed time will be recorded in seconds.',\n",
       "                   'timeFrame': '1 Minutes'}]},\n",
       "                'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Volunteer to participate in the study\\n* Being diagnosed with the neuromuscular disease\\n* No other systemic or neurological disease\\n* No significant visual or auditory loss\\n* Continuation of ambulation (10 m walking independently)\\n* Be able to understand simple commands\\n\\nExclusion Criteria:\\n\\n* Performing a drug change at 3 months before treatment or during treatment which may affect muscle strength\\n* Acute inflammation in the musculoskeletal system\\n* Finding any orthopedic problem that prevents activities during the research',\n",
       "                 'healthyVolunteers': False,\n",
       "                 'sex': 'ALL',\n",
       "                 'minimumAge': '6 Years',\n",
       "                 'maximumAge': '18 Years',\n",
       "                 'stdAges': ['CHILD', 'ADULT']},\n",
       "                'contactsLocationsModule': {'centralContacts': [{'name': 'Merve Kurt',\n",
       "                   'role': 'CONTACT',\n",
       "                   'phone': '5537241324',\n",
       "                   'phoneExt': '+90',\n",
       "                   'email': 'merveekurtt93@gmail.com'},\n",
       "                  {'name': 'Tülay Tarsuslu Şimşek',\n",
       "                   'role': 'CONTACT',\n",
       "                   'phone': '2324124923',\n",
       "                   'email': 'tulay_tarsuslu@yahoo.com'}],\n",
       "                 'overallOfficials': [{'name': 'Tülay Tarsuslu Şimşek',\n",
       "                   'affiliation': 'Professor Dr.',\n",
       "                   'role': 'STUDY_DIRECTOR'}],\n",
       "                 'locations': [{'facility': 'Dokuz Eylul University',\n",
       "                   'status': 'RECRUITING',\n",
       "                   'city': 'Izmir',\n",
       "                   'state': 'Balcova',\n",
       "                   'zip': '35340',\n",
       "                   'country': 'Turkey',\n",
       "                   'contacts': [{'name': 'Tülay Tarsuslu Simsek, Prof.',\n",
       "                     'role': 'CONTACT'}],\n",
       "                   'geoPoint': {'lat': 38.41273, 'lon': 27.13838}}]},\n",
       "                'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "                 'description': 'The IPD may share when requested',\n",
       "                 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF'],\n",
       "                 'timeFrame': 'IPD: Balance results, Functional Level, Diagnosis, demographic data',\n",
       "                 'accessCriteria': 'The IPD may share when requested.'}},\n",
       "               'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'},\n",
       "                'conditionBrowseModule': {'meshes': [{'id': 'D000009136',\n",
       "                   'term': 'Muscular Dystrophies'},\n",
       "                  {'id': 'D000020388', 'term': 'Muscular Dystrophy, Duchenne'},\n",
       "                  {'id': 'D000009133', 'term': 'Muscular Atrophy'},\n",
       "                  {'id': 'D000009134', 'term': 'Muscular Atrophy, Spinal'},\n",
       "                  {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "                  {'id': 'D000001284', 'term': 'Atrophy'}],\n",
       "                 'ancestors': [{'id': 'D000020763',\n",
       "                   'term': 'Pathological Conditions, Anatomical'},\n",
       "                  {'id': 'D000020966', 'term': 'Muscular Disorders, Atrophic'},\n",
       "                  {'id': 'D000009135', 'term': 'Muscular Diseases'},\n",
       "                  {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'},\n",
       "                  {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "                  {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'},\n",
       "                  {'id': 'D000040181', 'term': 'Genetic Diseases, X-Linked'},\n",
       "                  {'id': 'D000020879', 'term': 'Neuromuscular Manifestations'},\n",
       "                  {'id': 'D000009461', 'term': 'Neurologic Manifestations'},\n",
       "                  {'id': 'D000013118', 'term': 'Spinal Cord Diseases'},\n",
       "                  {'id': 'D000002493',\n",
       "                   'term': 'Central Nervous System Diseases'},\n",
       "                  {'id': 'D000016472', 'term': 'Motor Neuron Disease'},\n",
       "                  {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}],\n",
       "                 'browseLeaves': [{'id': 'M12093',\n",
       "                   'name': 'Muscular Dystrophies',\n",
       "                   'asFound': 'Muscular Dystrophy',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M22185',\n",
       "                   'name': 'Muscular Dystrophy, Duchenne',\n",
       "                   'asFound': 'Duchenne Muscular Dystrophy',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M4589',\n",
       "                   'name': 'Atrophy',\n",
       "                   'asFound': 'Atrophy',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M12090',\n",
       "                   'name': 'Muscular Atrophy',\n",
       "                   'asFound': 'Muscular Atrophy',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M12091',\n",
       "                   'name': 'Muscular Atrophy, Spinal',\n",
       "                   'asFound': 'Spinal Muscular Atrophy',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M12411',\n",
       "                   'name': 'Neuromuscular Diseases',\n",
       "                   'asFound': 'Neuromuscular Diseases',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'M22519',\n",
       "                   'name': 'Pathological Conditions, Anatomical',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M12092',\n",
       "                   'name': 'Muscular Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M22697',\n",
       "                   'name': 'Muscular Disorders, Atrophic',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M12097',\n",
       "                   'name': 'Musculoskeletal Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M23686',\n",
       "                   'name': 'Genetic Diseases, Inborn',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M24877',\n",
       "                   'name': 'Genetic Diseases, X-Linked',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M22619',\n",
       "                   'name': 'Neuromuscular Manifestations',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M12404',\n",
       "                   'name': 'Neurologic Manifestations',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M15915',\n",
       "                   'name': 'Spinal Cord Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M5742',\n",
       "                   'name': 'Central Nervous System Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M18879',\n",
       "                   'name': 'Motor Neuron Disease',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M4024',\n",
       "                   'name': 'Amyotrophic Lateral Sclerosis',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'M21558',\n",
       "                   'name': 'Neurodegenerative Diseases',\n",
       "                   'relevance': 'LOW'},\n",
       "                  {'id': 'T3963',\n",
       "                   'name': 'Muscular Dystrophy',\n",
       "                   'asFound': 'Muscular Dystrophy',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'T698',\n",
       "                   'name': 'Becker Muscular Dystrophy',\n",
       "                   'asFound': 'Duchenne Muscular Dystrophy',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'T1945',\n",
       "                   'name': 'Duchenne Muscular Dystrophy',\n",
       "                   'asFound': 'Duchenne Muscular Dystrophy',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'T5342',\n",
       "                   'name': 'Spinal Muscular Atrophy',\n",
       "                   'asFound': 'Spinal Muscular Atrophy',\n",
       "                   'relevance': 'HIGH'},\n",
       "                  {'id': 'T349',\n",
       "                   'name': 'Amyotrophic Lateral Sclerosis',\n",
       "                   'relevance': 'LOW'}],\n",
       "                 'browseBranches': [{'abbrev': 'BC05',\n",
       "                   'name': 'Musculoskeletal Diseases'},\n",
       "                  {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "                  {'abbrev': 'BC16',\n",
       "                   'name': 'Diseases and Abnormalities at or Before Birth'},\n",
       "                  {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "                  {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "                  {'abbrev': 'BC18',\n",
       "                   'name': 'Nutritional and Metabolic Diseases'},\n",
       "                  {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "               'hasResults': False}]})"
      ]
     },
     "execution_count": 80,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "eligable_studies_per_patient"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Patient_1\n",
      "NCT05137665\n",
      "NCT05474235\n",
      "NCT02916966\n",
      "NCT05340660\n",
      "Patient_2\n",
      "NCT05673057\n",
      "Patient_3\n",
      "NCT04322357\n",
      "NCT04626674\n",
      "NCT03689660\n"
     ]
    }
   ],
   "source": [
    "def ids_of_eligible_studies(eligable_studies_per_patient):\n",
    "    for patient in eligable_studies_per_patient.keys():\n",
    "        print(f'{patient}')\n",
    "        for study in eligable_studies_per_patient[patient]:\n",
    "            print(study['protocolSection']['identificationModule']['nctId'])\n",
    "\n",
    "ids_of_eligible_studies(eligable_studies_per_patient)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
